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NOVEL ANTIBACTERIAL COMPOUNDS 
AND METHODS OF MAKING AND USING 
SAME 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
[ 0001 ] This application claims priority to U . S . provisional 
patent application Ser . No . 62 / 175 , 079 , filed Jun . 12 , 2015 , 
the disclosure of which is incorporated by reference herein 
in its entirety . 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
[ 0002 ] This invention was made with government support 
under Grant No . 2P20GM103430 awarded by National 
Institutes of Health . The government has certain rights in the 
invention . 
BACKGROUND OF THE INVENTION 
[ 0003 ] Methods for the growth - inhibition and destruction 
of bacteria have long been a key area of study towards the 
improvement of human health . Numerous antibacterial 
agents have been designed and manufactured , but many are 
now exhibiting decreased efficacy due to microbial resis 
tance . The Centers for Disease Control estimates that at least 
a quarter of a million illnesses and 23 , 000 deaths over the 
past year in the U . S . were due to antibiotic resistance . A 
report published in 2009 by the Alliance for the Prudent Use 
of Antibiotics ( APUA ) estimated that over $ 20 billion 
dollars per year is consumed by healthcare costs to treat 
antibiotic - resistant infections . Although these figures could 
be improved by addressing the misuse and overuse of 
antibiotics in the clinic , an understanding of the mechanisms 
by which bacteria develop resistance and designing drugs to 
circumvent these is essential for the treatment of millions of 
infections . 
[ 0004 ) . There are three general molecular mechanisms that 
confer antibiotic resistance . The first is the inclusion of 
efflux pumps into the membrane of the bacteria . These 
pumps prevent the accumulation of intracellular - acting anti 
biotics such as protein synthesis inhibitors by actively 
pumping them out of the cytoplasm . Efflux pumps are 
generally adapted from existing membrane pumps used 
either to move lipophilic molecules in and out of the bacteria 
or rapidly expel naturally produced antibiotics meant to 
destroy neighboring bacteria . Drugs such as tetracyclines 
and erythromycins frequently fail to reach therapeutic con 
centrations due to expulsion through efflux pumps . 
[ 0005 ] A second method used by bacteria is to either destroy or modify the chemically relevant features of the 
antibiotic . This can include the cleavage of bonds within the 
antibiotic or chemical modification of groups on the antibi 
otic . 
[ 0006 ] The third most method of resistance does not act on 
the inhibitor at all , but instead modifies the target of inhi - 
bition . By reprogramming the target structure , bacteria can 
reduce the efficacy of the antibiotic while retaining the 
inherent function of the target . Further , bacteria develop into 
colonies that adhere to a surface within a dense extracellular 
matrix consisting of DNA , proteins , and polysaccharides , 
known as a biofilm . Biofilms are pervasive in implanted 
medical devices and damaged tissue , leading to unresolved 
infections . 
[ 0007 ] Though plagued by numerous resistance issues , 
cell wall - acting antibiotics are the most prevalent inhibitors 
of bacterial growth , such as penicillin . In particular , potent 
antibiotics target the synthesis of peptidoglycan , a key 
component of the bacterial cell wall . Peptidoglycan resists 
internal turgor , mediates cell growth and division , defines 
the shape of the cell , and helps to anchor proteins and 
glycoproteins to the cell wall . 
[ 0008 ] Peptidoglycan consists of the aminoglycosides 
N - acetylglucosamine ( GlcNAc ) and N - acetylmuramic acid 
( MurNAc ) linked in alternating chains through B - ( 1 - 4 ) 
bonds . In Bacillus subtilis , each individual chain is between 
50 and 250 disaccharide units . These linear glycan chains 
are cross - linked by short and variable peptide strands . The 
D - lactoyl group of MurNAc is amidated by a tetrapeptide in 
the mature macromolecule . Cross - linking of these peptides 
allows for the formation of a mesh - like matrix that sur 
rounds the cell . 
[ 0009 ] The cell wall has been a prominent target largely 
due to its absence in mammalian cells . Inhibitors designed 
for cell wall synthesis ideally only affect bacterial infections 
and do not damage host cells . Of the large number of cell 
wall synthesis inhibitors currently being developed and 
marketed , almost all fall into two major classes : B - lactams 
and macrocyclic polypeptides . 
[ 0010 ] B - Lactams comprise penicillins and cepha 
losporins use a reactive warhead ( a four - membered lactam 
ring ) to bind irreversibly to bacterial transpeptidases 
involved in assembly of the cross - bridge peptide chains 
within the peptidoglycan . Bacteria employ enzymes called 
B - lactamases to destroy the warhead , opening the lactam 
ring and rendering the antibiotic ineffective . 
[ 0011 ] Macrocyclic polypeptides include compounds like 
vancomycin . Vancomycin acts by tying up the peptide 
substrates used by transpeptidases and prevents their use as 
building blocks . Vancomycin ' s target , though , is the highly 
variable peptide cross - bridge that is readily modified by 
bacteria , thus preventing binding of vancomycin and elimi 
nating its potential activity . Additionally , macrocyclic poly 
peptide drugs pose a serious problem to synthetic chemists , 
due to their complexity . 
[ 0012 ] Presently , there are no successful antibiotics that 
target the natural recycling of the peptidoglycan . This hydro 
lytic breakdown and remodeling of the cell wall is carried 
out by a set of bacterial enzymes termed “ autolysins ” that 
are heavily implicated in peptidoglycan maturation , cell 
separation and expansion , motility , cell - wall turnover , and 
protein secretion . Within a single generation of bacterial 
growth , 50 % of the peptidoglycan layer is removed and 
recycled by the activity of autolysins . 
[ 0013 ] During vegetative growth of Bacillus subtilis , for 
example , two major enzymes present in the cell wall are 
involved with the autolytic activity occurring within the 
peptidoglycan : N - acetylmuramoyl - L - alanine amidase ( ami 
dase ) and endo - B - N - acetylglucosaminidase ( GlcNAcase ) . 
These enzymes are encoded by the LytC and LytD genes 
respectively and are regulated by the oD transcription factor . 
Despite their substantial expression and cell - wall localiza 
tion during exponential growth , neither of these enzymes is 
individually crucial to the survival or even proper cell - wall 
turnover of the cell . Furthermore , the double - knockout 
mutant of LytC / LytD had no reduction in cell separation and 
incomplete reduction in cell - wall turnover . The mutual com 
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pensatory nature of autolytic enzymes complicates any 
attempts to develop autolysin inhibitors as antibiotics . 
[ 0014 ] Several compounds have some inhibitory activity 
against purified autolysins but all have failed to exhibit any 
bacteriostatic or bactericidal effect . The B - hexosaminidase 
inhibitor , NAG - thiazoline , was only a weak binder of LT and 
had no effect on the viability of E . coli . Analogues of 
2 - acetamido - 2 - deoxynojirimycin were not active in vivo 
even at 1 mM . Targeting autolysin enzymes that which act 
on the invariant glycan chain may drastically reduce the 
potential for development of resistance . 
[ 0015 ] There is a need in the art to identify novel com 
pounds that can be used to treat or prevent bacterial infec 
tions in a subject . Treatment with such compounds should be 
efficacious and prone to minimal resistance build - up , or no 
resistance at all . The present invention addresses and meets 
this need . 
BRIEF SUMMARY OF THE INVENTION 
[ 0016 ] The invention provides a compound of formula I , 
or a salt or solvate thereof : 
- C ( O ) OH , CEO ) O ( CZ - C6 alkyl ) , C ( = O ) NH2 , 
- CEO ) NH ( C , - C6 alkyl ) , and — CEO ) N ( C - C6 alkyl ) 
( C1 - Co alkyl ) ; and 
[ 0021 ] R , is H or methyl . 
[ 0022 ] In certain embodiments , in Ri has at least one 
substituent ortho to the carbonyl group a selected from the 
group consisting of C7 - C , alkyl , OH , O ( C . - C . alkyl ) , F , CI , 
Br , I , NO , , CEO ) H , C ( O ) OH , CEO ) O ( C , - C6 
alkyl ) . - C ( O ) NH2 , CEO ) NH ( C , - C6 alkyl ) , and 
C = O ) N ( C . - C . alkyl ) ( C7 - C6 alkyl ) . In other embodi 
ments , at least one substituent ortho to the carbonyl group a 
is selected from the group consisting of C - C6 alkyl , OH , 
O ( CZ - C6 alkyl ) , F , C1 , Br and I . In yet other embodiments , 
R , is selected from the group consisting of phenyl , o - iodo 
phenyl , o - bromophenyl , o - chlorophenyl , o - fluorophenyl , 
0 - methoxyphenyl , p - iodophenyl , p - bromophenyl , p - chloro 
phenyl , p - fluorophenyl and p - methoxyphenyl . In yet other 
embodiments , R2 is selected from the group consisting of 
C , - C alkyl . C , - Co cycloalkyl , allyl , propargyl , homoprop 
argyl , phenyl , heteroaryl , aryl - ( CH2 )1 - 2 — , and heteroaryl 
( CH2 ) 1 - 2 , wherein the alkyl , cycloalkyl , phenyl , het 
eroaryl , aryl - ( CH2 ) 1 - 2 , or heteroaryl - ( CH ) 1 - 2 - group is 
optionally substituted with 1 - 3 substituents independently 
selected from the group consisting of C . - C . alkyl , OH , 
O ( C1 - C6 alkyl ) , F , C1 , Br , I , and NO2 . In yet other embodi 
ments , R2 is selected from the group consisting of C - C6 
alkyl , C5 - C6 cycloalkyl , allyl , propargyl , homopropargyl , 
phenyl , o - iodophenyl , o - bromophenyl , o - chlorophenyl , 
o - fluorophenyl , 0 - methoxyphenyl , p - iodophenyl , p - bro 
mophenyl , p - chlorophenyl , p - fluorophenyl , p - methoxyphe 
nyl , benzyl , Ph ( CH2 ) 2 - , Ph _ CHCH2 — , and Ph ( CH3 ) 
CH — . In yet other embodiments , Rz is selected from the 
group consisting of C5 - C6 cycloalkyl , phenyl , o - iodophenyl , 
o - bromophenyl , O - chlorophenyl , o - fluorophenyl , 
0 - methoxyphenyl , p - iodophenyl , p - bromophenyl , p - chloro 
phenyl , p - fluorophenyl , and p - methoxyphenyl . In yet other 
embodiments , R4 is selected from the group consisting of 
C - Co alkyl , Cz - Co cycloalkyl , benzyl , and phenyl - ( CH2 ) 
24 , wherein the alkyl , cycloalkyl , phenyl or benzyl group is 
optionally substituted with 1 - 3 substituents independently 
selected from the group consisting of C - C . alkyl . OH , 
O ( C - C alkyl ) , F , Cl , Br , and I . 
[ 0023 ] In certain embodiments , the compound of the 
invention is selected from the group consisting of : 
men R5 
R2 
wherein in compound I : 
[ 0017 ] R is selected from the group consisting of aryl and 
heteroaryl , wherein the aryl or heteroaryl group is optionally 
substituted with 1 - 3 substituents independently selected 
from the group consisting of C , - C . alkyl , OH , O ( C , - C6 
alkyl ) , F , C1 , Br , I , NO , , CEO ) H , C ( O ) OH , 
- C ( = O ) ( CZ - C6 alkyl ) . C ( O ) NH2 , CEO ) NH ( C1 - C6 alkyl ) , and CEO ) N ( C1 - C6 alkyl ) ( C1 - C6 alkyl ) ; [ 0018 ] R , is selected from the group consisting of CZ - C6 
alkyl , Cz - Cg cycloalkyl , allyl , propargyl , homopropargyl , 
aryl , heteroaryl , arylalkyl , and heteroarylalkyl , wherein the 
alkyl , cycloalkyl , aryl , heteroaryl , arylalkyl or heteroarylal 
kyl group is optionally substituted with 1 - 3 substituents 
independently selected from the group consisting of C , - C6 
alkyl , OH , O ( C . - C . alkyl ) , F , Cl , Br , I , NO2 , — CEO ) H , 
- C ( O ) OH , CEO ) O ( C , - C . alkyl ) , CEO ) NH2 , 
C ONH ( C . - C . alkyl ) , and CEO ) N ( C - C . alkyl ) ( C1 - C6 alkyl ) ; 
[ 0019 ] Rz is selected from the group consisting of C3 - C , 
cycloalkyl , aryl and heteroaryl , wherein the cycloalkyl , aryl 
or heteroaryl group is optionally substituted with 1 - 3 sub 
stituents independently selected from the group consisting of 
C - C6 alkyl , OH , O ( C . - C . alkyl ) , F , Cl , Br , I , NO2 , 
- C ( = O ) H , CEO ) OH , CEO ) O ( C1 - C6 alkyl ) , 
- C = O ) NH2 , CEO ) NH ( C , - C? alkyl ) , and CEO ) N ( C . - C . alkyl ) ( CZ - C , alkyl ) ; 
[ 0020 ] R4 is selected from the group consisting of C , - Co 
alkyl , C3 - C , cycloalkyl , arylalkyl and heteroarylalkyl , 
wherein the alkyl , cycloalkyl , arylalkyl or heteroarylalkyl 
group is optionally substituted with 1 - 3 substituents inde 
pendently selected from the group consisting of C , - C4 alkyl , 
OH , O ( C1 - C6 alkyl ) , F , CI , Br , I , NO2 , - C ( O ) H , 
Ph 
fgca 
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[ 0024 ] The compounds of the invention have shown anti 
bacterial activity against a variety of Gram - positive and 
Gram - negative bacteria including , but not limited to , B . 
subtilis Lyt , S . pneumoniae , C . difficile , and S . aureus . 
[ 0025 ] In certain embodiments , the compound of formula 
I is selected from the group consisting of fgkc , fgkb , rgba , 
fgoa , fgka , fgna , fgbb , fgqa and fgbc . In one embodiment , 
the compound is fgkc , fgkb , rgba , fgoa , fgka or fgna . These 
compounds have antibacterial activity against B . subtilis Lyt 
G . In another embodiment , the compound is fgkc , fgbb , or 
fgbc . These compounds have antibacterial activity against S . 
pneumoniae . In yet another embodiment , the compound is 
fgba or fgqa . These compounds have antibacterial activity 
against S . aureus . In another embodiment , the compound is 
fgna , which has antibacterial activity against C . difficile . 
[ 0026 ] In certain embodiments , the salt of compound I is 
an acid addition salt and is selected from the group consist 
ing of sulfate , hydrogen sulfate , hydrochloric , hydrobromic , 
hydriodic , nitric , carbonic , sulfuric , phosphoric , formic , 
acetic , propionic , succinic , glycolic , gluconic , lactic , malic , 
tartaric , citric , ascorbic , glucuronic , maleic , fumaric , pyru 
vic , aspartic , glutamic , benzoic , anthranilic , 4 - hydroxyben 
zoic , phenylacetic , mandelic , embonic ( pamoic ) , methane 
sulfonic , ethanesulfonic , benzenesulfonic , pantothenic , 
trifluoromethanesulfonic , 2 - hydroxyethanesulfonic , p - tolu 
enesulfonic , sulfanilic , cyclohexylaminosulfonic , stearic , 
alginic , B - hydroxybutyric , salicylic , galactaric and galactur 
onic acid , and any combinations thereof . In other embodi 
ments , the salt is a base addition salt and is selected from the 
group consisting of calcium , magnesium , potassium , 
sodium , ammonium , zinc , a basic amine salt , and any 
combinations thereof , wherein the basic amine is selected from the group consisting of triethylamine , diisopropyleth 
ylamine , trimethylamine . N , N - dibenzylethylene - diamine , 
chloroprocaine , choline , diethanolamine , ethylenediamine , 
meglumine , procaine and any combinations thereof . 
[ 0027 ] The invention also provides pharmaceutical com 
positions comprising at least one compound of the invention 
and a pharmaceutically acceptable carrier . In certain 
embodiments , the compositions further comprise at least one 
additional antibacterial agent . In other embodiments , the at 
least one additional antibacterial agent comprises at least 
one agent selected from the group consisting of amoxicillin , 
azithromycin , biaxin , biocef , cefaclor , cinoxacin , cipro 
floxacin , clindamycin , doryx , emgel , enoxacin , fortaz , gati 
floxacin , levofloxacin , linezolid , maxaquin , moxifloxacin , 
neomycin , ofloxacin , penicillin , rifampin , sparfloxacin , 
streptomycin , sulfatrim , tetracycline , trovafloxacin , vanco 
mycin and zotrim . In yet other embodiments , the compound 
and the agent are co - formulated m the composition . 
[ 0028 ] The invention further provides a method of inhib 
iting a N - acetylglucosaminidase in a cell comprising con 
tacting the cell with a compound of the invention . In certain 
embodiments , cell is a bacterium , a fungus or a cancer cell . 
In yet other embodiments , the N - acetylglucosaminidase 
comprises an autolysin . 
[ 0029 ] The invention also provides a method of inhibiting 
a N - acetylglucosaminidase in the cytosol of a cell . In certain 
embodiments , the method comprises contacting the 
N - acetylglucosaminidase with at least one compound of the 
invention . In other embodiments , the N - acetylglucosamini 
dase is derived from a bacterium , a fungus or a cancer cell . 
In yet other embodiments , the N - acetylglucosaminidase 
comprises an autolysin . 
[ 0030 ] The invention further provides a method of treating 
or preventing a bacterial infection in a subject comprising 
administering to a subject in need thereof a therapeutically 
effective amount of at least one compound of the invention , 
thereby treating or preventing a bacterial infection in the 
subject . 
[ 0031 ] In yet another embodiment , the subject is further 
administered at least one additional antibacterial agent . In 
certain embodiments , the at least one additional antibacterial 
agent comprises at least one agent selected from the group 
consisting of amoxicillin , azithromycin , biaxin , biocef , cefa 
clor , cinoxacin , ciprofloxacin , clindamycin , doryx , emgel , 
enoxacin , fortaz , gatifloxacin , levofloxacin , linezolid , maxa 
quin , moxifloxacin , neomycin , ofloxacin , penicillin , rifam 
pin , sparfloxacin , streptomycin , sulfatrim , tetracycline , 
trovafloxacin , vancomycin and zotrim . In certain embodi 
ments , the compound of the invention and the agent are 
co - administered to the subject . In other embodiments , the 
compound of the invention and the agent are co - formulated . 
[ 0032 ] In other embodiments , the compound is adminis 
tered to the subject by at least one route selected from the 
group consisting of intravenous , oral , inhalational , rectal , 
vaginal , transdermal , intranasal , buccal , sublingual , parent 
eral , intrathecal , intragastrical , ophthalmic , pulmonary and 
topical routes . In certain embodiments , the subject is a 
mammal . In other embodiments , the mammal is a human . 
[ 0033 ] In one embodiment of the methods of the invention 
described above , the bacterium is Gram - positive . In another 
embodiment , the Gram - positive bacterium is selected from 
the group consisting of Streptococcus sp . , Staphylococcus 
sp . , Enterococcus sp . , Corynebacterium sp . , Listeria sp . , 
Clostridium sp . and Bacillus sp . In yet another embodiment , 
the Gram - positive bacterium is Clostridium difficile ( also 
currently known as Peptoclostridium difficile ) , Streptococ 
cus pneumoniae , Staphylococcus aureus , vancomycin inter 
mediate resistance S . aureus ( VISA ) , Enterococcus faecalis , 
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vancomycin resistant enterococci ( VRE ) , Streptococcus 
pyogenes , Bacillus anthracis , Corynebacterium diphtheria 
or Bacillus cereus . 
[ 0034 ] In one embodiment of the methods of the invention 
described above , the bacterium is Gram - negative . In another 
embodiment , the Gram - negative bacterium is selected from 
the group consisting of Salmonella sp . , Escherichia sp . , 
Klebsiella sp . , Acinetobacter sp . , Pseudomonas sp . , Vibrio 
sp . and Enterobacter sp . In yet another embodiment , the 
Gram - negative bacterium is Salmonella enterica . 
[ 0035 ] Salmonella typhii , Escherichia coli , Klebsiella 
pneumoniae , Acinetobacter baumannii or Pseudomonas 
aerugenosa . 
[ 0036 ] In one embodiment of the method of treating or 
preventing a bacterial infection in a subject described above , 
the compound is fgkc , fgkb , rgba , fgoa , fgka or fgna and the 
bacteria is B . subtilis Lyt G . In another embodiment , the 
compound is fgkc , fgbb , or fgbc and the bacteria is S . 
pneumoniae . In yet another embodiment , the compound is 
fgba or fgqa and the bacteria is S . aureus . In still another 
embodiment , the compound is fgna and the bacteria is C . 
difficile . 
[ 0037 ] In another embodiment , the methods of the inven 
tion further comprise procuring the at least one compound of 
the invention . [ 0038 ] The invention further provides a prepackaged phar 
maceutical composition comprising at least one compound 
of the invention , or a salt or solvate thereof and an instruc 
tional material for use thereof . 
[ 0039 ] In certain embodiments , the instructional material 
comprises instructions for preventing or treating a bacterial 
infection in a subject . In other embodiments , the prepack 
aged pharmaceutical composition further comprises an 
applicator . 
[ 0040 ] Other aspects , embodiments , advantages , and fea 
tures of the present invention will become apparent from the 
following specification . 
experiments : Plate 1 , top left , and Plate , 2 top right . FIG . 6B 
is an image illustrating results of a single concentration 
whole - cell ; resazurin assay . 
[ 0048 ] FIG . 7 is a table illustrated selected MIC values for 
compounds of the invention against Gram - positive patho 
gens . 
[ 0049 ] FIG . 8 is a series of graphs illustrating the finding 
that fgkc treatment results in UDP - MurNAc - pentapeptide 
accumulation in B . subtilis . Ugi - derived terminal alkynes 
target peptidoglycan synthesis / metabolism . B . subtilis was 
grown to mid - exponential phase ( O . D . 600 ~ 0 . 6 ) and all cul 
tures treated with Chloramphenicol ( Cm ) ( 130 mg / mL ) for 
15 min . Cultures were then exposed to vancomycin ( Van ) ( 8 
mg / mL ) or fgkc ( 4xMIC ) for 1 h . Nucleotide sugars were 
extracted with hot water and separated by C18 - RP - HPLC . 
( * ) denotes retention time of UDP - MurNAc - pentapeptide . [ 0050 ] FIG . 9 is a graph illustrating inhibition of LytG 
( GH73 ) from B . subtilis by fgka . The assay involved in vitro 
GlcNAcase inhibition of B . subtilis LytG by fgka , as mea 
sured using turbidometric assays with purified peptidogly 
can ( Horsburgh , et al . , 2003 , Biochemistry 42 : 257 ) . 
10051 ] FIGS . 10A - 10B illustrate weak inhibition of other 
GH73 members by selected compounds of the invention : 
inhibition of FigJ ( GH73 ) from the Gram - negative pathogen 
Salmonella enterica by fgba ( FIG . 10A ) and BI . fgba ( FIG . 
10B ) . Activity was measured as described in Herlihey , et al . 
2014 , J . Biol Chem 289 ( 45 ) : 31029 . 
DETAILED DESCRIPTION OF THE 
INVENTION 
BRIEF DESCRIPTION OF THE DRAWINGS 
[ 0041 ] The following detailed description of various 
embodiments of the invention will be better understood 
when read in conjunction with the appended drawings . For 
the purpose of illustrating the invention , there are shown in 
the drawings certain specific embodiments . It should be 
understood , however , that the invention is not limited to the 
precise arrangements and instrumentalities of the embodi 
ments shown in the drawings . 
[ 0042 ] FIG . 1 is an illustration of the structure of pepti 
doglycan in a Gram - positive bacterium . See Tortora , G . J . , 
Funke , B . R . & Case , C . L . Microbiology : An Introduction . ( Benjamin Cummings , 2010 ) . 
[ 0043 ] FIG . 2 is an illustration of autolysins in B . subtilis 
and point of activity within peptidoglycan . 
[ 0044 ] FIG . 3 is a graph illustrating fluorescence values 
measured over time at 250 uM inhibitors for B . subtilis . 
[ 0045 ] FIG . 4 is a bar graph illustrating fluorescence 
readings in the resazurin assay at 60 minutes ( 250 UM 
inhibitor ) . 
[ 0046 ] FIG . 5 is a bar graph illustrating fluorescence 
readings in the resazurin assay at 60 minutes ( 250 uM 
inhibitor ) for multiple runs ( Run 1 : red ; Run 2 : blue : Run 3 : 
green ) . 
10047 ] FIG . 6A is an image illustrating serial dilution 
resazurin assay for fgkc , fgka , fgoa , and rgba Identical 
Definitions 
[ 0052 ] Unless defined otherwise , all technical and scien 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs . Although any methods and materials 
similar or equivalent to those described herein can be used 
in the practice or testing of the present invention , the certain 
specific methods and materials are described . 
[ 0053 ] As used herein , each of the following terms has the 
meaning associated with it in this section . 
10054 ] The articles " a " and " an " are used herein to refer to 
one or to more than one ( i . e . , to at least one ) of the 
grammatical object of the article . By way of example , " an 
element ” means one element or more than one element . 
[ 0055 ] “ About ” as used herein when referring to a mea 
surable value such as an amount , a temporal duration , and 
the like , is meant to encompass variations of + 20 % or + 10 % , 
more advantageously + 5 % , even more advantageously + 1 % , 
and still more advantageously + 0 . 1 % from the specified 
value , as such variations are appropriate to perform the 
disclosed methods . [ 0056 ] A disease or disorder is “ alleviated ” if the severity 
of a symptom of the disease or disorder , the frequency with 
which such a symptom is experienced by a patient , or both , 
is reduced . 
[ 0057 ] In one aspect , the terms " co - administered ” and 
“ co - administration " as relating to a subject refer to admin 
istering to the subject a compound of the invention or salt 
thereof along with a compound that may also treat the 
disorders or diseases contemplated within the invention . In 
one embodiment , the co - administered compounds are 
administered separately , or in any kind of combination as 
part of a single therapeutic approach . The co - administered 
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compound may be formulated in any kind of combination , 
as mixtures of solids and liquids under a variety of solid , gel , 
and liquid formulations , and as a solution . 
[ 0058 ] As used herein , the term “ composition ” or “ phar 
maceutical composition ” refers to a mixture of at least one 
compound useful within the invention with a pharmaceuti 
cally acceptable carrier . The pharmaceutical composition 
facilitates administration of the compound to a patient or 
subject . Multiple techniques of administering a compound 
exist in the art including , but not limited to , intravenous , 
oral , aerosol , parenteral , ophthalmic , pulmonary and topical 
administration . 
10059 ] " disease ” as used herein is a state of health of an 
animal wherein the animal cannot maintain homeostasis , 
and wherein if the disease is not ameliorated then the 
animal ' s health continues to deteriorate . 
[ 0060 ] A “ disorder ” as used herein in an animal is a state 
of health in which the animal is able to maintain homeosta 
sis , but in which the animal ' s state of health is less favorable 
than it would be in the absence of the disorder . Left 
untreated , a disorder does not necessarily cause a further 
decrease in the animal ' s state of health . 
[ 0061 ] As used herein , the term “ DMSO ” refers to dim 
ethyl sulfoxide . 
[ 0062 ] As used herein , the terms “ effective amount , " 
" pharmaceutically effective amount ” and “ therapeutically 
effective amount ” refer to a nontoxic but sufficient amount 
of an agent to provide the desired biological result . That 
result may be reduction and / or alleviation of the signs , 
symptoms , or causes of a disease , or any other desired 
alteration of a biological system . An appropriate therapeutic 
amount in any individual case may be determined by one of 
ordinary skill in the art using routine experimentation . 
10063 ] As used herein , the term “ GlcNAc ” refers to 
N - acetylglucosamine . 
[ 0064 ] As used herein , the term “ GNT ” refers to a GlcNAC 
triazole . [ 0065 ] As used herein , the term “ Gram - positive bacteria ” 
are bacteria that give a positive result in the Gram stain test . 
Gram - positive bacteria take up the crystal violet stain used 
in the test , and then appear to be purple - colored when seen 
through a microscope . Gram - positive bacterial include 
Streptococcus sp . , Staphylococcus sp . , Enterococcus sp . , 
Corynebacterium sp . , Listeria sp . , Clostridium sp . and 
Bacillus sp . Examples of Gram - positive bacteria include 
Clostridium difficile ( also currently known as Peptoclo 
stridium difficile ) , Streptococcus pneumoniae . Staphylococ 
cus aureus , vancomycin intermediate resistance S . aureus 
( VISA ) , Enterococcus faecalis , vancomycin resistant 
enterococci ( VRE ) , Streptococcus pyogenes , Bacillus 
anthracis , Corynebacterium diphtheria and Bacillus cereus . 
[ 0066 ] As used herein , the term “ Gram - negative bacteria ” 
are a group of bacteria that do not retain the crystal violet 
stain used in the Gram staining method of bacterial differ 
entiation . Gram - negative bacteria include Salmonella sp . , 
Escherichia sp . , Klebsiella sp . , Acinetobacter sp . , 
Pseudomonas sp . , Vibrio sp . and Enterobacter sp . Examples 
of Gram - negative bacteria include Salmonella enterica , Sal 
monella typhii , Escherichia coli , Klebsiella pneumoniae , 
Acinetobacter baumannii and Pseudomonas aerugenosa . 
[ 0067 ] “ Instructional material , ” as that term is used herein , 
includes a publication , a recording , a diagram , or any other 
medium of expression that can be used to communicate the 
usefulness of the composition and / or compound of the 
invention in a kit . The instructional material of the kit may , 
for example , be affixed to a container that contains the 
compound and / or composition of the invention or be 
shipped together with a container that contains the com 
pound and / or composition . Alternatively , the instructional 
material may be shipped separately from the container with 
the intention that the recipient uses the instructional material 
and the compound cooperatively . Delivery of the instruc 
tional material may be , for example , by physical delivery of 
the publication or other medium of expression communi 
cating the usefulness of the kit , or may alternatively be 
achieved by electronic transmission , for example by means 
of a computer , such as by electronic mail , or download from 
a website . 
[ 0068 ] The terms “ patient , ” “ subject ” or “ individual ” are 
used interchangeably herein , and refer to any animal , or cells 
thereof whether in vitro or in situ , amenable to the methods 
described herein . In a non - limiting embodiment , the patient , 
subject or individual is a human . 
[ 0069 ] As used herein , the term “ pharmaceutically accept 
able ” refers to a material , such as a carrier or diluent , which 
does not abrogate the biological activity or properties of the 
compound , and is relatively non - toxic , i . e . , the material may 
be administered to an individual without causing undesirable 
biological effects or interacting in a deleterious manner with 
any of the components of the composition in which it is 
contained . 
[ 0070 ] As used herein , the language “ pharmaceutically 
acceptable salt ” refers to a salt of the administered com 
pounds prepared from pharmaceutically acceptable non 
toxic acids , including inorganic acids , organic acids , sol 
vates , hydrates , or clathrates thereof . 
[ 0071 ] As used herein , the term “ pharmaceutically accept 
able carrier ” means a pharmaceutically acceptable material , 
composition or carrier , such as a liquid or solid filler , 
stabilizer , dispersing agent , suspending agent , diluent , 
excipient , thickening agent , solvent or encapsulating mate 
rial , involved in carrying or transporting a compound useful 
within the invention within or to the patient such that it may 
perform its intended function . Typically , such constructs are 
carried or transported from one organ , or portion of the body , 
to another organ , or portion of the body . Each carrier is 
" acceptable ” in the sense of being compatible with the other 
ingredients of the formulation , including the compound 
useful within the invention , and not injurious to the patient . 
Some examples of materials that may serve as pharmaceu 
tically acceptable carriers include : sugars , such as lactose , 
glucose and sucrose ; starches , such as corn starch and potato 
starch ; cellulose , and its derivatives , such as sodium car 
boxymethyl cellulose , ethyl cellulose and cellulose acetate ; 
powdered tragacanth ; malt ; gelatin ; talc ; excipients , such as 
cocoa butter and suppository waxes ; oils , such as peanut oil , 
cottonseed oil , safflower oil , sesame oil , olive oil , corn oil 
and soybean oil ; glycols , such as propylene glycol , polyols , 
such as glycerin , sorbitol , mannitol and polyethylene glycol ; 
esters , such as ethyl oleate and ethyl laurate ; agar ; buffering 
agents , such as magnesium hydroxide and aluminum 
hydroxide ; surface active agents ; alginic acid ; pyrogen - free 
water ; isotonic saline ; Ringer ' s solution ; ethyl alcohol ; 
phosphate buffer solutions ; and other non - toxic compatible 
substances employed in pharmaceutical formulations . As 
used herein , " pharmaceutically acceptable carrier " also 
includes any and all coatings , antibacterial and antifungal 
agents , and absorption delaying agents , and the like that are 
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compatible with the activity of the compound useful within 
the invention , and are physiologically acceptable to the 
patient . Supplementary active compounds may also be 
incorporated into the compositions . The " pharmaceutically 
acceptable carrier ” may further include a pharmaceutically 
acceptable salt of the compound useful within the invention 
Other additional ingredients that may be included in the 
pharmaceutical compositions used in the practice of the 
invention are known in the art and described , for example in 
Remington ' s Pharmaceutical Sciences ( Genaro , Ed . , Mack 
Publishing Co . , 1985 , Easton , Pa . ) , which is incorporated 
herein by reference . [ 0072 ] The term " prevent , " " preventing " or " prevention , ” 
as used herein , means avoiding or delaying the onset of 
symptoms associated with a disease or condition in a subject 
that has not developed such symptoms at the time the 
administering of an agent or compound commences . 
10073 ] As used herein , the term " procure ” or " procuring ” 
as relating to a subject in need of being administered a 
therapeutically active compound refers to the act of synthe 
sizing , packaging , prescribing , purchasing , providing or 
otherwise acquiring the compound so that the subject may 
be administered the compound . 
[ 0074 ] By the term “ specifically bind ” or “ specifically 
binds , " as used herein , is meant that a first molecule pref 
erentially binds to a second molecule ( e . g . , a particular 
receptor or enzyme ) , but does not necessarily bind only to 
that second molecule . 
[ 0075 ] A “ therapeutic ” treatment is a treatment adminis 
tered to a subject who exhibits signs of pathology , for the 
purpose of diminishing or eliminating those signs . 
[ 0076 ] As used herein , the term “ treatment ” or “ treating " 
is defined as the application or administration of a thera 
peutic agent , i . e . , a compound of the invention ( alone or in 
combination with another pharmaceutical agent ) , to a 
patient , or application or administration of a therapeutic 
agent to an isolated tissue or cell line from a patient ( e . g . , for 
diagnosis or ex vivo applications ) , who has a condition 
contemplated herein , a symptom of a condition contem 
plated herein or the potential to develop a condition con 
templated herein , with the purpose to cure , heal , alleviate , 
relieve , alter , remedy , ameliorate , improve or affect a con 
dition contemplated herein , the symptoms of a condition 
contemplated herein or the potential to develop a condition 
contemplated herein . Such treatments may be specifically 
tailored or modified , based on knowledge obtained from the 
field of pharmacogenomics . 
[ 0077 ] As used herein , the term “ alkyl , ” by itself or as part 
of another substituent means , unless otherwise stated , a 
straight or branched chain hydrocarbon having the number 
of carbon atoms designated ( i . e . , C . - C . , means one to ten 
carbon atoms ) and includes straight , branched chain , or 
cyclic substituent groups . Examples include methyl , ethyl , 
propyl , isopropyl , butyl , isobutyl , tert - butyl , pentyl , neopen 
tyl , hexyl , and cyclopropylmethyl . Certain specific examples 
include ( C , - C6 ) alkyl , such as , but not limited to , ethyl , 
methyl , isopropyl , isobutyl , n - pentyl , n - hexyl and cyclopro 
pylmethyl . 
[ 0078 ] As used herein , the term “ cycloalkyl , ” by itself or 
as part of another substituent means , unless otherwise stated , 
a cyclic chain hydrocarbon having the number of carbon 
atoms designated ( i . e . , Cz - Co means a cyclic group com 
prising a ring group consisting of three to six carbon atoms ) 
and includes straight , branched chain or cyclic substituent 
groups . Examples include cyclopropyl , cyclobutyl , cyclo 
pentyl , cyclohexyl , cycloheptyl , and cyclooctyl . Certain 
specific examples include ( C3 - C . ) cycloalkyl , such as , but 
not limited to , cyclopropyl , cyclobutyl , cyclopentyl and 
cyclohexyl . 
[ 0079 ] As used herein , the term “ alkenyl , ” employed alone 
or in combination with other terms , means , unless otherwise 
stated , a stable mono - unsaturated or poly - unsaturated 
straight chain or branched chain hydrocarbon group having 
the stated number of carbon atoms . Examples include vinyl , 
propenyl ( or allyl ) , crotyl , isopentenyl , butadienyl , 1 , 3 
pentadienyl , 1 , 4 - pentadienyl , and the higher homologs and 
isomers . A functional group representing an alkene is exem 
plified by _ CH , — CH = CH , 
[ 0080 ] As used herein , the term “ alkynyl , ” employed 
alone or in combination with other terms , means , unless 
otherwise stated , a stable straight chain or branched chain 
hydrocarbon group with a triple carbon - carbon bond , having 
the stated number of carbon atoms . Non - limiting examples 
include ethynyl and propynyl , and the higher homologs and 
isomers . The term “ propargylic ” refers to a group exempli 
fied by CH2C = CH . The term “ homopropargylic ” refers 
to a group exemplified by CH2CH2 - CECH . The term 
“ substituted propargylic ” refers to a group exemplified by 
CR , C = CR , wherein each occurrence of R is indepen 
dently H , alkyl , substituted alkyl , alkenyl or substituted 
alkenyl , with the proviso that at least one R group is not 
hydrogen . The term " substituted homopropargylic ” refers to 
a group exemplified by — CR , CR , C = CR , wherein each 
occurrence of R is independently H , alkyl , substituted alkyl , 
alkenyl or substituted alkenyl , with the proviso that at least 
one R group is not hydrogen . 
[ 0081 ] As used herein , the term " substituted alkyl , ” “ sub 
stituted cycloalkyl , ” “ substituted alkenyl ” or “ substituted 
alkynyl ” means alkyl , cycloalkyl , alkenyl or alkynyl , as 
defined above , substituted by one or more substituents 
selected from the group consisting of halogen , OH , 
alkoxy , tetrahydro - 2 - H - pyranyl , — NH N ( CH3 ) 2 , ( 1 - methyl - imidazol - 2 - yl ) , pyridin - 2 - yl , pyridin - 3 - yl , pyri 
din - 4 - yl , CCOOH , trifluoromethyl , — C = N , C O ) ) 
O ( C1 - C4 ) alkyl , - C ( O ) NH2 , CEO ) NH ( CZ - C4 ) alkyl , 
- C O ) N ( ( C / - C4 ) alkyl ) 2 , — SO2NH2 , CENH ) NH2 , 
and — NO2 , advantageously containing one or two substitu 
ents selected from halogen , OH , alkoxy , — NH2 , trifluo 
romethyl , — N ( CH3 ) 2 , and — CEO ) OH , more advanta 
geously selected from halogen , alkoxy and OH . Examples 
of substituted alkyls include , but are not limited to , 2 , 2 
difluoropropyl , 2 - carboxycyclopentyl and 3 - chloropropyl . 
[ 0082 ] As used herein , the term “ alkoxy ” employed alone 
or in combination with other terms means , unless otherwise 
stated , an alkyl group having the designated number of 
carbon atoms , as defined above , connected to the rest of the 
molecule via an oxygen atom , such as , for example , 
methoxy , ethoxy , 1 - propoxy , 2 - propoxy ( isopropoxy ) and 
the higher homologs and isomers . In certain embodiments , 
alkoxy includes ( C1 - C3 Jalkoxy , such as , but not limited to , 
ethoxy and methoxy . 
[ 0083 ] As used herein , the term “ halo ” or “ halogen ” alone 
or as part of another substituent means , unless otherwise 
stated , a fluorine , chlorine , bromine , or iodine atom , advan 
tageously , fluorine , chlorine , or bromine , more advanta 
geously , fluorine or chlorine . 
[ 0084 ] As used herein , the term " heteroalkyl ” by itself or 
in combination with another term means , unless otherwise 
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stated , a stable straight or branched chain alkyl group 
consisting of the stated number of carbon atoms and one or 
two heteroatoms selected from the group consisting of O , N , 
and S , and wherein the nitrogen and sulfur atoms may be 
optionally oxidized and the nitrogen heteroatom may be 
optionally quaternized . The heteroatom ( s ) may be placed at 
any position of the heteroalkyl group , including between the 
rest of the heteroalkyl group and the fragment to which it is 
attached , as well as attached to the most distal carbon atom in the heteroalkyl group . Examples include : - O CH2 – 
CH3 , CH3 , CH2 - CH2 - CH2OH , CH2CH2 — 
NH - CH3 , - CH2 - S – CH2 - CH3 , and — CH2CH2S 
GO ) CH3 . Up to two heteroatoms may be consecutive , 
such as , for example , CH2 NH _ OCHz , or CH2 — 
CH , S - S _ CHz [ 0085 ] As used herein , the term " heteroalkenyl ” by itself 
or in combination with another term means , unless other 
wise stated , a stable straight or branched chain monounsatu 
rated or poly - unsaturated hydrocarbon group consisting of 
the stated number of carbon atoms and one or more het 
eroatoms selected from the group consisting of O , N , and S , 
and wherein the nitrogen and sulfur atoms may optionally be 
oxidized and the nitrogen heteroatom may optionally be 
quaternized . Up to two heteroatoms may be placed consecu 
tively . Examples include CH = CH – O CH , 
- CH = CH - CH2 - OH , CH2CH = N / OCHZ , 
- CH = CH - N ( CH3 ) - CH3 , and CH2 - CH = CH - 
CH , SH . 
[ 0086 ] As used herein , the term “ aromatic ” refers to a 
carbocycle or heterocycle with one or more polyunsaturated 
rings and having aromatic character , i . e . having ( 4n + 2 ) 
delocalized I ( pi ) electrons , where n is an integer . 
[ 0087 ] As used herein , the term “ aryl , ” employed alone or 
in combination with other terms , means , unless otherwise 
stated , a carbocyclic aromatic system containing one or 
more rings ( typically one , two or three rings ) wherein such 
rings may be attached together in a pendent manner , such as 
a biphenyl , or may be fused , such as naphthalene . Examples 
include phenyl , anthracyl , and naphthyl . In certain embodi 
ments , aryl includes phenyl and naphthyl , in particular , 
phenyl . 
[ 0088 ] As used herein , the term " aryl - ( C , - CZ ) alkyl ” 
means a functional group wherein a one to three carbon alkyl 
chain is attached to an aryl group , e . g . , - CH2CH2 - phenyl or 
- CH2 - phenyl ( benzyl ) . Examples included aryl - CH2 - and 
aryl - CH ( CH3 ) — . The term “ substituted aryl - ( C1 - C3 ) alkyl ” 
means an aryl - ( C , - CZ ) alkyl functional group in which the 
aryl group is substituted . Specific examples include substi 
tuted aryl ( CH2 ) . Similarly , the term “ heteroaryl - ( C ) - C3 ) 
alkyl ” means a functional group wherein a one to three 
carbon alkylene chain is attached to a heteroaryl group , e . g . , 
- CH2CH2 - pyridyl . One embodiment is heteroaryl ( CH2 ) — The term “ substituted heteroaryl - ( C , - C3 ) alkyl ” 
means a heteroaryl - ( C1 - C3 ) alkyl functional group in which 
the heteroaryl group is substituted . Specific examples 
include substituted heteroaryl - ( CH2 ) — . . 
10089 ] As used herein , the term " heterocycle ” or “ hetero 
cyclyl ” or “ heterocyclic ” by itself or as part of another 
substituent means , unless otherwise stated , an unsubstituted 
or substituted , stable , mono - or multi - cyclic heterocyclic 
ring system that consists of carbon atoms and at least one 
heteroatom selected from the group consisting of N , O , and 
S , and wherein the nitrogen and sulfur heteroatoms may be 
optionally oxidized , and the nitrogen atom may be option 
ally quaternized . The heterocyclic system may be attached , 
unless otherwise stated , at any heteroatom or carbon atom 
that affords a stable structure . A heterocycle may be aromatic 
or non - aromatic in nature . In one embodiment , the hetero 
cycle is a heteroaryl . 
[ 0090 ] As used herein , the term " heteroaryl ” or “ het 
eroaromatic ” refers to a heterocycle having aromatic char 
acter . A polycyclic heteroaryl may include one or more rings 
that are partially saturated . Examples include tetrahydroqui 
noline and 2 , 3 - dihydrobenzofuryl . 
[ 0091 ] Examples of non - aromatic heterocycles include 
monocyclic groups such as aziridine , oxirane , thiirane , aze 
tidine , oxetane , thietane , pyrrolidine , pyrroline , imidazoline , 
pyrazolidine , dioxolane , sulfolane , 2 , 3 - dihydrofuran , 2 , 5 
dihydrofuran , tetrahydrofuran , thiophane , piperidine , 1 , 2 , 3 , 
6 - tetrahydropyridine , 1 , 4 - dihydropyridine , piperazine , mor 
pholine , thiomorpholine , pyran , 2 , 3 - dihydropyran , 
tetrahydropyran , 1 , 4 - dioxane , 1 , 3 - dioxane , homopiperazine , 
homopiperidine , 1 , 3 - dioxepane , 4 , 7 - dihydro - 1 , 3 - dioxepin 
and hexamethyleneoxide . 
[ 0092 ] Examples of heteroaryl groups include pyridyl , 
pyrazinyl , pyrimidinyl ( such as , but not limited to , 2 - and 
4 - pyrimidinyl ) , pyridazinyl , thienyl , furyl , pyrrolyl , imida 
zolyl , thiazolyl , oxazolyl , pyrazolyl , isothiazolyl , 1 , 2 , 3 - tri 
azolyl , 1 , 2 , 4 - triazolyl , 1 , 3 , 4 - triazolyl , tetrazolyl , 1 , 2 , 3 - thia 
diazolyl , 1 , 2 , 3 - oxadiazolyl , 1 , 3 , 4 - thiadiazolyl and 1 , 3 , 4 
oxadiazolyl . 
[ 0093 ] Examples of polycyclic heterocycles include indo 
lyl ( such as , but not limited to , 3 - , 4 - , 5 - , 6 - and 7 - indolyl ) , 
indolinyl , quinolyl , tetrahydroquinolyl , isoquinolyl ( such as , 
but not limited to , 1 - and 5 - isoquinolyl ) , 1 , 2 , 3 , 4 - tetrahy 
droisoquinolyl , cinnolinyl , quinoxalinyl ( such as , but not 
limited to , 2 - and 5 - quinoxalinyl ) , quinazolinyl , phthalazi 
nyl , 1 , 8 - naphthyridinyl , 1 , 4 - benzodioxanyl , coumarin , dihy 
drocoumarin , 1 , 5 - naphthyridinyl , benzofuryl ( such as , but 
not limited to , 3 - , 4 - , 5 - , 6 - and 7 - benzofuryl ) , 2 , 3 - dihyd 
robenzofuryl , 1 , 2 - benzisoxazolyl , benzothienyl ( such as , but 
not limited to , 3 - , 4 - , 5 - , 6 - , and 7 - benzothienyl ) , benzox 
azolyl , benzothiazolyl ( such as , but not limited to , 2 - benzo 
thiazolyl and 5 - benzothiazolyl ) , purinyl , benzimidazolyl , 
benztriazolyl , thioxanthinyl , carbazolyl , carbolinyl , acridi 
nyl , pyrrolizidinyl , and quinolizidinyl . 
[ 0094 ] The aforementioned listing of heterocyclyl and 
heteroaryl moieties is intended to be representative and not 
limiting . 
[ 0095 ] As used herein , the term “ substituted ” means that 
an atom or group of atoms has replaced hydrogen as the 
substituent attached to another group . 
[ 0096 ] For aryl , aryl - ( C , - CzJalkyl and heterocyclyl 
groups , the term “ substituted ” as applied to the rings of these 
groups refers to any level of substitution , for example , 
mono - , di - , tri - , tetra - , or penta - substitution , where such 
substitution is permitted . The substituents are independently 
selected , and substitution may be at any chemically acces 
sible position . In one embodiment , the substituents vary in 
number between one and four . In another embodiment , the 
substituents vary in number between one and three . In yet 
another embodiment , the substituents vary in number 
between one and two . In yet another embodiment , the 
substituents are independently selected from the group con 
sisting of C . , alkyl , — OH , C - , alkoxy , halo , amino , acet 
amido and nitro . As used herein , where a substituent is an 
alkyl or alkoxy group , the carbon chain may be branched , 
straight or cyclic , in particular , straight . 
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[ 0104 ] In certain embodiments , the compounds of the 
invention exhibit whole - cell antibiotic activity . In other 
embodiments , the compounds modulate an extracellular 
enzyme , do not contain a reactive warhead susceptible to 
cleavage , and their target does not act on highly variable 
substrates . Without wishing to be limited by any theory , the 
molecular resistance mechanisms of efflux pumps , rapid 
chemical inactivation , and target substrate modification may 
be ineffective against the compounds of the invention . 
Compounds and Compositions 
[ 0105 ] The invention includes a compound of formula I , 
or a salt or solvate thereof : 
[ 0097 ] In this disclosure , “ comprises , " " comprising , " 
" containing ” and “ having ” and the like can have the mean 
ing ascribed to them in U . S . Patent law and can mean 
“ includes , ” “ including ” and the like ; " consisting essentially 
of or " consists essentially ” likewise has the meaning 
ascribed in U . S . Patent law and the term is open - ended , 
allowing for the presence of more than that which is recited 
so long as basic or novel characteristics of that which is 
recited is not changed by the presence of more than that 
which is recited , but excludes prior art embodiments . 
[ 0098 ] Throughout this disclosure , various aspects of the 
invention can be presented in a range format . It should be 
understood that the description in range format is merely for 
convenience and brevity and should not be construed as an 
inflexible limitation on the scope of the invention . Accord 
ingly , the description of a range should be considered to 
have specifically disclosed all the possible sub - ranges as 
well as individual numerical values within that range . For 
example , description of a range such as from 1 to 6 should 
be considered to have specifically disclosed sub - ranges such 
as from 1 to 3 , from 1 to 4 , from 1 to 5 , from 2 to 4 , from 
2 to 6 , from 3 to 6 etc . , as well as individual numbers within 
that range , for example , 1 , 2 , 2 . 7 , 3 , 4 , 5 , 5 . 1 , 5 . 3 , 5 . 5 , and 
6 . This applies regardless of the breadth of the range . 
[ 0099 ] The invention is based , at least in part , on the 
unexpected identification of novel small molecule inhibitors 
of N - acetylglucosaminidases . In certain embodiments , the 
compounds of the invention inhibit bacterial autolysins . 
[ 0100 ] In one embodiment , the compounds of the inven 
tion are active against Gram - positive bacteria . In another 
embodiment , the Gram - positive bacterium is selected from 
the group consisting of Streptococcus sp . , Staphylococcus 
sp . , Enterococcus sp . , Corynebacterium sp . , Listeria sp . , 
Clostridium sp . and Bacillus sp . In yet another embodiment , 
the Gram - positive bacterium is Clostridium difficile ( now 
Peptoclostridium difficile , Streptococcus pneumoniae , 
Staphylococcus aureus , vancomycin intermediate resistance 
S . aureus ( VISA ) , Enterococcus faecalis , vancomycin resis 
tant enterococci ( VRE ) . Streptococcus pyogenes , Bacillus 
anthracis , Corynebacterium diphtheria or Bacillus cereus . 
[ 0101 ] In another embodiment , the compounds of the 
invention are active against Gram - negative bacteria . In 
another embodiment , the Gram - negative bacterium is 
selected from the group consisting of Salmonella sp . , 
Escherichia sp . , Klebsiella sp . , Acinetobacter sp . , 
Pseudomonas sp . , Vibrio sp . and Enterobacter sp . In yet 
another embodiment , the Gram - negative bacterium is Sal 
monella enterica , Salmonella typhii , Escherichia coli , Kleb 
siella pneumoniae . Acinetobacter baumannii or Pseudomo 
nas aerugenosa . 
[ 0102 ] In one embodiment , compounds of formula I fgkc , 
fgkb , rgba , fgoa , fgka and fgna are effective against B . 
subtilis Lyt G In another embodiment , compounds of for 
mula I fgkc , fgbb and fgbc are active against S . pneumoniae . 
In yet another embodiment , compounds of formula I are 
fgba and fgqa and are active against S . aureus . In still 
another embodiment , the compound of formula I is fgna and 
is active against C . difficile . 
[ 0103 ] As demonstrated herein , the compounds of the 
invention inhibit GlcNAcases , such as bacterial GlcNA 
cases . For example , compound BI .fgba ( Scheme 1 ) inhibits 
the GlcNAcase LytG , and has concentration - dependent bac 
teriostatic activity in the bacterial strain B . subtilis . 
o Rz 
RaN mo RS 
wherein in compound I : 
[ 0106 ] R , is selected from the group consisting of aryl 
and heteroaryl , wherein the aryl or heteroaryl group is 
optionally substituted with 1 - 3 substituents indepen 
dently selected from the group consisting of C - C6 
alkyl , OH , O ( C . - C . alkyl ) , F , C1 , Br , I , NO , , CEO ) 
H , CEO ) OH , C ( = O ) O ( C - C . alkyl ) , C ( = O ) 
NH2 , C O ) NH ( C , - C6 alkyl ) , and C ( = O ) N ( C , 
Co alkyl ) ( C . - C . alkyl ) ; 
[ 0107 ] R is selected from the group consisting of CZ - C6 
alkyl , Cz - Cg cycloalkyl , allyl , propargyl , homopropar 
gyl , aryl , heteroaryl , arylalkyl , and heteroarylalkyl , 
wherein the alkyl , cycloalkyl , aryl , heteroaryl , arylalkyl 
or heteroarylalkyl group is optionally substituted with 
1 - 3 substituents independently selected from the group 
consisting of C , - Co alkyl , OH , O ( C2 - C6 alkyl ) , F , C1 , 
Br , I , NO2 , C = O ) H , C ( O ) OH , CEO ) O ( C . - C . alkyl ) , C ( O ) NH2 , C ( O ) NH ( C - C . 
alkyl ) , and CEO ) N ( C1 - C6 alkyl ) ( C1 - Co alkyl ; [ 0108 ] Rz is selected from the group consisting of C3 - C , 
cycloalkyl , aryl and heteroaryl , wherein the cycloalkyl , 
aryl or heteroaryl group is optionally substituted with 
1 - 3 substituents independently selected from the group 
consisting of C , - C . alkyl , OH , O ( C , - C6 alkyl ) , F , CI , 
Br , I , NO2 , CEO ) H , - C ( O ) OH , CEO ) O 
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( C - Co alkyl ) , C ( O ) NH2 , CEO ) NH ( CZ - C6 
alkyl ) , and C ON ( C1 - C6 alkyl ) ( C1 - C6 alkyl ) ; [ 0109 ] R4 is selected from the group consisting of C , - C6 
alkyl , C3 - C , cycloalkyl , arylalkyl and heteroarylalkyl , 
wherein the alkyl , cycloalkyl , arylalkyl or heteroaryl 
alkyl group is optionally substituted with 1 - 3 substitu 
ents independently selected from the group consisting 
of C , - C6 alkyl , OH , O ( C . - C . alkyl ) , F , C1 , Br , I , NO2 , 
CO )H , COOH , CEO ) O ( C - C . alkyl ) , 
C ( O ) NH2 , CEO ) NH ( C . - C . alkyl ) , and 
CEO ) N ( C , - C alkyl ) ( C , - C alkyl ) ; and [ 0110 ] Rs is H or methyl . 
[ 0111 ] In certain embodiments , in R , has at least one 
substituent ortho to the carbonyl group a is selected from the 
group consisting of C , - C , alkyl . OH , O ( C , - Co alkyl ) , F , C1 , 
Br , I , NO2 , CEO ) H , C ( O ) OH , CEO ) O ( C , - C6 
alkyl ) , C ( = O ) NH , , - C ( O ) NH ( C , - Co alkyl ) , and 
- CEO ) N ( C , - C6 alkyl ) ( C1 - C6 alkyl ) . In other embodi 
ments , at least one substituent ortho to the carbonyl group a 
is selected from the group consisting of C ; - C alkyl , OH , 
O ( C , - C alkyl ) , F , C1 , Br and I . In yet other embodiments , 
Rj is selected from the group consisting of phenyl , o - iodo 
phenyl , o - bromophenyl , o - chlorophenyl , o - fluorophenyl , 
0 - methoxyphenyl , p - iodophenyl , p - bromophenyl , p - chloro 
phenyl , p - fluorophenyl and p - methoxyphenyl . 
[ 0112 ] In certain embodiments , R , is selected from the group consisting of C , - C6 alkyl , Cz - Co cycloalkyl , allyl , 
propargyl , homopropargyl , phenyl , heteroaryl , aryl - ( CH2 ) 2 
27 , and heteroaryl - ( CH2 ) 1 - 2 — , wherein the alkyl , 
cycloalkyl , phenyl , heteroaryl , aryl - ( CH2 ) 1 - 2 - , or het 
eroaryl - ( CH2 ) 1 - 2 - group is optionally substituted with 1 - 3 
substituents independently selected from the group consist 
ing of C - C . alkyl , OH , O ( C1 - C alkyl ) , F , C1 , Br , I , and 
NO2 . In other embodiments , R2 is selected from the group 
consisting of C , - C . alkyl , Cz - Co cycloalkyl , allyl , propargyl , 
homopropargyl , phenyl , o - iodophenyl , o - bromophenyl , 
0 - chlorophenyl , o - fluorophenyl , o - methoxyphenyl , p - iodo 
phenyl , p - bromophenyl , p - chlorophenyl , p - fluorophenyl , 
p - methoxyphenyl , benzyl , Ph ( CH2 ) 2 - , Ph2CHCH2 – , and 
Ph ( CH3 ) CH . [ 0113 ] In certain embodiments , Rz is selected from the 
group consisting of C - Co cycloalkyl , phenyl , o - iodophenyl , 
o - bromophenyl , 0 - chlorophenyl , O - fluorophenyl , 
0 - methoxyphenyl , p - iodophenyl , p - bromophenyl , p - chloro 
phenyl , p - fluorophenyl , and p - methoxyphenyl . 
[ 0114 ] In certain embodiments , R4 is selected from the group consisting of C , - C alkyl , Cz - Co cycloalkyl , benzyl , 
and phenyl - ( CH2 ) 2 - , wherein the alkyl , cycloalkyl , phenyl 
or benzyl group is optionally substituted with 1 - 3 substitu 
ents independently selected from the group consisting of 
C - C . alkyl , OH . O ( C , - C alkyl ) , F , C1 , Br , and I . [ 0115 ] In certain embodiments , the compound of formula ( I ) is selected from the group consisting of : 
fgja 
fgbd 
N 
fgkd 
NH 
rgba fgca 
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N 
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NH 
LZ 
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fgka 
qgba 
fgna 
NH 
fhba fgqb 
N N 
fiba fgba 
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ngke ( 69 % ) 
rgna ( 52 % ) 
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Br 
0gkc ( 72 % ) ugkc ( 78 % ) 
7 .
N 
0 
fhka ( 65 % ) 
vgkc ( 53 % ) 
fhkc ( 67 % ) 
faqa 
tgka ( 71 % ) faaAa 
fhqa tgkc ( 74 % ) 
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NH 
fgaEa ( n = 2 ) , fgaFa ( n = 3 ) , 
fgaGa ( n = 4 ) , fgaHa ( n = 5 ) fgqd 
MJ02 
OH 
[ 0116 ] The compounds of the invention have shown anti 
bacterial activity against a variety of Gram - positive and 
Gram - negative bacteria including , but not limited to B . 
subtilis Lyt , S . pneumonia , C . difficile , and S . aureus . 
[ 0117 ] In certain embodiments , the compound of formula 
I is selected from the group consisting of fgkc , fgkb , rgba , 
fgoa , fgka , fgna , fgbb , fgqa and fgbc . In one embodiment , 
the compound is fgkc , fgkb , rgba , fgoa , fgka or fgna . These 
compounds have antibacterial activity against B . subtilis Lyt 
G . In another embodiment , the compound is fgkc , fgbb , or 
fgbc . These compounds have antibacterial activity against S 
pneumoniae . In yet another embodiment , the compound is 
fgba or fgqa . These compounds have antibacterial activity 
against S . aureus . In another embodiment , the compound is 
fgna , which has antibacterial activity against C . difficile . 
[ 0118 ] In certain embodiments , the salt of compound I is 
an acid addition salt and is selected from the group consist ing of sulfate , hydrogen sulfate , hydrochloric , hydrobromic , 
hydriodic , nitric , carbonic , sulfuric , phosphoric , formic , 
acetic , propionic , succinic , glycolic , gluconic , lactic , malic , 
tartaric , citric , ascorbic , glucuronic , maleic , fumaric , pyru 
vic , aspartic , glutamic , benzoic , anthranilic , 4 - hydroxyben 
zoic , phenylacetic , mandelic , embonic ( pamoic ) , methane 
sulfonic , ethanesulfonic , benzenesulfonic , pantothenic , 
trifluoromethanesulfonic , 2 - hydroxyethanesulfonic , p - tolu 
enesulfonic , sulfanilic , cyclohexylaminosulfonic , stearic , 
alginic , 3 - hydroxybutyric , salicylic , galactaric and galactur 
onic acid , and any combinations thereof . 
[ 0119 ] . In certain embodiments , the salt is a base addition 
salt and is selected from the group consisting of calcium , 
magnesium , potassium , sodium , ammonium , zinc , a basic 
amine salt , and any combinations thereof , wherein the basic 
amine is selected from the group consisting of triethylamine , 
diisopropylethylamine , trimethylamine , N , N - dibenzylethyl 
ene - diamine , chloroprocaine , choline , diethanolamine , eth 
ylenediamine , meglumine , procaine and any combinations 
thereof . 
fgaBa 
fgaCa 
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[ 0120 ] The invention further provides a pharmaceutical 
composition comprising at least one compound of the inven 
tion and a pharmaceutically acceptable carrier . In certain 
embodiments , the composition further comprises at least one 
additional antibacterial agent . In other embodiments , the at 
least one additional antibacterial agent comprises at least 
one agent selected from the group consisting of amoxicillin , 
azithromycin , biaxin , biocef , cefaclor , cinoxacin , cipro floxacin , clindamycin , doryx , emgel , enoxacin , fortaz , gati 
floxacin , levofloxacin , linezolid , maxaquin , moxifloxacin , 
neomycin , ofloxacin , penicillin , rifampin , sparfloxacin , 
streptomycin , sulfatrim , tetracycline , trovafloxacin , vanco 
mycin and zotrim . In yet other embodiments , the compound 
and the agent are co - formulated in the composition . 
[ 0121 ] The compounds of the invention may possess one 
or more stereocenters , and each stereocenter may exist 
independently in either the ( R ) or ( S ) configuration . In one 
embodiment , compounds described herein are present in 
optically active or racemic forms . The compounds described 
herein encompass racemic , optically - active , regioisomeric 
and stereoisomeric forms , or combinations thereof that pos 
sess the therapeutically useful properties described herein . 
Preparation of optically active forms is achieved in any 
suitable manner , including by way of non - limiting example , 
by resolution of the racemic form with recrystallization 
techniques , synthesis from optically - active starting materi 
als , chiral synthesis , or chromatographic separation using a 
chiral stationary phase . In one embodiment , a mixture of one 
or more isomer is utilized as the therapeutic compound 
described herein . In another embodiment , compounds 
described herein contain one or more chiral centers . These 
compounds are prepared by any means , including stereose 
lective synthesis , enantioselective synthesis and / or separa 
tion of a mixture of enantiomers and / or diastereomers . 
Resolution of compounds and isomers thereof is achieved by 
any means including , by way of non - limiting example , 
chemical processes , enzymatic processes , fractional crystal 
lization , distillation , and chromatography . 
[ 0122 ] The methods and formulations described herein include the use of N - oxides ( if appropriate ) , crystalline 
forms ( also known as polymorphs ) , solvates , amorphous 
phases , and / or pharmaceutically acceptable salts of com 
pounds having the structure of any compound of the inven 
tion , as well as metabolites and active metabolites of these 
compounds having the same type of activity . Solvates 
include water , ether ( e . g . , tetrahydrofuran , methyl tert - butyl 
ether ) or alcohol ( e . g . , ethanol ) solvates , acetates and the 
like . In one embodiment , the compounds described herein 
exist in solvated forms with pharmaceutically acceptable 
solvents such as water , and ethanol . In another embodiment , 
the compounds described herein exist in unsolvated form . 
[ 0123 ] In one embodiment , the compounds of the inven 
tion exist as tautomers . All tautomers are included within the 
scope of the compounds recited herein . 
[ 0124 ] In one embodiment , the compounds of the inven 
tion exist as polymorphs . All polymorphs are included 
within the scope of the compounds recited herein . 
[ 0125 ] In one embodiment , compounds described herein 
are prepared as prodrugs ( see for example Hacker , et al . , 
Pharmacology : Principles and Practice . Academic Press . 
Jun . 19 , 2009 . pp . 216 - 217 ) . A “ prodrug ” is an agent 
converted into the parent drug in vivo . In one embodiment , 
upon in vivo administration , a prodrug is chemically con 
verted to the biologically , pharmaceutically or therapeuti 
cally active form of the compound . In another embodiment , 
a prodrug is enzymatically metabolized by one or more steps 
or processes to the biologically , pharmaceutically or thera 
peutically active form of the compound . 
[ 0126 ] In certain embodiments , sites on , for example , the 
aromatic ring portion of compounds of the invention are 
susceptible to various metabolic reactions . Incorporation of 
appropriate substituents on the aromatic ring structures may 
reduce , minimize or eliminate this metabolic pathway . 
Accordingly , in one embodiment , a prodrug is created by 
methods well known in the art , by which the appropriate 
substituent to decrease or eliminate the susceptibility of the 
aromatic ring to metabolic reactions is added , by way of 
example only , a deuterium , a halogen , or an alkyl group . 
[ 0127 ] Compounds described herein also include isotopi 
cally - labeled compounds wherein one or more atoms is 
replaced by an atom having the same atomic number , but an 
atomic mass or mass number different from the atomic mass 
or mass number usually found in nature . Examples of 
isotopes suitable for inclusion in the compounds described 
herein include and are not limited to 2H , 3H , 11C , 130 , 14C , 36C1 , 18F , 1231 , 1231 , 13N , 15N , 150 , 170 , 180 , 32P , and 35S . In 
one embodiment , isotopically - labeled compounds are useful 
in drug and / or substrate tissue distribution studies . In 
another embodiment , substitution with heavier isotopes such 
as deuterium affords greater metabolic stability ( for 
example , increased in vivo half - life or reduced dosage 
requirements ) . In yet another embodiment , substitution with 
positron emitting isotopes , such as 11c , 18F , 150 , and 13N , is 
useful in Positron Emission Topography ( PET ) studies for 
examining substrate receptor occupancy . Isotopically - la 
beled compounds are prepared by any suitable method or by 
processes using an appropriate isotopically - labeled reagent 
in place of the non - labeled reagent otherwise employed . 
[ 0128 ] In one embodiment , the compounds described 
herein are labeled by other means , including , but not limited 
to , the use of chromophores or fluorescent moieties , biolu 
minescent labels , or chemiluminescent labels . 
Synthesis 
[ 0129 ] The compounds described herein , and other related 
compounds having different substituents , are synthesized 
using techniques and materials described herein and tech 
niques known in the art such as those described , for 
example , in Fieser & Fiescr ’ s Reagents for Organic Synthe 
sis , Volumes 1 - 17 ( John Wiley and Sons , 1991 ) ; Rodd ' s 
Chemistry of Carbon Compounds , Volumes 1 - 5 and Supple 
ments ( Elsevier Science Publishers , 1989 ) ; Organic Reac 
tions . Volumes 1 - 40 ( John Wiley and Sons , 1991 ) , Larock ' s 
Comprehensive Organic Transformations ( VCH Publishers 
Inc . , 1989 ) . March , Advanced Organic Chemistry 4th Ed . , 
( Wiley 1992 ) ; Carey & Sundberg , Advanced Organic Chem 
istry 4th Ed . , Vols . A and B ( Plenum 2000 , 2001 ) , and Green 
& Wuts , Protective Groups in Organic Synthesis 3rd Ed , 
( Wiley 1999 ) ( all of which are incorporated by reference for 
such disclosure ) . General methods for the preparation of 
compounds as described herein are modified by the use of 
appropriate reagents and conditions , for the introduction of 
the various moieties found in the formula as provided herein . 
[ 0130 ] Compounds described herein are synthesized using 
any suitable procedures starting from compounds that are 
available from commercial sources , or are prepared using 
procedures described herein or known in the art . 
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[ 0131 ] In one embodiment , reactive functional groups , 
such as hydroxyl , amino , imino , thio or carboxy groups , are 
protected in order to avoid their unwanted participation in 
reactions . Protecting groups are used to block some or all of 
the reactive moieties and prevent such groups from partici 
pating in chemical reactions until the protective group is 
removed . In another embodiment , each protective group is 
removable by a different means . Protective groups that are 
cleaved under totally disparate reaction conditions fulfill the 
requirement of differential removal . 
[ 0132 ] In one embodiment , protective groups are removed 
by acid , base , reducing conditions ( such as , for example , 
hydrogenolysis ) , and / or oxidative conditions . Groups such 
as trityl , dimethoxytrityl , acetal and t - butyldimethylsilyl are 
acid labile and are used to protect carboxy and hydroxy 
reactive moieties in the presence of amino groups protected 
with Cbz groups , which are removable by hydrogenolysis , 
and Fmoc groups , which are base labile . Carboxylic acid and 
hydroxy reactive moieties are blocked with base labile 
groups such as , but not limited to , methyl , ethyl , and acetyl , 
in the presence of amines that are blocked with acid labile 
groups , such as t - butyl carbamate , or with carbamates that 
are both acid and base stable but hydrolytically removable . 
[ 0133 ] In one embodiment , carboxylic acid and hydroxy 
reactive moieties are blocked with hydrolytically removable 
protective groups such as the benzyl group , while amine 
groups capable of hydrogen bonding with acids are blocked 
with base labile groups such as Fmoc . Carboxylic acid 
reactive moieties are protected by conversion to simple ester 
compounds as exemplified herein , which include conversion 
to alkyl esters , or are blocked with oxidatively - removable 
protective groups such as 2 , 4 - dimethoxy benzyl , while co 
existing amino groups are blocked with fluoride labile silyl 
carbamates . 
[ 0134 ] Allyl blocking groups are useful in the presence of 
acid - and base - protecting groups since the former are stable 
and are subsequently removed by metal or pi - acid catalysts . 
For example , an allyl - blocked carboxylic acid is deprotected 
with a palladium - catalyzed reaction in the presence of acid 
labile t - butyl carbamate or base - labile acetate amine pro 
tecting groups . Yet another form of protecting group is a 
resin to which a compound or intermediate is attached . As 
long as the residue is attached to the resin , that functional 
group is blocked and does not react . Once released from the 
resin , the functional group is available to react . 
[ 0135 ] Typically blocking protecting groups may be 
selected from : 
Fmoc 
[ 0136 ] Other protecting groups , plus a detailed description 
of techniques applicable to the creation of protecting groups 
and their removal are described in Greene & Wuts , Protec 
tive Groups in Organic Synthesis , 3rd Ed . , John Wiley & 
Sons , New York , N . Y . , 1999 , and Kocienski , Protective 
Groups , Thieme Verlag , New York , N . Y . , 1994 , which are 
incorporated herein by reference for such disclosure . 
[ 0137 ] The compounds of the invention may be prepared 
according to the general methodology illustrated in the 
synthetic schemes described below . The reagents and con 
ditions described herein may be modified to allow the 
preparation of the compounds of the invention , and such 
modifications are known to those skilled in the art . The 
scheme included herein are intended to illustrate but not 
limit the chemistry and methodologies that one skilled in the 
art may use to make compounds of the invention . 
Salts 
allyl Bn 
[ 0138 ] The compounds described herein may form salts 
with acids , and such salts are included in the present 
invention . In one embodiment , the salts are pharmaceuti 
cally acceptable salts . The term “ salts ” embraces addition 
salts of free acids that are useful within the methods of the 
invention . The term “ pharmaceutically acceptable salt ” 
refers to salts that possess toxicity profiles within a range 
that affords utility in pharmaceutical applications . Pharma 
ceutically unacceptable salts may nonetheless possess prop 
erties such as high crystallinity , which have utility in the 
practice of the present invention , such as for example utility 
in process of synthesis , purification or formulation of com 
pounds useful within the methods of the invention . 
[ 0139 ] Suitable pharmaceutically acceptable acid addition 
salts may be prepared from an inorganic acid or from an 
organic acid . Examples of inorganic acids include hydro 
O 
alloc 
Cbz 
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chloric , hydrobromic , hydriodic , nitric , carbonic , sulfuric 
( including sulfate and hydrogen sulfate ) , and phosphoric 
acids ( including hydrogen phosphate and dihydrogen phos 
phate ) . Appropriate organic acids may be selected from 
aliphatic , cycloaliphatic , aromatic , araliphatic , heterocyclic , 
carboxylic and sulfonic classes of organic acids , examples of 
which include formic , acetic , propionic , succinic , glycolic , 
gluconic , lactic , malic , tartaric , citric , ascorbic , glucuronic , 
maleic , malonic , saccharin , fumaric , pyruvic , aspartic , glu 
tamic , benzoic , anthranilic , 4 - hydroxybenzoic , phenylacetic , 
mandelic , embonic ( pamoic ) , methanesulfonic , ethanesulfo 
nic , benzenesulfonic , pantothenic , trifluoromethanesulfonic , 
2 - hydroxyethanesulfonic , p - toluenesulfonic , sulfanilic , 
cyclohexylaminosulfonic , stearic , alginic , B - hydroxybu 
tyric , salicylic , galactaric and galacturonic acid . 
[ 0140 ] Suitable pharmaceutically acceptable base addition 
salts of compounds of the invention include , for example , 
metallic salts including alkali metal , alkaline earth metal and 
transition metal salts such as , for example , calcium , mag 
nesium , potassium , sodium and zinc salts . Pharmaceutically 
acceptable base addition salts also include organic salts 
made from basic amines such as , for example , N , N - diben 
zylethylene - diamine , chloroprocaine , choline , dietha 
nolamine , ethylenediamine , meglumine ( N - methylglu 
camine ) and procaine . All of these salts may be prepared 
from the corresponding compound by reacting , for example , 
the appropriate acid or base with the compound . 
Klebsiella sp . , Acinetobacter sp . , Pseudomonas sp . , Vibrio 
sp . and Enterobacter sp . In yet another embodiment , the 
Gram - negative bacterium is Salmonella enterica , Salmo 
nella typhii , Escherichia coli . Klebsiella pneumoniae , 
Acinetobacter baumannii or Pseudomonas aerugenosa . 
10146 ] In yet other embodiments , the subject is further 
administered at least one additional antibacterial agent . In 
yet other embodiments , the at least one additional antibac 
terial agent comprises at least one agent selected from the 
group consisting of amoxicillin , azithromycin , biaxin , bio 
cef , cefaclor , cinoxacin , ciprofloxacin , clindamycin , doryx , 
emgel , enoxacin , fortaz , gatifloxacin , levofloxacin , lin 
ezolid , maxaquin , moxifloxacin , neomycin , ofloxacin , peni 
cillin , rifampin , sparfloxacin , streptomycin , sulfatrim , tetra 
cycline , trovafloxacin , vancomycin and zotrim . 
[ 0147 ] In certain embodiments , the compound of the 
invention and the additional agent are separately adminis 
tered to the subject . In other embodiments , the compound 
and the agent are co - administered to the subject . In yet other 
embodiments , the compound and the agent are co - formu 
lated . In yet other embodiments , the compound is adminis 
tered to the subject by at least one route selected from the 
group consisting of intravenous , oral , inhalational , rectal , 
vaginal , transdermal , intranasal , buccal , sublingual , parent 
eral , intrathecal , intragastrical , ophthalmic , pulmonary and 
topical routes . In yet other embodiments , the subject is a 
mammal . In yet other embodiments , the mammal is a 
human . In yet other embodiments , the method further com 
prises procuring the at least one compound of the invention 
for the subject . 
Kits 
[ 0148 ] The invention includes a kit comprising a com 
pound of the invention , an applicator , and an instructional 
material for use thereof . The instructional material included 
in the kit comprises instructions for preventing or treating a 
disorder or disease contemplated within the invention in a 
subject . The instructional material recites the amount of , and 
frequency with which , the compound of the invention 
should be administered to the subject . In certain embodi 
ments , the kit further comprises at least one additional 
antibacterial agent . 
Methods 
[ 0141 ] The invention provides a method of inhibiting a 
N - acetylglucosaminidase in a cell . In certain embodiments , 
the method comprises contacting the cell with at least one 
compound of the invention . In other embodiments , the cell 
is a bacterium , a fungus or a cancer cell . In yet other 
embodiments , the N - acetylglucosaminidase comprises an 
autolysin . 
[ 0142 ] The invention also provides a method of inhibiting 
a N - acetylglucosaminidase in the cytosol of a cell . In certain 
embodiments , the method comprises contacting the 
N - acetylglucosaminidase with at least one compound of the 
invention . In other embodiments , the N - acetylglucosamini 
dase is derived from a bacterium , a fungus or a cancer cell . 
[ 0143 ] The invention further provides a method of treating 
or preventing a bacterial infection in a subject in need 
thereof . In certain embodiments , the method comprises 
administering a therapeutically effective amount of at least 
one compound of the invention to the subject . 
[ 0144 ] In one embodiment of the methods of the invention 
described above , the bacterium is Gram - positive . In another 
embodiment , the Gram - positive bacterium is selected from 
the group consisting of Streptococcus sp . , Staphylococcus 
sp . , Enterococcus sp . , Corynebacterium sp . , Listeria sp . , 
Clostridium sp . and Bacillus sp . In yet another embodiment , 
the Gram - positive bacterium is Clostridium difficile ( also 
currently known as Peptoclostridium difficile ) , Streptococ 
cus pneumoniae , Staphylococcus aureus , vancomycin inter 
mediate resistance S . aureus ( VISA ) , Enterococcus faecalis , 
vancomycin resistant enterococci ( VRE ) , Streptococcus 
pyogenes , Bacillus anthracis , Corynebacterium diphtheria 
or Bacillus cereus . 
[ 0145 ] In one embodiment of the methods of the invention 
described above , the bacterium is Gram - negative . In another 
embodiment , the Gram - negative bacterium is selected from 
the group consisting of Salmonella sp . , Escherichia sp . , 
Combination Therapies 
[ 0149 ] In certain embodiments , the compounds of the 
invention are useful in the methods of the invention in 
combination with at least one additional agent useful for 
treating or preventing bacterial infection . This additional 
agent may comprise compounds identified herein or com 
pounds , e . g . , commercially available compounds , known to 
treat , prevent or reduce the symptoms of bacterial infection . 
[ 0150 ] Non - limiting examples of additional agents con 
templated within the invention include amoxicillin , azithro 
mycin , biaxin , biocef , cefaclor , cinoxacin , ciprofloxacin , 
clindamycin , doryx , emgel , enoxacin , fortaz , gatifloxacin , 
levofloxacin , linezolid , maxaquin , moxifloxacin , neomycin , 
ofloxacin , penicillin , rifampin , sparfloxacin , streptomycin , 
sulfatrim , tetracycline , trovafloxacin , vancomycin and 
zotrim . [ 0151 ] A synergistic effect may be calculated , for 
example , using suitable methods such as , for example , the 
Sigmoid - Emor equation ( Holford & Scheiner , 19981 , Clin . 
Pharmacokinet . 6 : 429 - 453 ) , the equation of Loewe addi 
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tivity ( Loewe & Muischnek , 1926 , Arch . Exp . Pathol Phar 
macol . 114 : 313 - 326 ) and the median - effect equation ( Chou 
& Talalay , 1984 , Adv . Enzyme Regul . 22 : 27 - 55 ) . Each 
equation referred to above may be applied to experimental 
data to generate a corresponding graph to aid in assessing the 
effects of the drug combination . The corresponding graphs 
associated with the equations referred to above are the 
concentration - effect curve , isobologram curve and combi 
nation index curve , respectively . 
Administration / Dosage / Formulations 
[ 0152 ] The regimen of administration may affect what 
constitutes an effective amount . The therapeutic formula 
tions may be administered to the subject either prior to or 
after the onset of a disease or disorder contemplated in the 
invention . Further , several divided dosages , as well as 
staggered dosages may be administered daily or sequen 
tially , or the dose may be continuously infused , or may be a 
bolus injection . Further , the dosages of the therapeutic 
formulations may be proportionally increased or decreased 
as indicated by the exigencies of the therapeutic or prophy 
lactic situation . [ 0153 ] Administration of the compositions of the present 
invention to a patient , in particular a mammal , more par 
ticularly a human , may be carried out using known proce 
dures , at dosages and for periods of time effective to treat a 
disease or disorder contemplated in the invention . An effec 
tive amount of the therapeutic compound necessary to 
achieve a therapeutic effect may vary according to factors 
such as the state of the disease or disorder in the patient ; the 
age , sex , and weight of the patient ; and the ability of the 
therapeutic compound to treat a disease or disorder contem 
plated in the invention . Dosage regimens may be adjusted to 
provide the optimum therapeutic response . For example , 
several divided doses may be administered daily or the dose 
may be proportionally reduced as indicated by the exigen 
cies of the therapeutic situation . A non - limiting example of 
an effective dose range for a therapeutic compound of the 
invention is from about 1 and 5 , 000 mg / kg of body weight / 
per day . One of ordinary skill in the art would be able to 
study the relevant factors and make the determination 
regarding the effective amount of the therapeutic compound 
without undue experimentation . 
[ 0154 ] Actual dosage levels of the active ingredients in the 
pharmaceutical compositions of this invention may be var 
ied so as to obtain an amount of the active ingredient that is 
effective to achieve the desired therapeutic response for a 
particular patient , composition , and mode of administration , 
without being toxic to the patient . 
[ 0155 ] In particular , the selected dosage level depends 
upon a variety of factors including the activity of the 
particular compound employed , the time of administration , 
the rate of excretion of the compound , the duration of the 
treatment , other drugs , compounds or materials used in 
combination with the compound , the age , sex , weight , 
condition , general health and prior medical history of the 
patient being treated , and like factors well , known in the 
medical arts . 
101561 . A medical doctor , e . g . , physician or veterinarian , 
having ordinary skill in the art may readily determine and 
prescribe the effective amount of the pharmaceutical com - 
position required . For example , the physician or veterinarian 
could start doses of the compounds of the invention 
employed in the pharmaceutical composition at levels lower 
than that required in order to achieve the desired therapeutic 
effect and gradually increase the dosage until the desired 
effect is achieved . 
101571 . In particular embodiments , it is especially advan 
tageous to formulate the compound in dosage unit form for 
ease of administration and uniformity of dosage . Dosage 
unit form as used herein refers to physically discrete units 
suited as unitary dosages for the patients to be treated ; each 
unit containing a predetermined quantity of therapeutic 
compound calculated to produce the desired therapeutic 
effect in association with the required pharmaceutical 
vehicle . The dosage unit forms of the invention are dictated 
by and directly dependent on ( a ) the unique characteristics 
of the therapeutic compound and the particular therapeutic 
effect to be achieved , and ( b ) the limitations inherent in the 
art of compounding / formulating such a therapeutic com 
pound for the treatment of a disease or disorder contem 
plated in the invention . 
[ 0158 ] In one embodiment , the compositions of the inven 
tion are formulated using one or more pharmaceutically 
acceptable excipients or carriers . In one embodiment , the 
pharmaceutical compositions of the invention comprise a 
therapeutically effective amount of a compound of the 
invention and a pharmaceutically acceptable carrier . 
[ 0159 ] The carrier may be a solvent or dispersion medium 
containing , for example , water , ethanol , polyol ( for example , 
glycerol , propylene glycol , and liquid polyethylene glycol , 
and the like ) , suitable mixtures thereof , and vegetable oils . 
The proper fluidity may be maintained , for example , by the 
use of a coating such as lecithin , by the maintenance of the 
required particle size in the case of dispersion and by the use 
of surfactants . Prevention of the action of microorganisms 
may be achieved by various antibacterial and antifungal 
agents , for example , parabens , chlorobutanol , phenol , ascor 
bic acid , thimerosal , and the like . In many cases , it is 
advantageous to include isotonic agents , for example , sug 
ars , sodium chloride , or polyalcohols such as mannitol and 
sorbitol , in the composition . Prolonged absorption of the 
injectable compositions may be brought about by including 
in the composition an agent which delays absorption , for 
example , aluminum monostearate or gelatin . 
( 0160 ] In one embodiment , the compounds / compositions 
of the invention are administered to the patient in dosages 
that range from one to five times per day or more . In another 
embodiment , the compositions of the invention are admin 
istered to the patient in range of dosages that include , but are 
not limited to , once every day , every two , days , every three 
days to once a week , and once every two weeks . It is readily 
apparent to one skilled in the art that the frequency of 
administration of the various combination compositions of 
the invention varies from individual to individual depending 
on many factors including , but not limited to , age , disease or 
disorder to be treated , gender , overall health , and other 
factors . Thus , the invention should not be construed to be limited to any particular dosage regime and the precise 
dosage and composition to be administered to any patient is 
determined by the attending physical taking all other factors 
about the patient into account . 
0161 ] Compounds of the invention for administration 
may be in the range of from about 1 Og to about 10 , 000 mg , 
about 20 Og to about 9 , 500 mg , about 40 Og to about 9 . 000 
mg , about 75 Og to about 8 , 500 mg , about 150 g to about 
7 , 500 mg , about 200 g to about 7 , 000 mg , about 3050 Dg 
to about 6 , 000 mg , about 500 Og to about 5 , 000 mg , about 
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powder or aerosolized formulations for inhalation , compo 
sitions and formulations for intravesical administration and 
the like . It should be understood that the formulations and 
compositions that would be useful in the present invention 
are not limited to the particular formulations and composi 
tions that are described herein . 
750 Og to about 4 . 000 mg , about 1 mg to about 3 , 000 mg , 
about 10 mg to about 2 , 500 mg , about 20 mg to about 2 . 000 
mg , about 25 mg to about 1 , 500 mg , about 30 mg to about 
1 . 000 mg , about 40 mg to about 900 mg , about 50 mg to 
about 800 mg , about 60 mg to about 750 mg , about 70 mg 
to about 600 mg , about 80 mg to about 500 mg , and any and 
all whole or partial increments therebetween . 
[ 0162 ] In some embodiments , the dose of a compound of 
the invention is from about 1 mg and about 2 , 500 mg . In 
some embodiments , a dose of a compound of the invention 
used in compositions described herein is less than about 
10 , 000 mg , or less than about 8 , 000 mg , or less than about 
6 , 000 mg , or less than about 5 , 000 mg , or less than about 
3 , 000 mg , or less than about 2 , 000 mg , or less than about 
1 . 000 mg , or less than about 500 mg , or less than about 200 
mg , or less than about 50 mg . Similarly , in some embodi 
ments , a dose of a second compound as described herein is 
less than about 1 , 000 mg , or less than about 800 mg , or less 
than about 600 mg , or less than about 500 mg , or less than 
about 400 mg , or less than about 300 mg , or less than about 
200 mg , or less than about 100 mg , or less than about 50 mg , 
or less than about 40 mg , or less than about 30 mg , or less 
than about 25 mg , or less than about 20 mg , or less than 
about 15 mg , or less than about 10 mg , or less than about 5 
mg , or less than about 2 mg , or less than about 1 mg , or less 
than about 0 . 5 mg , and any and all whole or partial incre 
ments thereof . 
[ 0163 ] In one embodiment , the present invention is directed to a packaged pharmaceutical composition com 
prising a container holding a therapeutically effective 
amount of a compound of the invention , alone or in com 
bination with a second pharmaceutical agent ; and instruc 
tions for using the compound to treat , prevent , or reduce one 
or more symptoms of a disease or disorder contemplated in 
the invention . 
[ 0164 ] Formulations may be employed in admixtures with 
conventional excipients , i . e . , pharmaceutically acceptable 
organic or inorganic carrier substances suitable for oral , 
parenteral , nasal , intravenous , subcutaneous , enteral , or any 
other suitable mode of administration , known to the art . The 
pharmaceutical preparations may be sterilized and if desired 
mixed with auxiliary agents , e . g . , lubricants , preservatives , 
stabilizers , wetting agents , emulsifiers , salts for influencing 
osmotic pressure buffers , coloring , flavoring and / or aromatic 
substances and the like . They may also be combined where 
desired with other active agents , e . g . , other analgesic agents . 
0165 ) Routes of administration of any of the composi 
tions of the invention include oral , nasal , rectal , intravaginal , 
parenteral , buccal , sublingual or topical . The compounds for 
use in the invention may be formulated for administration by 
any suitable route , such as for oral or parenteral , for 
example , transdermal , transmucosal ( e . g . , sublingual , lin 
gual , ( trans ) buccal , ( trans ) urethral , vaginal ( e . g . , trans - and 
perivaginally ) , ( intra ) nasal and ( trans ) rectal ) , intravesical , intrapulmonary , intraduodenal , intragastrical , intrathecal , 
subcutaneous , intramuscular , intradermal , intra - arterial , 
intravenous , intrabronchial , inhalation , and topical admin 
istration . 
[ 0166 ] Suitable compositions and dosage forms include , 
for example , tablets , capsules , caplets , pills , gel caps , tro 
ches , dispersions , suspensions , solutions , syrups , granules , 
beads , transdermal patches , gels , powders , pellets , magmas , 
lozenges , creams , pastes , plasters , lotions , discs , supposito - 
ries , liquid sprays for nasal or oral administration , dry 
Oral Administration 
[ 0167 ] For oral application , particularly suitable are tab 
lets , dragees , liquids , drops , suppositories , or capsules , 
caplets and gelcaps . The compositions intended for oral use 
may be prepared according to any method known in the art 
and such compositions may contain one or more agents 
selected from the group consisting of inert , non - toxic phar 
maceutically excipients that are suitable for the manufacture 
of tablets . Such excipients include , for example an inert 
diluent such as lactose ; granulating and disintegrating agents 
such as cornstarch ; binding agents such as starch ; and 
lubricating agents such as magnesium stearate . The tablets 
may be uncoated or they may be coated by known tech 
niques for elegance or to delay the release of the active 
ingredients . Formulations for oral use may also be presented 
as hard gelatin capsules wherein the active ingredient is 
mixed with an inert diluent . 
[ 0168 ] For oral administration , the compounds of the 
invention may be in the form of tablets or capsules prepared 
by conventional means with pharmaceutically acceptable 
excipients such as binding agents ( e . g . , polyvinylpyrroli 
done , hydroxypropylcellulose or hydroxypropylmethylcel 
lulose ) ; fillers ( e . g . , cornstarch , lactose , microcrystalline 
cellulose or calcium phosphate ) ; lubricants ( e . g . , magnesium 
stearate , talc , or silica ) ; disintegrates ( e . g . , sodium starch 
glycollate ) ; or wetting agents ( e . g . , sodium lauryl sulphate ) . 
If desired , the tablets may be coated using suitable methods 
and coating materials such as OPADRYTM film coating 
systems available from Colorcon , West Point , Pa . ( e . g . , 
OPADRYTM OY Type , OYC Type , Organic Enteric OY - P 
Type , Aqueous Enteric OY - A Type , OY - PM Type and 
OPADRYTM White , 32K18400 ) . Liquid preparation for oral 
administration may be in the form of solutions , syrups or 
suspensions . The liquid preparations may be prepared by 
conventional means with pharmaceutically acceptable addi 
tives such as suspending agents ( e . g . , sorbitol syrup , methyl 
cellulose or hydrogenated edible fats ) ; emulsifying agent 
( e . g . , lecithin or acacia ) ; non - aqueous vehicles ( e . g . , almond 
oil , oily esters or ethyl alcohol ) ; and preservatives ( e . g . , 
methyl or propyl p - hydroxy benzoates or sorbic acid ) . 
[ 0169 ] Granulating techniques are well known in the phar 
maceutical art for modifying starting powders or other 
particulate materials of an active ingredient . The powders 
are typically mixed with a binder material into larger per 
manent free - flowing agglomerates or granules referred to as 
a " granulation . ” For example , solvent - using “ wet ” granula 
tion processes are generally characterized in that the pow 
ders are combined with a binder material and moistened 
with water or an organic solvent under conditions resulting 
in the formation of a wet granulated mass from which the 
solvent may then be evaporated . 
0170 ] Melt granulation generally consists in the use of 
materials that are solid or semi - solid at room temperature ( i . e . having a relatively low softening or melting point 
range ) to promote granulation of powdered or other mate 
rials , essentially in the absence of added water or other 
liquid solvents . The low melting solids , when heated to a 
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temperature in the melting point range , liquefy to act as a 
binder or granulating medium . The liquefied solid spreads 
itself over the surface of powdered materials with which it 
is contacted , and on cooling , forms a solid granulated mass 
in which the initial materials are bound together . The result 
ing melt granulation may then be provided to a tablet press 
or be encapsulated for preparing the oral dosage form . Melt 
granulation improves the dissolution rate and bioavailability 
of an active ( i . e . drug ) by forming a solid dispersion or solid 
solution . [ 0171 ] U . S . Pat . No . 5 , 169 , 645 discloses directly com 
pressible wax - containing granules having improved flow 
properties . The granules are obtained when waxes are 
admixed in the melt with certain flow improving additives , 
followed by cooling and granulation of the admixture . In 
certain embodiments , only the wax itself melts in the melt 
combination of the wax ( es ) and additives ( s ) , and in other 
cases both the wax ( es ) and the additives ( s ) melt . 
[ 0172 ] The present invention also includes a multi - layer 
tablet comprising a layer providing for the delayed release of 
one or more compounds of the invention , and a further layer 
providing for the immediate release of a medication for 
treatment of a disease or disorder contemplated in the 
invention . Using a wax / pH - sensitive polymer mix , a gastric 
insoluble composition may be obtained in which the active 
ingredient is entrapped , ensuring its delayed release . 
aqueous or oily suspension or solution . This suspension or 
solution may be formulated according to the known art , and 
may comprise , in addition to the active ingredient , additional 
ingredients such as the dispersing agents , wetting agents , or 
suspending agents described herein . Such sterile injectable 
formulations may be prepared using a non - toxic parenter 
ally - acceptable diluent or solvent , such as water or 1 , 3 
butanediol , for example . Other acceptable diluents and sol 
vents include , but are not limited to , Ringer ' s solution , 
isotonic sodium chloride solution , and fixed oils such as 
synthetic mono - or di - glycerides . Other parentally - adminis 
trable formulations which are useful include those which 
comprise the active ingredient in microcrystalline form , in a 
liposomal preparation , or as a component of a biodegradable 
polymer system . Compositions for sustained release or 
implantation may comprise pharmaceutically acceptable 
polymeric or hydrophobic materials such as an emulsion , an 
ion exchange resin , a sparingly soluble polymer , or a spar 
ingly soluble salt . 
Topical Administration 
Parenteral Administration 
[ 0173 ] As used herein , " parenteral administration ” of a 
pharmaceutical composition includes any route of adminis 
tration characterized by physical breaching of a tissue of a 
subject and administration of the pharmaceutical composi 
tion through the breach in the tissue . Parenteral administra 
tion thus includes , but is not limited to , administration of a 
pharmaceutical composition by injection of the composition , 
by application of the composition through a surgical inci 
sion , by application of the composition through a tissue 
penetrating non - surgical wound , and the like . In particular , 
parenteral administration is contemplated to include , but is 
not limited to , subcutaneous , intravenous , intraperitoneal , 
intramuscular , intrasternal injection , and kidney dialytic 
infusion techniques . 
[ 0174 ] Formulations of a pharmaceutical composition 
suitable for parenteral administration comprise the active 
ingredient combined with a pharmaceutically acceptable 
carrier , such as sterile water or sterile isotonic saline . Such 
formulations may be prepared , packaged , or sold in a form 
suitable for bolus administration or for continuous admin 
istration . Injectable formulations may be prepared , pack 
aged , or sold in unit dosage form , such as in ampules or in 
multidose containers containing a preservative . Formula 
tions for parenteral administration include , but are not 
limited to , suspensions , solutions , emulsions in oily or 
aqueous vehicles , pastes , and implantable sustained - release 
or biodegradable formulations . Such formulations may fur 
ther comprise one or more additional ingredients including , 
but not limited to , suspending , stabilizing , or dispersing 
agents . In one embodiment of a formulation for parenteral 
administration , the active ingredient is provided in dry ( i . e . , 
powder or granular ) form for reconstitution with a suitable 
vehicle ( e . g . , sterile pyrogen - free water ) prior to parenteral 
administration of the reconstituted composition . 
101751 The pharmaceutical compositions may be pre - 
pared , packaged , or sold in the form of a sterile injectable 
[ 0176 ] An obstacle for topical administration of pharma 
ceuticals is the stratum corneum layer of the epidermis . The 
stratum corneum is a highly resistant layer comprised of 
protein , cholesterol , sphingolipids , free fatty acids and vari 
ous other lipids , and includes cornified and living cells . One 
of the factors that limit the penetration rate ( flux ) of a 
compound through the stratum corneum is the amount of the 
active substance that can be loaded or applied onto the skin 
surface . The greater the amount of active substance which is 
applied per unit of area of the skin , the greater the concen 
tration gradient between the skin surface and the lower 
layers of the skin , and in turn the greater the diffusion force 
of the active substance through the skin . Therefore , a for 
mulation containing a greater concentration of the active 
substance is more likely to result in penetration of the active 
substance through the skin , and more of it , and at a more 
consistent rate , than a formulation having a lesser concen 
tration , all other things being equal . 
[ 0177 ] Formulations suitable for topical administration 
include , but are not limited to , liquid or semi - liquid prepa 
rations such as liniments , lotions , oil - in - water or water - in - oil 
emulsions such as creams , ointments or pastes , and solutions 
or suspensions . Topically administrable formulations may , 
for example , comprise from about 1 % to about 10 % ( w / w ) 
active ingredient , although the concentration of the active 
ingredient may be as high as the solubility limit of the active 
ingredient in the solvent . Formulations for topical adminis 
tration may further comprise one or more of the additional 
ingredients described herein . 
10178 ] Enhancers of permeation may be used . These mate 
rials increase the rate of penetration of drugs across the skin . 
Typical enhancers in the art include ethanol , glycerol mono 
laurate , PGML ( polyethylene glycol monolaurate ) , dimeth 
ylsulfoxide , and the like . Other enhancers include oleic acid , 
oleyl alcohol , ethoxydiglycol , laurocapram , alkanecarbox 
ylic acids , dimethylsulfoxide , polar lipids , or N - methyl - 2 
pyrrolidone . 
[ 0179 ] One acceptable vehicle for topical delivery of some 
of the compositions of the invention may contain liposomes . 
The composition of the liposomes and their use are known 
in the art ( for example , see Constanza , U . S . Pat . No . 
6 , 323 , 219 ) . 
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[ 0180 ] In alternative embodiments , the topically active 
pharmaceutical composition may be optionally combined 
with other ingredients such as adjuvants , anti - oxidants , 
chelating agents , surfactants , foaming agents , wetting 
agents , emulsifying agents , viscosifiers , buffering agents , 
preservatives , and the like . In another embodiment , a per 
meation or penetration enhancer is included in the compo 
sition and is effective in improving the percutaneous pen 
etration of the active ingredient into and through the stratum 
corneum with respect to a composition lacking the perme 
ation enhancer . Various permeation enhancers , including 
oleic acid , oleyl alcohol , ethoxydiglycol , laurocapram , 
alkanecarboxylic acids , dimethylsulfoxide , polar lipids , or 
N - methyl - 2 - pyrrolidone , are known to those of skill in the 
art . In another aspect , the composition may further comprise 
a hydrotropic agent , which functions to increase disorder in 
the structure of the stratum corneum , and thus allows 
increased transport across the stratum corneum . Various 
hydrotropic agents such as isopropyl alcohol , propylene 
glycol , or sodium xylene sulfonate , are known to those of 
skill in the art . 
[ 0181 ] The topically active pharmaceutical composition 
should be applied in an amount effective to affect desired 
changes . As used herein " amount effective ” shall mean an 
amount sufficient to cover the region of skin surface where 
a change is desired . An active compound should be present 
in the amount of from about 0 . 0001 % to about 15 % by 
weight volume of the composition . In particular , it is advan 
tageously present in an amount from about 0 . 0005 % to about 
5 % of the composition ; more particularly , it is advanta 
geously present in an amount of from about 0 . 001 % to about 
1 % of the composition . Such compounds may be syntheti 
cally - or naturally derived . 
[ 0184 ] Suppository formulations may be made by com bining the active ingredient with a non - irritating pharma 
ceutically acceptable excipient which is solid at ordinary 
room temperature ( i . e . , about 20° C . ) and which is liquid at 
the rectal temperature of the subject ( i . e . , about 37° C . in a 
healthy human ) . Suitable pharmaceutically acceptable 
excipients include , but are not limited to , cocoa butter , 
polyethylene glycols , and various glycerides . Suppository 
formulations may further comprise various additional ingre 
dients including , but not limited to , antioxidants , and pre 
servatives . 
[ 0185 ] Retention enema preparations or solutions for rec 
tal or colonic irrigation may be made by combining the 
active ingredient with a pharmaceutically acceptable liquid 
carrier . As is well known in the art , enema preparations may 
be administered using , and may be packaged within , a 
delivery device adapted to the rectal anatomy of the subject . 
Enema preparations may further comprise various additional 
ingredients including , but not limited to , antioxidants , and 
preservatives . 
Additional Administration Forms 
[ 0186 ] Additional dosage forms of this invention include 
dosage forms as described in U . S . Pat . Nos . 6 , 340 , 475 ; 
6 , 488 . 962 ; 6 , 451 , 808 ; 5 , 972 , 389 ; 5 , 582 , 837 ; and 5 , 007 , 790 . 
Additional dosage forms of this invention also include 
dosage forms as described in U . S . Patent Applications Nos . 
20030147952 ; 20030104062 ; 20030104053 ; 20030044466 ; 
20030039688 ; and 20020051820 . Additional dosage forms 
of this invention also include dosage forms as described in 
PCT Applications Nos . WO 03 / 35041 ; WO 03 / 35040 ; WO 
03 / 35029 , WO 03 / 35177 ; WO 03 / 35039 ; WO 02 / 96404 ; 
WO 02 / 32416 ; WO 01 / 97783 ; WO 01 / 56544 ; WO 
01 / 32217 ; WO 98 / 55107 WO 98 / 11879 ; WO 97 / 47285 ; WO 
93 / 18755 ; and WO 90 / 11757 . Buccal Administration 
10182 ] A pharmaceutical composition of the invention 
may be prepared , packaged , or sold in a formulation suitable 
for buccal administration . Such formulations may , for 
example , be in the form of tablets or lozenges made using 
conventional methods , and may contain , for example , 0 . 1 to 
20 % ( w / w ) of the active ingredient , the balance comprising 
an orally dissolvable or degradable composition and , option 
ally , one or more of the additional ingredients described 
herein . Alternately , formulations suitable for buccal admin 
istration may comprise a powder or an aerosolized or 
atomized solution or suspension comprising the active ingre 
dient . Such powdered , aerosolized , or aerosolized formula 
tions , when dispersed , preferably have an average particle or 
droplet size in the range from about 0 . 1 to about 200 
nanometers , and may further comprise one or more of the 
additional ingredients described herein . The examples of 
formulations described herein are not exhaustive and it is 
understood that the invention includes additional modifica 
tions of these and other formulations not described herein , 
but which are known to those of skill in the art . 
Controlled Release Formulations and Drug Delivery Systems 
[ 0187 ] In one embodiment , the formulations of the present 
invention may be , but are not limited to , short - term , rapid 
offset , as well as controlled , for example , sustained release , 
delayed release and pulsatile release formulations . 
[ 0188 ] The term sustained release is used in its conven 
tional sense to refer to a drug formulation that provides for 
gradual release of a drug over an extended period of time , 
and that may , although not necessarily , result in substantially 
constant blood levels of a drug over an extended time period . 
The period of time may be as long as a month or more and 
should be a release which is longer that the same amount of 
agent administered in bolus form . 
[ 0189 ] For sustained release , the compounds may be for 
mulated with a suitable polymer or hydrophobic material 
which provides sustained release properties to the com 
pounds . As such , the compounds for use the method of the 
invention may be administered in the form of microparticles , 
for example , by injection or in the form of wafers or discs 
by implantation . 
0190 ] In one embodiment of the invention , the com 
pounds of the invention are administered to a patient , alone 
or in combination with another pharmaceutical agent , using 
a sustained release formulation . 
[ 0191 ] The term delayed release is used herein in its 
conventional sense to refer to a drug formulation that 
Rectal Administration 
[ 0183 ] A pharmaceutical composition of the invention 
may be prepared , packaged , or sold in a formulation suitable 
for rectal administration . Such a composition may be in the 
form of , for example , a suppository , a retention enema 
preparation , and a solution for rectal or colonic irrigation . 
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provides for an initial release of the drug after some delay 
following drug administration and that may , although not 
necessarily , includes a delay of from about 10 minutes up to 
about 12 hours . [ 0192 ] The term pulsatile release is used herein in its 
conventional sense to refer to a drug formulation that 
provides release of the drug in such a way as to produce 
pulsed plasma profiles of the drug after drug administration . 
[ 0193 ] The term immediate release is used in its conven 
tional sense to refer to a drug formulation that provides for 
release of the drug immediately after drug administration . 
[ 0194 ] As used herein , short - term refers to any period of 
time up to and including about 8 hours , about 7 hours , about 
6 hours , about 5 hours , about 4 hours , about 3 hours , about 
2 hours , about 1 hour , about 40 minutes , about 20 minutes , 
or about 10 minutes and any or all whole or partial incre 
ments thereof after drug administration after drug adminis 
tration . 
[ 0195 ] As used herein , rapid - offset refers to any period of 
time up to and including about 8 hours , about 7 hours , about 
6 hours , about 5 hours , about 4 hours , about 3 hours , about 
2 hours , about 1 hour , about 40 minutes , about 20 minutes , 
or about 10 minutes , and any and all whole or partial 
increments thereof after drug administration . 
Dosing 
[ 0196 ] The therapeutically effective amount or dose of a 
compound of the present invention depends on the age , sex 
and weight of the patient , the current medical condition of 
the patient and the progression of a disease or disorder 
contemplated in the invention . The skilled artisan is able to 
determine appropriate dosages depending on these and other 
factors . [ 0197 ] A suitable dose of a compound of the present 
invention may be in the range of from about 0 . 01 mg to 
about 5 , 000 mg per day , such as from about 0 . 1 mg to about 
1 , 000 mg , for example , from about 1 mg to about 500 mg , 
such as about 5 mg to about 250 mg per day . The dose may 
be administered in a single dosage or in multiple dosages , 
for example from 1 to 4 or more times per day . When 
multiple dosages are used , the amount of each dosage may 
be the same or different . For example , a dose of 1 mg per day 
may be administered as two 0 . 5 mg doses , with about a 
12 - hour interval between doses . 
[ 0198 ] It is understood that the amount of compound 
dosed per day may be administered , in non - limiting 
examples , every day , every other day , every 2 days , every 3 
days , every 4 days , or every 5 days . For example , with every 
other day administration , a 5 mg per day dose may be 
initiated on Monday with a first subsequent 5 mg per day 
dose administered on Wednesday , a second subsequent 5 mg 
per day dose administered on Friday , and so on . 
[ 0199 ] In the case wherein the patient ' s status does 
improve , upon the doctor ' s discretion the administration of 
the inhibitor of the invention is optionally given continu 
ously ; alternatively , the dose of drug being administered is 
temporarily reduced or temporarily suspended for a certain 
length of time ( i . e . , a “ drug holiday ” ) . The length of the drug 
holiday optionally varies between 2 days and 1 year , includ 
ing by way of example only , 2 days , 3 days , 4 days , 5 days , 
6 days , 7 days , 10 days , 12 days , 15 days , 20 days , 28 days , 
35 days , 50 days , 70 days , 100 days , 120 days , 150 days , 180 
days , 200 days , 250 days , 280 days , 300 days , 320 days , 350 
days , or 365 days . The dose reduction during a drug holiday 
includes from 10 % - 100 % , including , by way of example 
only , 10 % , 15 % , 20 % , 25 % , 30 % , 35 % , 40 % , 45 % , 50 % , 
55 % , 60 % , 65 % , 70 % , 75 % , 80 % , 85 % , 90 % , 95 % , or 
100 % . 
[ 0200 ] Once improvement of the patient ' s conditions has 
occurred , a maintenance dose is administered if necessary . 
Subsequently , the dosage or the frequency of administration , 
or both , is reduced , as a function of the disease or disorder , 
to a level at which the improved disease is retained . In one 
embodiment , patients require intermittent treatment on a 
long - term basis upon any recurrence of symptoms and / or 
infection . 
[ 0201 ] The compounds for use in the method of the 
invention may be formulated in unit dosage form . The term 
" unit dosage form ” refers to physically discrete units suit 
able as unitary dosage for patients undergoing treatment , 
with each unit containing a predetermined quantity of active 
material calculated to produce the desired therapeutic effect , 
optionally in association with a suitable pharmaceutical 
carrier . The unit dosage form may be for a single daily dose 
or one of multiple daily doses ( e . g . , about 1 to 4 or more 
times per day ) . When multiple daily doses are used , the unit 
dosage form may be the same or different for each dose . 
[ 0202 ] Toxicity and therapeutic efficacy of such therapeu 
tic regimens are optionally determined in cell cultures or 
experimental animals , including , but not limited to , the 
determination of the LD5 , ( the dose lethal to 50 % of the 
population ) and the ED50 ( the dose therapeutically effective 
in 50 % of the population ) . The dose ratio between the toxic 
and therapeutic effects is the therapeutic index , which is 
expressed as the ratio between LDs , and ED 0 . The data 
obtained from cell culture assays and animal studies are 
optionally used in formulating a range of dosage for use in 
human . The dosage of such compounds lies advantageously 
within a range of circulating concentrations that include the 
EDs with minimal toxicity . The dosage optionally varies 
within this range depending upon the dosage form employed 
and the route of administration utilized . 
[ 0203 ] Those skilled in the art will recognize , or be able to 
ascertain using no more than routine experimentation , 
numerous equivalents to the specific procedures , embodi 
ments , claims , and examples described herein . Such equiva 
lents were considered to be within the scope of this invention 
and covered by the claims appended hereto . For example , it 
should be understood , that modifications in reaction condi 
tions , including but not limited to reaction times , reaction 
size / volume , and experimental reagents , such as solvents , 
catalysts , pressures , atmospheric conditions , e . g . , nitrogen 
atmosphere , and reducing / oxidizing agents , with art - recog 
nized alternatives and using no more than routine experi 
mentation , are within the scope of the present application . 
[ 0204 ] It is to be understood that wherever values and 
ranges are provided herein , all values and ranges encom 
passed by these values and ranges , are meant to be encom 
passed within the scope of the present invention . Moreover , 
all values that fall within these ranges , as well as the upper 
or lower limits of a range of values , are also contemplated 
by the present application . 
[ 0205 ] The following examples further illustrate aspects 
of the present invention . However , they are in no way a 
limitation of the teachings or disclosure of the present 
invention as set forth herein . 
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EXAMPLES 
10206 ] . The invention is now described with reference to 
the following Examples . These Examples are provided for 
the purpose of illustration only and the invention should in 
no way be construed as being limited to these Examples , but 
rather should be construed to encompass any and all varia 
tions which become evident as a result of the teaching 
provided herein . 
Materials and Methods 
02071 Compounds were purchased from standard suppli 
ers and used without further purification . Thin layer chro 
matography was carried out on Merck silica gel 60 F254 
precoated glass plates . Spots were detected by UV light and 
immersion in p - anisaldehyde stain or potassium permangan 
ate stain . Evaporation of solvents was performed under 
reduced pressure at 30 - 40° C . NMR spectra were recorded 
on Bruker Avance III HD Ascend 600 MHz and Bruker 
Avance Ultra - Shield 400 MHz . ' H , 13C , COSY , HSQC and 
13C - DEPT135 were referenced to residual solvent peaks . 
The coupling constants are given in [ Hz ] and chemical shifts 
in ( ppm ) . Electrospray ionization ( ESI ) and fast atom bom 
bardment ( FAB ) mass spectra were obtained using JEOL 
JMS - 600H double focusing magnetic sector mass spectrom 
eter for HRMS and Thermo LCQ Deca XP Max ion trap 
mass spectrometer with Shimadzu HPLC system for LRMS 
in positive mode . The Ugi products as well as the glycosyl 
triazoles may exist as mixtures of rotamers ( and diastereo 
meric mixtures in the case of the triazoles ) , resulting in 
multiple peaks in the NMR spectra . Compounds may also 
exist as mixtures of cis / trans amide isomers , resulting in 
multiple peaks in the NMR spectra . Partial assignments are 
provided . 
General Procedure for ‘ Click ’ Reaction : 
[ 0209 ] The reactions were run using stock solutions of the 
2 - N - acetylamido - 2 - deoxy - f - D - glucopyranosyl azide ( Hong , 
et al . , 2007 , J . Am . Chem . Soc . 129 : 10966 - 7 ) , the catalyst 
system and the solvent mixture . 
[ 0210 ] For a 20 mg scale of ( 1 ) ( 0 . 081 mmol ) : The 
Ugi - derived dipeptide ( 0 . 11 mmol , 1 . 3 eq . ) was dissolved in 
a 1 : 1 MeCN / H2O solution ( 4 . 05 mL , 26 mM ) . To this 
solution CuSO4 . H2O ( 10 uL of 0 . 8M CuSO4 . H2O in H , O , 
10 mol % , 8 . 10 umol ) and Cu - powder ( 10 . 00 uL of a 5 . 7M 
Cu powder suspension in H , O , 0 . 06 mmol , 0 . 7 eq . ) was 
added . Lastly 1 ( 71 uL of a 1 . 1M solution in H , O , 0 . 08 
mmol ) was added and the reaction was stirred at 45° C . in 
a capped scintillation vial in an aluminum block until TLC 
showed completion . At 4 hours into the reaction , an addi 
tional 5 uL of both the CuSO4 . H , O and Cu - powder solutions 
were added . [ 0211 ] For the TLC the following solvents could be 
applied : 5 : 1 DCM / MeOH , 3 : 1 DCM / MeOH or 2 : 1 DCM / 
MeOH . For visualization of the TLC p - anisaldehyde stain or 
potassium permanganate stain was used . 
[ 0212 ] After completion of the reaction 3 - 4 spatulas of 
CupriSorbTM and H2O ( 2 - 3 mL ) were added and the mixture 
was slowly stirred at room temperature overnight . The 
content was carefully transferred to a new scintillation vial , 
avoiding the CupriSorbTM beads . MeOH was used for rins 
ing the CupriSorbTM beads and the reaction vial and the 
MeCN / H , O solvent mixture was removed using a centrifan . 
The residue was dissolved in 20 : 1 DCM / MeOH ( 1 - 2 mL ) 
and purified with a silica - plug . After approximately two test 
tubes in which the unreacted dipeptide was collected , the 
solvent was switched to 5 : 1 DCM / MeOH in order to elute 
the product . Collected fractions were tested with ESI - MS 
and TLC for any residual alkyne ( 20 : 1 DCM / MeOH , potas 
sium permanganate stain ) or 1 ( 5 : 1 DCM / MeOH , p - anisal 
dehyde stain or potassium permanganate stain ) . Clean prod 
uct fractions were collected , the solvent residue was 
removed in vacuo and the product was dried under high 
vacuum . 
General Procedure for Ugi Reaction : 
[ 0208 ] A 0 . 1 M solution of each reactant ( amine , alde 
hyde , acid and isocyanide ) in MeOH was prepared . Amine 
( 5 . 0 mL ) and aldehyde ( 5 . 0 mL ) were stirred in a capped 
scintillation vial for 30 min . at 35 - 40° C . maintained using 
a drilled out aluminum block . Isocyanide ( 5 . 0 mL ) was 
added to this solution and the reaction mixture was stirred 
for additional 20 minutes at 50° C . Lastly the acid ( 5 . 0 mL 
of 0 . 1 M ) was added and the reaction mixture was continu 
ously stirred at 55° C . for 3 - 5 h . The progress of the reaction 
was monitored by TLC using UV - light and p - anisaldehyde 
or potassium permanganate for visualization . Upon con 
sumption of the starting materials and complete product 
formation according to TLC , the solvent was removed in 
vacuo and the crude product was dried under high vacuum . 
An NMR and ESI - LRMS were obtained of the crude prod 
uct . Depending on purity of the crude product , it was either 
taken forward to the next reaction or it was purified using an 
acid / base extraction . In case of incomplete reaction , the 
solvent was removed in vacuo and the residue was dried 
under high vacuum for at least 30 minutes to ensure that all 
methanol was evaporated . The dried residue was dissolved 
in 30 mL of ethyl acetate . The organic layer was then 
extracted with 1 M HC1 , H2O , saturated NaHCO2 , H2O and 
brine ( 2x ) . The organic layer was dried with Na2SO4 , the 
solvent was evaporated in vacuo and the residue was dried 
under high vacuum . 
Antimicrobial Testing : 
[ 0213 ] 1 . Bacterial Strains and Growth Conditions 
[ 02141 Bacillus subtilis ATCC 11775 was plated on agar 
from a 20 % glycerol stock solution stored at - 80° C . 
Inoculated plates were then incubated at 37° C . under 
aerobic conditions for 16 hours . Single cultures were trans 
ferred to Nutrient Broth ( NB ) and cultured for 16 hours 
under the same conditions . 
[ 0215 ] Samples of first passage cultures that exhibited 
growth were transferred again to fresh NB media and 
cultured for 6 hours under identical conditions . Second 
passage cultures were standardized to O . D . 600 mm = 1 . 0 . 
[ 0216 ] 2 . Antimicrobial Screening Assay 
[ 0217 ] The resazurin microtiter assay procedure described 
by Palomino and coworkers was used for assessing antimi 
crobial activity ( Palomino . et al . , 2002 , Antimicrob . Agents 
Chemother . 46 : 2720 - 2722 ) . The assay was performed in LB 
broth . Resazurin sodium salt powder was prepared in dis 
tilled water and filter sterilized at 0 . 001 % ( w / v ) for MIC 
assays and at 0 . 01 % ( w / v ) for single concentration assays . 
Compounds were first screened in MIC assays to assess 
whether growth inhibition was dependent on inhibitor con 
centration . The plates were incubated for 30 min under 
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ae robic conditions . Growth controls containing no inhibitory 
compound , sterility controls without inoculation , and con 
trols containing a known antibiotic , chloramphenicol , were 
also included . The innoculum was prepared from second 
passage cultures in Nutrient Broth ( NB ) and standardized to 
O . D . 600 mm = 1 . 0 and the wells inoculated with a 1 : 20 dilution . 
Serial two - fold dilutions of each compound in 100 uL of 
medium were prepared directly in 96 well plates at concen 
trations ranging from 250 uM to 7 uM . After incubation 30 
uL of resazurin solution was added to each well and incu 
bated for 30 min . A change in color from blue to pink 
indicated reduction of resazurin , and therefore bacterial 
growth . Minimum inhibitory concentration ( MIC ) was 
determined as the lowest drug concentration that prevented 
the color change from blue to pink . Inhibition was quantified 
by observation of color change . Later studies were carried 
out at a single inhibitor concentration of 250 uM . The plates 
were incubated for 4 h under aerobic conditions with the 
same controls . After incubation 30 uL of resazurin solution 
was added to each well and incubated for 60 min . Inhibition 
was quantified by fluorescence readings from plate reader 
SAFIRE , Firmware : V 2 . 20 08 / 02 Safire . Excitation wave 
length set to 560 nm , emission wavelength set to 590 nm . 
Well containing dye and non - inoculated cells was used as 
gain set . Plates were held at 37° C . and fluorescence 
measurements were taken at 0 , 5 , 10 , 20 , 30 , and 60 min 
after addition of dye . Lower fluorescence values correlate to 
greater degrees of inhibition . 
2H , 22 ) , 2 . 73 - 2 . 57 ( m , 1H , 21 ) , 2 . 23 - 2 . 07 ( m , 1H , 15 ) , 
[ 1 . 94 - 0 . 95 ( m ) ; 0 . 95 - 0 . 83 ( m ) , 5H , 20 , 19 , 24 , 25 , 26 ] , 
1 . 94 - 0 . 95 ( m , 4H , 25 , 27 ) , 0 . 95 - 0 . 83 ( m , 3H , 28 ) ppm . 
ogba : 
[ 0220 ] Yield : 191 mg ( 88 % , 0 . 44 mmol ) , yellow solid . ' H 
NMR ( 400 MHz , Acetone - d ) 8 [ 7 . 78 ( dd , J = 7 . 6 , 1 . 9 Hz ) ; 
7 . 70 - 7 . 56 ( m ) , 7 . 52 - 7 . 29 ( m ) ; 7 . 26 ( dd , J = 7 . 5 , 1 . 7 Hz ) ; 7 . 18 
( dd , J = 7 . 3 , 2 . 0 Hz ) , 4H , aromatic ] , [ 5 . 04 ( dd , J = 17 . 4 , 2 . 6 
Hz ) ; 4 . 90 - 4 . 75 ( m ) ; 4 . 59 ( d , J = 2 . 5 Hz ) ; 4 . 58 - 4 . 56 ( m ) ; 4 . 55 
( d , J = 2 . 5 Hz ) ; 4 . 53 ( d , J = 2 . 5 Hz ) ; 3 . 75 - 3 . 61 ( m ) , 2H , 13 ) , 
4 . 90 - 4 . 75 ( m ) ; 3 . 75 - 3 . 61 ( m ) , 1H , 12 ) , 3 . 35 - 3 . 05 ( m , 2H , 
24 ) , 2 . 74 - 2 . 56 ( m , 1H , 21 ) , 2 . 22 - 2 . 13 ( m , 1H , 14 ) , [ 1 . 80 - 0 . 
98 ( m ) ; 0 . 96 - 0 . 81 ( m ) , 14H , 17 , 18 , 22 , 23 , 25 , 26 , 27 ] , 
0 . 96 - 0 . 81 ( m , 3H , 28 ) ppm . 
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[ 0221 ] Yield : 179 mg ( 93 % , 0 . 47 mmol ) , yellow solid . ' H 
NMR ( 600 MHz , Chloroform - d ) 8 [ 9 . 61 ( d , J = 1 . 4 Hz ) ; 
8 . 07 - 8 . 03 ( m ) ; 7 . 62 ( d , J = 8 . 2 Hz ) ; 6 . 97 - 6 . 89 ( m ) , 411 , 
aromatic ] , 6 . 97 - 6 . 89 ( m , 4H , NH - 19 ) , [ 4 . 44 - 4 . 25 ( m ) ; 4 . 04 
3 . 90 ( m ) , 3H , 11 , 12 ) , [ 3 . 87 ( s ) ; 3 . 85 ( s ) , 3H , 29 ) , 3 . 24 ( q , 
J = 6 . 7 Hz , 2H , 23 ) , 2 . 32 ( s , 1H , 20 ) , 2 . 09 - 1 . 99 ( m , 1H , 13 ) , [ 1 . 83 - 1 . 62 ( m ) , 1 . 38 - 1 . 12 ( m ) , 6H , 21 , 22 , 24 ] , 1 . 48 ( p , J = 7 . 1 
Hz , 2H , 25 ) , 1 . 38 - 1 . 12 ( m , 2H , 26 ) , 1 . 04 - 0 . 84 ( m , 7H , 16 , 
17 , 27 ) ppm . 
qgba : 
[ 0222 ] Yield : 176 mg ( 91 % , 0 . 46 mmol ) , yellow solid . ' H 
NMR ( 600 MHz , Acetone - do ) & 17 . 43 - 7 . 14 ( m ) ; 7 . 08 - 6 . 97 
( m ) , 5H , 2 , 3 , 5 , 7 , NH - 19 ] , [ 4 . 86 - 4 . 40 ( m ) ; 4 . 28 - 4 . 15 ( m ) ; 
3 . 97 - 3 . 89 ( m ) ; 2H , 12 ] , [ 4 . 86 - 4 . 40 ( m ) ; 3 . 65 ( d , J = 11 . 0 Hz ) , 
1H , 11 ) , 3 . 82 ( 3H , 29 ) , 3 . 33 - 3 . 08 ( m , 2H , 23 ) , 2 . 64 - 2 . 52 ( m , 
1H , 20 ) , 2 . 19 - 2 . 08 ( m , 1H , 13 ) , [ 1 . 81 - 1 . 59 ( m ) ; 1 . 30 - 1 . 14 ( m ) ; 1 . 08 - 0 . 95 ( m ) ; 0 . 85 - 0 . 66 ( m ) , 10H , 16 , 17 , 21 , 22 , 241 , 
1 . 56 - 1 . 45 ( m , 2H , 25 ) , 1 . 44 - 1 . 30 ( m , 2H , 26 ) , 0 . 91 ( t , J = 7 . 3 
Hz , 3H , 27 ) ppm . 
25 
ogba 
ngba : 
[ 0219 ] Yield : 171 mg ( 88 % , 0 . 44 mmol ) , yellow solid . ' H 
NMR ( 400 MHz , Acetone - do ) a [ 7 . 85 - 7 . 78 ( m ) ; 7 . 59 - 6 . 94 ( m , 5H , aromatic , NH - 18 ) ] , 5 . 01 ( dd , J = 17 . 4 , 2 . 6 Hz ) ; 
4 . 90 - 4 . 69 ( m ) ; 4 . 56 ( dd , J = 17 . 4 , 2 . 9 Hz ) ; 3 . 74 - 3 . 62 ( m ) , 2H , 
13 ] , [ 4 . 90 - 4 . 69 ( m ) ; 3 . 74 - 3 . 62 ( m ) , 1H , 12 ) , 3 . 35 - 3 . 05 ( m , 
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[ 0225 ] Yield : 171 mg ( 96 % , 0 . 48 mmol ) , yellow solid . ' H 
NMR ( 600 MHz , Acetone - do ) 8 [ 18 . 09 - 8 . 02 ( m ) ; 7 . 64 - 7 . 00 
( m ) , 5H , 2 , 3 , 4 , 5 , 7 ] , 7 . 64 - 7 . 00 ( m , 1H , NH - 19 ) , 4 . 90 - 4 . 40 
( m , 1H , 11 ) , [ 4 . 90 - 4 . 40 ( m ) ; 4 . 21 - 4 . 13 ( m ) ; 4 . 02 - 3 . 78 ( m ) , 
2H , 12 ) , 3 . 29 - 3 . 12 ( m , 2H , 23 ) , 2 . 89 - 2 . 55 ( m , 1H , 20 ) , 
2 . 25 - 2 . 09 ( m , 1H , 13 ) , [ 1 . 83 - 1 . 58 ( m ) ; 1 . 30 - 0 . 96 ( m ) , 10H , 
16 , 17 , 21 , 22 , 24 ] , 1 . 55 - 1 . 43 ( m , 2H , 25 ) , 1 . 35 ( h , J = 7 . 2 Hz , 
2H , 26 ) , 0 . 91 ( t , J = 7 . 4 Hz , 3H , 27 ) . 
fgbd : 
[ 0226 ] Yield : 296 mg ( 540 / % , 0 . 54 mmol ) , yellow solid . 
' H NMR ( 600 MHz , Chloroform - d ) 8 8 . 79 ( s , 1H , NH - 19 ) , 
[ 8 . 31 - 8 . 22 ( m ) ; 7 . 88 - 7 . 65 ( m ) ; 7 . 47 - 7 . 32 ( m ) ; 7 . 16 - 7 . 10 ( m ) , 
11H , 1 , 2 , 4 , 7 , 25 , 28 - 33 ) , 5 . 23 - 5 . 13 ( m , 1H , 11 ) , [ 4 . 53 ( d , 
J = 18 . 8 Hz ) ; 3 . 80 ( d , J = 18 . 8 Hz ) , 2H , 12 ) . 2 . 37 - 2 . 27 ( m , 1H , 
13 ) , 2 . 18 ( s , 1H , 20 ) , [ 2 . 03 - 1 . 69 ( m ) ; 1 . 47 - 1 . 31 ( m ) ; 1 . 23 
1 . 09 ( m ) ; 0 . 92 - 0 . 77 ( m ) , 10H , 16 , 17 , 21 , 22 , 24 ] ppm . 
fhba : 
[ 0223 ] Yield : 205 mg ( 88 % , 0 . 44 mmol ) , yellow solid . ' H 
NMR ( 400 MHz , Acetone - do ) 8 [ 8 . 18 - 7 . 71 ( m ) ; 7 . 57 - 7 . 01 
( m ) , 4H , 2 , 3 , 5 , 8 ] , 7 . 57 - 7 . 01 ( m , 1H , NH - 18 ) , 5 . 19 - 3 . 50 ( m , 
3H , 12 , 13 ) , 3 . 43 - 3 . 04 ( m , 2H , 20 ) , 2 . 81 - 2 . 45 ( m , 2H , 14 , 
19 ) , 1 . 86 - 1 . 09 ( m , 12H , 21 , 22 , 24 , 25 , 26 , 27 ) , 1 . 10 - 0 . 61 ( m , 
3H , 23 ) ppm . 
fiba : 
[ 0224 ] Yield : 59 mg ( 25 % , 0 . 125 mmol ) , yellow solid . ' H 
NMR ( 600 MHz , Acetone - do ) [ 8 . 01 - 7 . 88 ( m ) ; 7 . 80 - 7 . 07 
( m ) , 9H , 1 , 3 , 6 , 7 , 16 , 17 , 21 , 22 , 24 ] , 7 . 80 - 7 . 07 ( m , 1H , 
NH - 19 ) , [ 6 . 25 ( s ) ; 6 . 04 ( s ) ; 5 . 62 ( s ) ; 5 . 39 - 5 . 13 ( m ) , 1H , 11 ] , 
4 . 62 - 3 . 72 ( m , 2H , 12 ) , 3 . 37 - 3 . 09 ( m , 2H , 23 ) , [ 2 . 24 - 2 . 13 
( m ) ; 2 . 04 - 1 . 94 ( m ) , 1H , 20 ] , [ 1 . 56 - 1 . 41 ( m ) ; 1 . 39 - 1 . 32 ( m ) , 
2H , 25 ] , [ 1 . 39 - 1 . 32 ( m ) ; 1 . 32 - 1 . 20 ( m ) , 2H , 26 ] , 0 . 93 - 0 . 83 
( m , 3H , 27 ) ppm . 
35 - 34 
33 
36 
I 31230 27 = 26 
_ N . 14 . 
NH 
18 
15 16 
20 fgkd 
1 ?2 - 1 = 
N142326 
C1 CNH - 25 CH3 
19 27 
= 
O 
17 
21 - 
7 .79 ( m ) : 17 . ) 18 . 41 Yellow solid . ? 
fgkd : 
[ 0227 ] Yield : 275 mg ( 46 % , 0 . 46 mmol ) , yellow solid . " H 
NMR ( 600 MHz , Chloroform - d ) 8 [ 8 . 41 ( d , J = 2 . 0 Hz ) ; 
7 . 89 - 7 . 85 ( m ) ; 7 . 82 - 7 . 79 ( m ) ; 7 . 79 - 7 . 75 ( m ) ; 7 . 62 - 7 . 58 ( m ) ; 
7 . 45 - 7 . 41 ( m ) ; 7 . 39 - 7 . 35 ( m ) ; 7 . 24 - 7 . 20 ( m ) ; 7 . 14 - 7 . 10 ( m ) , 
11H , 1 , 2 , 4 , 7 , 23 , 26 - 31 ) , 3 . 53 ( d , J = 11 . 1 Hz , 1H , 11 ) , 3 . 23 
( tt , J = 11 . 8 , 3 . 6 Hz , 1H , 12 ) , 3 . 01 ( dtt , J = 11 . 5 , 3 . 4 Hz , 1H , 
13 ) , [ 2 . 02 - 1 . 30 ( m ) ; 1 . 24 - 0 . 75 ( m ) , 20H , 15 , 16 , 19 , 20 , 22 , 
32 - 36 ] ppm . 
22 
A 
rgba 
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Example 2 : Click Reaction Products 
( 0228 ] 
( 1 – 2021 - 23 
1924 
- OH 
13 . 16 
4 12 
14 
NH15 
31 
CH3 HO - 
[ 5 . 53 - 4 . 95 ( m ) ; 4 . 51 - 4 . 42 ( m , 2H , 11 ) , 4 . 78 - 4 . 53 ( m , 1H , 
12 ) , 4 . 37 - 3 . 99 ( m , 1H , 2 ) , [ 3 . 99 - 3 . 85 ( m ) , 3 . 83 - 3 . 63 ( m ) , 2H , 
6 ) , 3 . 83 - 3 . 63 ( m , 1H , 3 ) , 3 . 64 - 3 . 46 ( m , 3H , 4 , 5 , 12 ) , 
3 . 32 - 3 . 02 ( m , 2H , 14 ) , 2 . 42 - 2 . 08 ( m , 1H , 25 ) , [ 2 . 07 - 1 . 97 
( m ) ; 1 . 76 - 1 . 52 ( m ) ; 1 . 25 - 1 . 02 ( m ) ; 0 . 92 - 0 . 54 ( m ) , 10H , 30 , 
26 , 29 , 27 , 28 ) . 1 . 96 - 1 . 77 ( m , 3H , 8 ) , 1 . 49 ( p , J = 7 . 5 Hz , 2H , 
15 ) , 1 . 46 - 1 . 25 ( m , 2H , 16 ) , 1 . 01 - 0 . 91 ( m , 3H , 17 ) . 13C NMR 
( 151 MHz , Methanol - da ) 8 [ 173 . 47 , 173 . 03 — 7 , 13 , 18 ) , 
[ 139 . 15 , 123 . 56 , 120 . 44 — 10 , 19 , 20 ] , [ 134 . 66 , 134 . 39 , 
132 . 42 , 132 . 10 , 132 . 04 , 130 . 66 , 130 . 66 , 129 . 97 , 129 . 39 , 
129 . 19 , 129 . 09 , 129 . 00 , 128 . 90 , 128 . 78 — 9 , 21 - 24 ] , [ 88 . 36 , 
88 . 14 , 87 . 99 — 1 ] , [ 81 . 52 , 81 . 48 , 81 . 40 , 81 . 28 – 4 or 5 ] , [ 76 . 75 , 76 . 35 , 75 . 84 , 75 . 74 — 3 ] , [ 71 . 76 , 71 . 55 — 4 or 5 ] , 
69 . 72 , 68 . 51 , 65 . 06 — 12 ] , [ 62 . 81 , 62 . 606 ] , [ 57 . 28 , 56 . 88 , 
56 . 46 — 2 ] , [ 40 . 33 , 40 . 25 — 14 ] , [ 40 . 21 , 40 . 11 — 11 ] , [ 39 . 48 , 
39 . 38 , 39 . 11 , 38 . 88 , 38 . 26 – 25 ] , [ 33 . 32 , 33 . 26 , 32 . 67 , 
32 . 48 , 32 . 36 , 32 . 34 , 32 . 32 , 32 . 17 , 31 . 63 , 30 . 93 , 30 . 78 — 15 ) , 
[ 27 . 57 , 27 . 20 , 27 . 16 , 27 . 10 , 26 . 82 , 26 . 72 , 26 . 61 – 26 - 301 , 
[ 23 . 09 , 22 . 95 , 22 . 85 , 22 . 82 — 8 ] , [ 21 . 52 , 21 . 45 , 21 . 37 — 16 ] , [ 14 . 28 , 14 . 23 , 14 . 2017 ] ppm . ESI ( + ) - HRMS ( m / z ) : Calcd 
for C3 . H43BrNGO , [ M + H ] + 679 . 2449 . found 679 . 2445 . 
N . ?? . 17 
26 BI . ngba ?? 
O : 2027 BI . ngba 28 
H3 
24 
BI . ngba : 
[ 0229 ] Yield : 47 mg ( 91 % , 0 . 074 mmol ) , white solid . ' H 
NMR ( 600 MHz , Methanol - dA ) 8 . 40 - 7 . 90 ( m , 1H , 9 ) , 
7 . 82 - 7 . 15 ( m , 5H , 24 , NH - 31 , 21 , 23 , 22 ) , 5 . 89 - 5 . 67 ( m , 1H , 
1 ) . 15 . 48 - 4 . 88 ( m ) ; 4 . 48 - 4 . 41 ( m ) , 2H , 11 ) , 4 . 83 - 4 . 49 m , 1H , 
12 ) , 4 . 35 - 4 . 02 ( m , 1H , 2 ) , [ 3 . 94 - 3 . 84 ( m ) , 3 . 80 - 3 . 61 ( m ) , 2H , 
6 ) , 3 . 80 - 3 . 61 ( m , iH , 3 ) , 3 . 61 - 3 . 46 ( m , 3H , 4 , 5 , 12 ) , 
3 . 36 - 3 . 04 ( m , 2H , 14 ) , 2 . 39 - 1 . 99 ( m , 1H , 25 ) , 1 . 98 - 1 . 76 m , 
3H , 8 ) , [ 1 . 76 - 1 . 54 ( m ) ; 1 . 29 - 0 . 99 ( m ) ; 0 . 90 - 0 . 52 ( m ) , 10H , 
30 , 26 , 29 , 27 , 28 ) . 1 . 54 - 1 . 43 ( m , 2H , 15 ) , 1 . 42 - 1 . 29 ( m , 2H , 
16 ) , 0 . 99 - 0 . 91 ( m , 3H , 17 ) ppm . 13C NMR ( 151 MHz , 
Methanol - d4 ) [ 1174 . 99 , 172 . 01 , 171 . 94 , 171 . 49 , 170 . 35 — 
7 , 13 , 18 ] , 135 . 49 ( 10 ) , [ 131 . 64 , 130 . 81 , 130 . 65 , 130 . 51 , 
130 . 43 , 129 . 91 , 129 . 85 , 129 . 64 , 129 . 33 , 128 . 86 , 128 . 42 , 
128 . 20 , 127 . 89 , 127 . 85 , 127 . 64 , 127 . 11 , 127 . 02 , 126 . 96 — 
21 - 24 ] , [ 130 . 32 , 130 . 13 — 19 , 20 ) , 122 . 19 ( 9 ) , [ 86 . 82 , 86 . 61 , 
86 . 44 - 1 ] , [ 79 . 99 , 79 . 88 , 79 . 76 — 4 or 5 ] , [ 74 . 82 , 74 . 44 , 
74 . 30 , 74 . 20 — 3 ] , [ 70 . 20 , 70 . 06 , 70 . 03 — 4 or 5 ] , 6 [ 8 . 22 , 
67 . 05 , 67 . 02 — 12 ) , [ 61 . 25 , 61 . 07 — 6 ] , [ 55 . 78 , 55 . 73 , 55 . 38 , 
54 . 93 , 54 . 90 — 2 ] , 41 . 65 , 39 . 06 - 11 ] , [ 38 . 74 , 38 . 68 , 38 . 53 — 
14 ] , [ 37 . 92 , 37 . 81 , 37 . 50 , 37 . 30 , 36 68 — 25 ] , [ 31 . 31 , 31 . 10 , 
30 . 96 , 30 . 90 , 30 . 85 , 30 . 76 , 30 . 59 , 30 . 09 — 15 ] , [ 29 . 25 , 
29 . 14 , 26 . 02 , 25 . 72 , 25 . 68 , 25 . 59 , 25 . 55 , 25 . 33 , 25 . 18 , 
25 . 07 , 25 . 02 — 26 - 30 ] , [ 21 . 56 , 21 . 38 , 21 . 34 , 21 . 29 % 8 ] , [ 19 . 
93 , 19 . 81 — 16 ] , [ 12 . 76 , 12 . 71 , 12 . 69 — 17 ] ppm . ESI ( + ) 
HRMS ( m / z ) : Calcd for C30H43CINGO , [ M + H ] + 635 . 2955 , 
found 635 . 2946 . 
6 - OH NN N . 13 . 14 CNH C15 HONO 12 16 CCH , 
17 31 
BI .pgba 30 - 25 - 26 Bl . pgba ?? 
1.30  71.02 12  142 65 . 39 - 28 - 27 BI . pgba 
Br20 
1974 
LOH N = N 
- 14 216 
NH15 
BI .pgba : 
[ 0231 ] Yield : 33 mg ( 65 % , 0 . 053 mmol ) , white solid . ' H 
NMR ( 600 MHz , Methanol - da ) 8 8 . 36 - 7 . 66 ( m , 2H , 9 , 
NH - 31 ) , 7 . 53 - 7 . 27 ( m , 2H , 20 , 24 ) , 7 . 01 ( d , J = 8 . 2 Hz , 2H , 
21 , 23 ) , 5 . 86 - 5 . 75 ( m , 1H , 1 ) , 5 . 53 - 4 . 56 ( m , 3H , 11 , 12 ) , 
4 . 39 - 4 . 09 ( m , 1H , 2 ) , [ 3 . 99 - 3 . 87 ( m ) ; 3 . 82 - 3 . 65 ( m ) , 2H , 6 ] , 
3 . 87 ( s , 3H , 32 ) , 3 . 82 - 3 . 65 ( m , 1H , 3 ) , 3 . 62 - 3 . 51 ( m , 2H , 4 , 
5 ) , 3 . 28 - 3 . 11 ( m , 2H , 14 ) , 2 . 17 ( dd , J = 32 . 6 , 16 . 8 Hz , 1H , 25 ) , 
1 . 79 ( s , 3H , 8 ) , [ 1 . 75 - 1 . 62 ( m ) ; 1 . 35 - 1 . 03 ( m ) ; 0 . 90 - 0 . 59 
( m ) , 10H , 30 , 26 , 29 , 27 , 28 ] , 1 . 58 - 1 . 45 ( m , 2H , 15 ) , 
1 . 44 - 1 . 35 ( m , 2H , 16 ) , 0 . 98 ( q , J = 7 . 4 Hz , 3H , 17 ) ppm . 13C 
NMR ( 151 MHz , Methanol - d . ) 8 [ 175 . 43 , 173 . 35 , 172 . 10 , 
172 . 02 – 7 , 13 , 187 , [ 162 . 56 , 162 . 46 — 22 ) , 129 . 82 ( 20 , 24 ) , 
129 . 35 ( 10 ) , 129 . 32 ( 19 ) , 124 . 15 ( 9 ) , 115 . 12 ( 21 , 23 ) , 
[ 87 . 97 , 87 . 92 — 1 ] , 81 . 23 ( 4 or 5 ) , 75 . 64 ( 3 ) , [ 71 . 44 , 
71 . 41 — 4 or 5 ] , [ 62 . 42 , 62 . 39 — 6 ] , [ 56 . 98 , 55 . 96 — 2 ] , [ 55 . 
88 , 55 . 86 – 32 ] , [ 40 . 17 , 40 . 05 — 147 , 39 . 18 ( 25 ) , [ 32 . 34 , 
32 . 31 — 15 ] , [ 27 . 24 , 26 . 89 , 26 . 87 , 26 . 72 — 26 - 30 ] , [ 22 . 78 , 
22 . 66 — 8 ] , [ 21 . 22 , 21 . 19 , 21 . 07 — 16 ] , [ 14 . 12 , 14 . 10 — 17 ] 
ppm . ESI ( + ) - HRMS ( m / z ) : Calcd for C31H46N608 [ M + H ] + 
631 . 3377 , found 631 . 3449 . 
CH3 HO - 4 . 
?? . BI .ngba 
NH 30 26 
7 29 . 27 
( 28 BI . ngba 
BI .ogba : 
[ 0230 ] Yield : 45 mg ( 81 % , 0 . 066 mmol ) , white solid . ' H 
NMR ( 600 MHz , Methanol - d . ) 8 8 . 52 - 8 . 02 ( m , 1H , 9 ) , 
8 . 02 - 6 . 92 ( m , 5H , 24 , 31 , 21 , 23 , 22 ) , 5 . 99 - 5 . 59 ( m , 1H , 1 ) , 
US 2018 / 0290967 A1 Oct . 11 , 2018 
34 
H3C 
19 ) O = 18 NN 
0 HO HOCO CH3 I 
14 | NH15 
BI . qgba 
26 NH 
2H , 61 . 3 . 82 - 3 . 68 ( m , 1H , 3 ) , 3 . 68 - 3 . 49 ( m , 2H , 4 , 5 ) , 
3 . 39 - 3 . 04 ( m , 2H , 14 ) , 2 . 94 - 2 . 57 ( m , 1H , 25 ) , [ 2 . 03 - 1 . 85 
( m ) ; 1 . 75 - 1 . 00 ( m ) ; 0 . 93 - 0 . 81 ( m ) , 12H , 15 , 16 , 26 - 29 ] , 
1 . 84 - 1 . 76 ( m , 3H , 8 ) , 1 . 00 - 0 . 94 ( m , 31 - 17 ) ppm . 13C NMR 
( 151 MHz , Methanol - d . ) 8 [ 173 . 89 , 172 . 91 , 172 . 24 — 7 , 13 , 
18 ] , [ 141 . 25 , 140 . 86 , 140 . 44 , 132 . 11 , 131 . 84 , 131 . 71 , 129 . 
63 , 129 . 46 , 129 . 12 , 128 . 60 — 10 , 19 , 21 - 24 ) , 123 . 73 ( 9 ) , 
193 . 39 , 93 . 02 — 20 ] , [ 88 . 28 , 87 . 90 , 87 . 54 — 1 ] , [ 81 . 48 , 81 . 32 , 
81 . 16 — 4 or 5 ] , [ 76 . 93 , 76 . 30 , 75 . 73 , 75 . 63 , 75 . 38 — 3 ] , [ 71 . 68 , 71 . 38 — 4 or 5 ] , [ 68 . 67 , 67 . 09 , 64 . 43 — 12 ] , [ 62 . 68 , 
62 . 45 — 6 ] , [ 57 . 36 , 57 . 11 , 56 . 56 , 56 . 45 , 56 . 27 – 2 ] , [ 42 . 36 , 
42 . 33 , 41 . 81 , 41 . 58 — 25 ] , [ 40 . 34 , 40 . 31 — 11 ] , [ 40 . 16 , 
40 . 04 — 14 ] , [ 32 . 93 , 32 . 54 , 32 . 40 , 32 . 37 , 32 . 18 , 32 . 15 , 
31 . 68 , 31 . 61 , 31 . 04 , 30 . 93 , 30 . 48 , 26 . 34 , 26 . 15 , 26 . 04 , 
25 . 93 , 25 . 83 , 25 . 73 , 25 . 60 — 15 , 26 - 29 ] , [ 22 . 99 , 22 . 89 , 
22 . 81 , 22 . 708 ] , [ 21 . 42 , 21 . 30 — 16 ] , [ 14 . 15 , 14 . 09 , 
14 . 07 — 17 ] ppm . ESI ( + ) - HRMS ( m / z ) : Calcd for 
C2H4 , INGO , [ M + H ] + 713 . 2081 , found 713 . 2153 . 
30 
CH3 29 . 27 
BI .qgba 
4 , 32 ) ,3 .785 ( m ) ;3 . 98 - 5m ) ,11 , 120 .574 , 36 
21 - 22 I - - - 26 
199 
OH 
BI .qgba : 
[ 0232 ] Yield : 41 mg ( 80 % , 0 . 065 mmol ) , white solid . ' H 
NMR ( 600 MHz , Methanol - d . ) 8 8 . 39 - 7 . 75 ( m , 1H , 9 ) , 
18 . 39 - 7 . 75 ( m ) ; 7 . 65 - 6 . 77 ( m ) , 1H , NH - 31 ] , 7 . 65 - 6 . 77 ( m , 
4H , 21 - 24 ) , 5 . 89 - 5 . 67 m , 1H , 1 ) , ( 5 . 30 - 4 . 92 ( m ) ; 4 . 85 - 4 . 36 
( m ) , 2H , 11 ] , [ 4 . 85 - 4 . 36 ( m ) ; 3 . 66 - 3 . 60 ( m ) , 1H , 12 ] , 4 . 31 
3 . 98 ( m , 1H , 2 ) , [ 3 . 96 - 3 . 88 ( m ) ; 3 . 78 - 3 . 66 ( m ) , 2H , 6 ) , 
3 . 87 - 3 . 79 ( m , 3H , 32 ) , 3 . 78 - 3 . 66 ( m , 1H , 3 ) , 3 . 60 - 3 . 40 ( m , 
2H , 4 , 5 ) , 3 . 37 - 2 . 99 ( m , 2H , 14 ) , 2 . 42 - 2 . 11 ( m , 11 , 25 ) , 
[ 2 . 11 - 1 . 95 ( m ) ; 1 . 76 - 1 . 00 ( m ) ; 0 . 88 - 0 . 49 ( m ) , 1H , 15 , 16 , 
26 - 30 ] , 1 . 95 - 1 . 76 ( m , 3H , 8 ) , 1 . 00 - 0 . 89 ( m , 3H , 17 ) ppm . 
13C NMR ( 151 MHz , Methanol - dd ) 8 [ 173 . 40 , 173 . 33 , 
173 . 29 , 173 . 00 — 7 , 13 , 18 ] , 156 . 59 ( 20 ) , 135 . 18 ( 10 ) , [ 132 . 
17 , 132 . 04 , 129 . 72 , 129 . 29 , 123 . 37 , 122 . 05 , 121 . 95 , 112 . 77 , 
112 . 57 – 9 , 21 - 24 ] , 126 . 89 ( 19 ) , 88 . 11 ( 1 ) , [ 81 . 41 , 81 . 31 , 
81 . 164 or 5 ] , [ 76 . 04 , 75 . 66 , 75 . 55 — 31 ) , 71 . 48 ( 4 or 5 ) , 
68 . 28 ( 12 ) , [ 62 . 47 , 62 . 44 — 6 ] , [ 57 . 29 , 56 . 95 , 56 . 58 , 56 . 40 
2 ] , [ 56 . 23 , 56 . 17 – 32 ] , 40 . 41 ( 14 ) , [ 40 . 28 , 39 . 99 — 11 ] , [ 39 . 41 , 39 . 25 , 38 . 71 , 37 . 94 — 25 ] , [ 32 . 45 , 32 . 42 – 15 ] , [ 31 . 
75 , 31 . 64 , 30 . 91 , 27 . 48 , 27 . 16 , 26 . 94 , 26 . 67 , 26 . 59 – 26 - 30 ] , 
[ 22 . 86 , 22 . 68 , 22 . 65 — 8 ] , [ 21 . 29 , 21 . 22 , 21 . 17 – 16 ] , [ 14 . 16 , 
14 . 10 — 17 ] ppm . ESI ( + ) - HRMS ( m / z ) : Calcd for 
C31H46N , 08 [ M + H ] + 631 . 3377 , found 631 . 3442 . 
NN 16 
HOO4 N 1 / C12 I 
13 14 
CNH 
BI . qgba 15 CH3 17 
NH 20 26 yo 
CH3 pop 
BI .fiba 
BI . fiba : 
- OH N 
13 16 
HO 2 
14 
NH15 30 CH3 17 
NH 
26 
2877 CH3 
[ 0234 ] Yield : 54 mg ( 92 % , 0 . 075 mmol ) , white solid . ' H 
NMR ( 600 MHz , Methanol - d . ) 8 8 . 19 - 7 . 03 ( m , 10H , 21 - 24 , 
26 - 30 ) , [ 16 . 11 - 5 . 99 ( m ) ; 5 . 50 - 5 . 40 ( m ) ; 5 . 24 - 5 . 21 ( m ) , 1H , 
12 ] , 5 . 79 - 5 . 60 ( m , 1H , 1 ) . [ 5 . 11 - 4 . 90 ( m ) , 4 . 84 - 4 . 78 ( m ) , 
4 . 52 - 4 . 19 ( m ) , 2H , 11 ] , 4 . 18 - 3 . 96 ( m , 1H , 2 ) , [ 3 . 96 - 3 . 86 ( m ) ; 
3 . 80 - 3 . 69 ( m ) , 2H , 6 ] , [ 3 . 80 - 3 . 69 ( m ) ; 3 . 69 - 3 . 59 ( m ) , 1H , 
31 , 3 . 58 - 3 . 45 ( m , 2H , 4 , 5 ) , 3 . 29 - 3 . 09 ( m , 2H , 14 ) , 2 . 01 - 1 . 72 
( m , 3H , 8 ) , 1 . 64 - 1 . 20 ( m , 4H , 15 , 16 ) , 0 . 91 ( t , J = 7 . 4 , 2 . 6 Hz , 
3H , 17 ) ppm . 13C NMR ( 151 MHz , Methanol - d . ) 8 1173 . 70 , 
173 . 52 , 173 . 37 , 173 . 18 , 171 . 607 , 13 , 18 ) , [ 142 . 83 , 142 . 
71 — 19 ] , [ 140 . 95 , 140 . 76 , 132 . 10 , 132 . 06 , 131 . 86 , 131 . 47 , 
131 . 26 , 131 . 17 , 130 . 25 , 130 . 12 , 130 . 00 , 129 . 95 , 129 . 82 , 
129 . 54 , 129 . 51 , 128 . 94 , 128 . 44 , 128 . 36 — 21 - 24 , 26 - 30 ] , 
136 . 52 ( 25 ) , [ 135 . 05 , 134 . 95 — 10 ] , [ 124 . 23 , 123 . 50 , 123 . 
24 - 9 ] , [ 93 . 63 , 93 . 47 — 20 ] , [ 87 . 99 , 87 . 78 , 87 . 43 — 1 ] , [ 81 . 
28 , 81 . 20 , 81 . 16 — 4 or 5 ] , [ 76 . 47 , 75 . 74 , 75 . 563 ] , [ 71 . 58 , 
71 . 40 , 71 . 37 – 4 or 5 ] , [ 67 . 73 , 65 . 73 — 12 ] , [ 62 . 61 , 62 . 50 , 
62 . 42 – 6 ] , [ 57 . 27 , 56 . 50 — 7 ] . [ 41 . 80 , 41 . 56 — 11 ] , [ 40 . 50 , 
40 . 27 , 40 . 13 — 14 ) , [ 32 . 21 , 32 . 10 — 15 ] , [ 23 . 00 , 22 . 92 , 
22 . 84 , 22 . 79 — 8 ] , [ 21 . 22 , 21 . 16 , 21 . 10 , 21 . 08 — 16 ) , [ 14 . 11 , 
14 . 05 , 13 . 99 — 17 ] ppm . ESI ( + ) - HRMS ( m / z ) : Calcd for 
C30H37NGO , [ M + H ] + 721 . 1768 , found 721 . 1836 . 
BI . fhba 
BI . fhba : 
[ 0233 ] Yield : 42 mg ( 73 % , 0 . 059 mmol ) , white solid . ' H 
NMR ( 600 MHz , Methanol - d . ) 8 58 . 37 - 7 . 98 ( m ) ; 7 . 84 - 7 . 65 
( m ) , 2H , 9 , NH - 30 ] , [ 7 . 97 - 7 . 87 ( m ) ; 7 . 55 - 7 . 06 ( m ) , 4H , 
21 - 24 ) , 5 . 93 - 5 . 71 ( m , 1H , 1 ) , [ 5 . 53 - 5 . 39 ( m ) ; 5 . 25 - 4 . 92 ( m ) ; 
4 . 47 - 4 . 39 ( m ) , 2H , 11 ] , [ 4 . 79 - 4 . 47 ( m ) ; 3 . 68 - 3 . 49 ( m ) , 1H , 
12 ] , 4 . 38 - 4 . 07 ( m , 1H , 2 ) , [ 3 . 96 - 3 . 87 ( m ) ; 3 . 82 - 3 . 68 ( m ) , 
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NEN 
12 10 - 11 N 12 
14 
NH 215 
BI . rgba  RS CH 17 
NH 30 - 25 
CH3 
BI . rgba 
BI . rgba : [ 0235 ] Yield : 39 mg ( 80 % , 0 . 065 mmol ) , white solid . ' H 
NMR ( 600 MHz , Methanol - d . ) 8 8 . 37 - 7 . 66 ( m , 2H , 9 , 31 ) , 
7 . 60 - 7 . 29 ( m , 5H , 20 - 24 ) , 5 . 87 - 5 . 70 ( m , 1H , 1 ) , ( 5 . 27 - 4 . 92 
( m ) ; 3 . 81 - 3 . 62 ( m ) , 1H , 12 ] , [ 5 . 27 - 4 . 92 ( m ) ; 4 . 79 - 4 . 47 ( m ) , 
2H , 11 ] . 4 . 37 - 4 . 10 ( m , 1H , 2 ) , [ 3 . 94 - 3 . 85 ( m ) ; 3 . 81 - 3 . 62 ( m ) , 
21H , 6 ] , 3 . 81 - 3 . 62 ( m , 1H , 3 ) , 3 . 62 - 3 . 49 ( m , 2H , 4 , 5 ) , 
3 . 25 - 3 . 09 ( m , 2H , 14 ) , 2 . 23 ( t , J = 50 . 6 Hz , 1H , 25 ) , [ 1 . 87 
1 . 79 ( m ) ; 1 . 74 - 1 . 44 ( m ) ; 1 . 33 - 0 . 98 ( m ) ; 0 . 93 - 0 . 55 ( m ) , 10H , 
26 - 30 ] , 1 . 77 ( t , J = 13 . 7 Hz , 3H , 8 ) , 1 . 74 - 1 . 44 ( m , 2H , 15 ) , 
1 . 43 - 1 . 33 ( m , 2H , 16 ) , 0 . 96 ( q , J = 7 . 3 Hz , 3H , 17 ) ppm . 13C 
NMR ( 151 MHz , Methanol - d . ) 8 173 . 36 ( 7 , 13 , 18 ) , [ 133 . 
88 , 131 . 06 , 130 . 94 , 129 . 91 , 129 . 88 , 127 . 85 , 125 . 15 — 9 , 10 , 
19 - 24 ] , 88 . 09 ( 1 ) , 81 . 28 ( 4 or 5 ) , 75 . 68 ( 3 ) , 71 . 50 ( 4 or 5 ) , 
69 . 13 ( 12 ) , 62 . 46 ( 6 ) , [ 57 . 07 , 56 . 20 — 2 ] , [ 44 . 26 , 43 . 71 – 
11 ] , 40 . 15 ( 14 ) , 39 . 16 ( 25 ) , 32 . 34 ( 15 ) , [ 27 . 13 , 26 . 89 , 
26 . 86 — 26 - 30 ] , [ 22 . 78 , 22 . 67 — 8 ] , [ 21 . 21 , 21 . 18 — 16 ] , 
14 . 07 ( 17 ) ppm . ESI ( + ) - HRMS ( m / z ) : Calcd for 
C30H44NGO , [ M + H ] + 601 . 327 , found 601 . 3344 . 
fgca : 
[ 0236 ] " H NMR ( 600 MHz , Acetone - do ) 8 7 . 97 - 7 . 06 ( m , 
9H , aromatic ) , [ 7 . 03 ( br s ) ; 6 . 96 ( br s ) ; 1H , NH - 25 ] , [ 5 . 28 ( d , 
J = 10 . 7 Hz ) ; 5 . 25 ( d , J = 11 . 0 Hz ) ; 5 . 13 ( d , J = 14 . 8 ) ; 4 . 97 ( d , 
J = 15 . 0 Hz ) ; 4 . 89 ( d , J = 17 . 1 Hz ) ; 4 . 79 ( br ) ; 4 . 63 ( d , J = 15 . 4 
Hz ) ; 4 . 39 ( br ) ; 4 . 28 ( br ) , 2H , 26 ) , [ 3 . 79 ( d , J = 10 . 5 Hz ) ; 3 . 70 
( d , J = 10 . 1 Hz ) , 1H , 11 ] , 3 . 34 - 3 . 05 ( m , 2H , 16 ) , 1 . 98 - 1 . 94 ( m , 
1H , 13 ) , 1 . 94 - 0 . 67 ( m , 17H , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 
24 ) . 13C NMR ( 151 MHz , Acetone ) 8 [ 172 . 6 , 172 . 2 , 170 . 7 , 
170 . 1 — 8 , 12 ] , [ 144 . 1 , 143 . 2 , 138 . 4 4 , 27 ] , [ 141 . 1 , 140 . 8 , 
140 . 7 , 131 . 2 , 131 . 0 , 130 . 8 , 130 . 0 , 129 . 4 , 129 . 2 , 128 . 9 , 
128 . 8 , 128 . 72 , 128 . 67 , 128 . 0 , 127 . 5 , 127 . 3 — 1 , 2 , 3 , 6 , 28 , 
29 , 30 , 31 , 32 ) , 93 . 8 ( 5 ) , 169 . 0 , 67 . 8 — 11 ] , 51 . 0 , 47 . 9 , 
47 . 1 — 261 , 39 . 6 ( 16 ) , 37 . 7 ( 13 ) , [ 33 . 4 , 32 . 5 , 32 . 2 , 32 . 1 , 31 . 6 , 
31 . 0 , 30 . 5 , 30 . 4 , 30 . 3 , 27 . 1 , 26 . 89 , 26 . 85 , 26 . 8 , 26 . 7 , 26 . 5 , 
26 . 4 , 26 . 3 , 26 . 2 , 21 . 0 , 20 . 9 , 20 . 5 — 17 , 18 , 20 , 21 , 22 , 23 , 
24 ] , 14 . 1 ( 19 ) . FAB - HRMS ( m / z ) : calcd . For C26H33IN , 02 + 
H : 533 . 1665 , found 533 . 1655 . 
fgia : 
[ 0237 ] ' H NMR ( 600 MHz , Acetone - do ) 8 [ 8 . 10 - 7 . 75 ( m ) ; 
7 . 59 - 7 . 09 ( m ) , 4H , aromatic ] , [ 7 . 59 - 7 . 09 ( m ) ; 7 . 00 ( brs ) ; 
6 . 94 ( br s ) ; 1H , NH - 23 ] , [ 6 . 17 - 6 . 08 ( m ) ; 5 . 85 - 5 . 60 ( m ) , 1H , 
12 ] , [ 5 . 31 - 5 . 25 ( m ) ; 5 . 19 - 5 . 05 ( m ) ; 4 . 95 - 4 . 53 ( m ) , 2H , 22 ] , [ 5 . 19 - 5 . 05 ( m ) ; 4 . 95 - 4 . 53 ( m ) ; 3 . 71 - 3 . 37 ( m ) , 1H , 13 ] . 
4 . 48 - 3 . 76 ( m , 2H , 11 ) , 3 . 28 - 3 . 05 ( m , 2H , 24 ) , [ 2 . 37 - 2 . 13 
( m ) ; 1 . 83 - 0 . 57 ( m ) , 17H , 15 , 16 , 17 , 18 , 19 , 25 , 26 , 27 ] , 
1 . 99 - 1 . 84 ( m , 1H , 14 ) . 13C NMR ( 151 MHz , Acetone ) 
[ 172 . 1 , 171 . 5 — 8 , 20 ) , 144 . 0 ( 4 ) , [ 142 . 2 , 140 . 5 , 140 . 1 , 
132 . 0 , 131 . 0 , 130 . 6 , 129 . 0 , 128 . 9 , 128 . 6 1 , 2 , 3 , 6 ) , [ 136 . 6 , 
135 . 6 , 133 . 9 — 12 ] , [ 117 . 4 , 116 . 4 22 ) , 109 . 1 ( 5 ) , 180 . 0 , 
68 . 4 , 67 . 1 , 62 . 4 13 ] , [ 49 . 5 , 46 . 8 — 11 ] , [ 39 . 4 , 36 . 9 - 24 ] , 
[ 33 . 1 , 32 . 4 , 32 . 2 , 32 . 1 , 31 . 2 , 30 . 9 , 30 . 3 , 28 . 7 , 28 . 6 , 27 . 1 , 
26 . 9 , 26 . 84 , 26 . 76 , 26 . 7 , 26 . 6 , 26 . 5 , 26 . 4 , 26 . 2 , 26 . 1 , 25 . 7 , 
21 . 0 , 20 . 8 — 14 , 15 , 16 , 17 , 18 , 19 , 25 , 26 ] , 14 . 1 ( 27 ) . 
FAB - HRMS ( m / z ) : calcd . For C22H3 IN2O2 + H : 483 . 1509 , 
found 483 . 1507 . 
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28 1 250 
23 V 910 CH3 
24 
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[ 0238 ] H NMR ( 600 MHz , Acetone - ds ) 8 [ 7 . 94 - 7 . 82 ( m ) ; 
7 . 53 - 7 . 38 ( m ) ; 7 . 34 - 7 . 10 ( m ) , 4H , aromatic ] , [ 7 . 56 ( br s ) ; 
7 . 34 - 7 . 10 ( m ) ; 6 . 98 - 6 . 91 ( m ) , 1H , NH - 20 ] , [ 4 . 67 ( d , J = 11 . 1 
Hz ) ; 4 . 26 ( br s ) ; 3 . 62 - 3 . 58 ( m ) , 1H , 10 ] , [ 3 . 84 - 3 . 75 ( m ) ; 
3 . 57 - 3 . 49 ( m ) ; 3 . 47 - 3 . 35 ( m ) , 3 . 33 - 3 . 02 ( m ) , 4H , 21 , 25 ] , 
[ 2 . 36 - 2 . 29 ( m ) ; 2 . 16 - 2 . 08 ( m ) ; 1 . 94 - 1 . 89 ( m ) , 1H , 11 ] , 
1 . 89 - 0 . 59 ( m ; 28H , 13 , 14 , 15 , 16 , 17 , 22 , 23 , 24 , 26 , 27 , 28 , 
29 , 30 ) . 13C NMR ( 1 . 51 MHz , Acetone ) 8 [ 172 . 1 , 171 . 3 , 
170 . 8 , 170 . 2 , 169 . 6 — 8 , 18 ] , [ 144 . 1 , 143 . 8 , 143 . 4 - 4 ] , [ 140 . 9 , 
140 . 6 , 140 . 3 , 131 . 0 , 130 . 5 , 130 . 0 , 128 . 9 , 128 . 8 , 128 . 7 , 
128 . 6 , 128 . 5 — 1 , 2 , 3 , 6 ] , [ 94 . 0 , 93 . 1 — 5 ] , [ 68 . 4 , 67 . 0 , 62 . 9 , 
39 . 1 — 10 ] , [ 47 . 1 , 44 . 6 , 44 . 4 , 39 . 5 , 39 . 3 — 21 , 25 ] , [ 38 . 6 , 
37 . 2 , 36 . 8 — 11 ] , [ 33 . 2 , 32 . 44 , 32 . 40 , 32 . 3 , 32 . 2 , 31 . 6 , 31 . 2 , 
31 . 0 , 30 . 39 , 30 . 35 , 28 . 6 , 28 . 2 , 28 . 0 , 27 . 9 , 27 . 2 , 27 . 03 , 26 . 97 , 
26 . 74 , 26 . 69 , 26 . 5 , 26 . 4 , 23 . 4 , 22 . 9 , 21 . 0 , 20 . 8 — 22 , 23 , 26 , 
27 , 28 , 29 ] , [ 14 . 2 , 14 . 08 — 24 , 30 ] . FAB - HRMS ( m / z ) : calcd . 
For C25H3 IN2O2 + H : 527 . 2135 , found 527 . 2125 . 
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fgka : 
[ 0239 ] " H NMR ( 600 MHz , Acetone - do ) 18 . 32 ( s ) ; 
7 . 93 - 7 . 87 ( m ) ; 6 . 88 ( s ) , 1H , NH - 20 ] , [ 7 . 93 - 7 . 87 ( m ) ; 7 . 53 
7 . 49 ( m ) ; 7 . 31 ( dd , J = 7 . 7 , 1 . 6 Hz ) ; 7 . 25 - 7 . 15 ( m ) , 4H , 
aromatic ] , 3 . 36 ( d , J = 11 . 1 Hz , 1H , 11 ) , 3 . 33 - 3 . 05 ( m , 3H , 21 , 
25 ) , 2 . 83 - 2 . 73 ( m , 1H , 12 ) , 2 . 02 - 0 . 56 ( m , 27H , 13 , 14 , 15 , 
16 , 17 , 22 , 23 , 24 , 26 , 27 , 28 , 29 , 30 ) . 13C NMR ( 151 MHz , 
Acetone ) 8 [ 172 . 8 , 172 . 3 — 8 , 18 ] , 144 . 3 ( 4 ) , [ 140 . 4 , 131 . 1 , 
129 . 4 , 126 . 9 — 1 , 2 , 3 , 6 ] , 93 . 1 ( 5 ) , 69 . 5 ( 11 ) , 62 . 2 ( 25 ) , 39 . 4 
( 21 ) , 37 . 0 ( 12 ) , [ 32 . 70 , 32 . 69 , 32 . 53 , 32 . 46 , 32 . 2 , 31 . 9 , 31 . 6 , 
31 . 5 , 31 . 43 , 31 . 38 , 30 . 3 , 27 . 04 , 26 . 99 , 26 . 9 , 26 . 81 , 26 . 77 , 
26 . 7 , 26 . 6 , 26 . 5 , 26 . 2 , 25 . 5 , 21 . 0 , 20 . 8 — 13 , 14 , 15 , 16 , 17 , 
22 , 23 , 26 , 27 , 28 , 29 , 30 ) , 14 . 1 ( 24 ) . FAB - HRMS ( m / z ) : 
calcd . For C25Hz , IN202 + H : 525 . 1978 . found 525 . 1971 . 
fgla : 
[ 0240 ] H NMR ( 600 MHz , Acetone - do ) & [ 8 . 02 - 7 . 82 ( m ) ; 
7 . 59 - 7 . 08 ( m ) ; 6 . 79 - 6 . 73 ( m ) , 9H , aromatic ] , [ 7 . 59 - 7 . 08 ( m ) ; 
7 . 02 ( br s ) , 1H , NH - 21 ] , [ 4 . 87 - 4 . 52 ( m ) ; 3 . 69 - 3 . 65 ( m ) , 1H , 
12 ] , [ 4 . 07 - 3 . 92 ( m ) ; 3 . 80 - 3 . 71 ( m ) ; 3 . 64 - 3 . 55 ( m ) ; 3 . 42 - 3 . 15 
( m ) ; 3 . 15 - 2 . 94 ( m ) ; 2 . 78 - 2 . 57 ( m ) , 4H , 11 , 26 ) , 3 . 42 - 3 . 15 
( m , 2H , 22 ) , [ 2 . 38 - 2 . 06 ( m ) ; 2 . 05 - 0 . 76 m ) , 17H , 14 , 15 , 16 , 
17 , 18 , 23 , 24 , 25 ) . 13C NMR ( 151 MHz , Acetone - do ) 8 
[ 172 . 1 , 169 . 6 — 8 , 19 ] , [ 143 . 9 , 143 . 7 , 140 . 6 , 140 . 4 , 140 . 3 , 
139 . 7 , 139 . 6 – 4 , 27 ] , [ 131 . 2 , 131 . 1 , 130 . 7 , 129 . 81 , 129 . 77 , 
129 . 3 , 129 . 2 , 129 . 0 , 128 . 84 , 128 . 81 , 128 . 79 , 128 . 5 , 127 . 2 , 
126 . 9 , 126 . 8 — 1 , 2 , 3 , 6 , 28 , 29 , 30 , 31 , 32 ) , 93 . 8 ( 5 ) , [ 67 . 0 , 
62 . 4 - 12 ] , [ 49 . 0 , 46 . 4 — 11 , 26 ) , 39 . 3 ( 22 ) , 39 . 1 ( 13 ) , [ 38 . 6 , 
37 . 3 , 37 . 0 , 36 . 9 , 36 . 4 , 34 . 8 , 34 . 5 , 33 . 0 , 32 . 4 , 32 . 3 , 32 . 2 , 
31 . 02 , 30 . 95 , 30 . 40 , 30 . 38 , 30 . 35 , 27 . 2 , 27 . 00 , 26 . 96 , 26 . 67 , 
26 . 65 , 26 . 4 , 26 . 3 , 21 . 0 , 20 . 8 — 14 , 15 , 16 , 17 , 18 , 23 , 24 ] , 
14 . 1 ( 25 ) . FAB - HRMS ( m / z ) : calcd . For C2 , H35IN O2 + H : 
547 . 1822 , found 547 . 1815 . 
30 = 29 
fgma : 
[ 0241 ] ' H NMR ( 600 MHz , Acetone - dd ) 8 [ 8 . 07 - 7 . 02 ( m ) ; 
7 . 02 - 6 . 93 ( m ) ; 6 . 80 - 6 . 62 ( m ) , 1H , NH - 20 ] , [ 8 . 07 - 7 . 02 ( m ) ; 
7 . 02 - 6 . 93 ( m ) ; 6 . 80 - 6 . 62 ( m ) ; 6 . 57 - 6 . 39 ( m ) , 14H , aro 
matic ] , 4 . 65 - 4 . 60 ( m , 1H , 26 ) , [ 4 . 33 - 4 . 26 ( m ) ; 4 . 14 ( br d ) ; 
3 . 63 ( d , J = 10 . 2 Hz ) ; 3 . 53 ( d , J = 10 . 3 Hz ) , 1H , 11 ] , 4 . 11 - 3 . 87 
( m , 2H , 25 ) , 3 . 35 - 3 . 01 ( m , 2H , 21 ) , 2 . 39 - 2 . 22 ( m , 1H , 12 ) , 
2 . 03 - 0 . 42 ( m , 17H , 13 , 14 , 15 , 16 , 17 , 22 , 23 , 24 ) . 13C NMR 
( 151 MHz , Acetone ) [ 172 . 8 , 172 . 7 , 170 . 7 , 170 . 3 — 8 , 18 ] , 
[ 143 . 6 , 143 . 5 , 143 . 42 , 143 . 37 , 142 . 9 , 142 . 8 — 4 , 27 , 28 ) , 
[ 141 . 2 , 140 . 3 , 139 . 8 , 131 . 3 , 131 . 0 , 130 . 9 , 130 . 0 , 129 . 9 , 
129 . 7 , 129 . 6 , 129 . 51 , 129 . 45 , 129 . 4 , 129 . 34 , 129 . 27 , 129 . 24 , 
129 . 16 , 129 . 11 , 129 . 07 , 128 . 96 , 128 . 91 , 128 . 82 , 128 . 75 , 
128 . 5 , 127 . 5 , 127 . 40 , 127 . 37 , 127 . 2 , 126 . 9 — 1 , 2 , 3 , 6 , 29 , 
30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ] , [ 93 . 9 , 92 . 7 — 5 ] , 69 ( 11 ) , 
[ 56 . 4 , 55 . 7 — 25 ] , [ 50 . 5 , 50 . 4 , 50 . 1 — 26 ] , [ 39 . 6 , 39 . 5 — 21 ] , 
[ 38 . 3 , 37 . 2 – 12 ] , [ 32 . 9 , 32 . 43 , 32 . 40 , 32 . 1 , 31 . 3 , 31 . 2 , 30 . 9 , 
30 . 4 , 27 . 04 , 26 . 97 , 26 . 6 , 26 . 5 , 26 . 3 , 26 . 2 , 20 . 9 , 20 . 8 — 13 , 
14 , 15 , 16 , 17 , 22 , 23 ] , 14 . 1 ( 24 ) . FAB - HRMS ( m / z ) : calcd . 
For C33H39IN2O2 + H : 623 . 2135 , found 623 . 2127 . 
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[ 0242 ] ' H NMR ( 600 MHz , Acetone - d ) 8 [ 8 . 63 ( brs ) ; 
8 . 14 - 6 . 76 ( m ) , 1H , NH - 20 ] , 8 . 14 - 6 . 76 ( m , 4H , aromatic ) , 
3 . 63 - 3 . 48 ( m , 1H , 10 ) , 3 . 32 - 3 . 11 ( m , 2H , 21 ) , 2 . 71 - 2 . 60 ( m , 
1H , 11 ) , 2 . 20 - 0 . 52 ( m , 26H , 12 , 13 , 14 , 15 , 16 , 22 , 23 , 24 , 
26 , 27 , 28 ) . 13C NMR ( 151 MHz , Acetone ) 8 [ 173 . 3 , 173 . 2 , 
168 . 9 , 166 . 4 8 , 18 ] , 146 . 6 ( 4 ) , [ 142 . 2 , 141 . 1 , 140 . 3 , 133 . 9 , 
132 . 0 , 131 . 1 , 131 . 0 , 129 . 10 , 128 . 98 , 128 . 6 , 127 . 7 — 1 , 2 , 3 , 
6 ] , [ 96 . 8 , 96 . 7 — 5 ] , 72 . 5 ( 10 ) , 50 . 3 ( 25 ) , [ 39 . 45 , 39 . 33 , 
39 . 29 - 21 ] , 37 . 1 ( 11 ) , [ 30 . 9 , 14 . 3 , 13 . 8 — 26 , 27 , 28 ] , [ 32 . 6 , 
32 . 5 , 32 . 4 , 31 . 7 . 31 . 1 . 30 . 3 , 28 . 6 , 27 . 2 , 27 . 0 , 26 . 9 , 26 . 8 26 . 7 , 
26 . 6 , 26 . 5 , 26 . 4 , 25 . 7 , 20 . 9 , 20 . 8 , 20 . 7 – 12 , 13 , 14 , 15 , 16 , 
22 , 23 ] , [ 14 . 5 , 14 . 1 - 24 ] . FAB - HRMS ( m / z ) : calcd . For 
C23H35IN , O2 + H : 499 . 1822 , found 499 . 1816 . 
fgoa : 
[ 0243 ] ' H NMR ( 600 MHz , Acetone - do ) d [ 8 . 33 ( brs ) ; 
7 . 98 - 7 . 90 ( m ) ; 7 . 35 - 7 . 29 ( m ) ; 7 . 23 - 7 . 15 ( m ) , 1H , NH - 20 ] , [ 7 . 98 - 7 . 90 ( m ) ; 7 . 58 - 7 . 49 ( m ) ; 7 . 35 - 7 . 29 ( m ) ; 7 . 23 - 7 . 15 ( m ) , 
4H , aromatic ] , 3 . 80 - 3 . 65 ( m , 1H , 25 ) , 3 . 35 - 3 . 22 ( m , 1H , 10 ) , [ 3 . 35 - 3 . 22 ( m ) ; 3 . 22 - 3 . 08 ( m ) , 2H , 21 ) , 2 . 82 - 2 . 75 ( m , 1H , 
11 ) , 2 . 03 - 0 . 55 ( m , 23H , 13 , 14 , 15 , 16 , 17 , 22 , 23 , 24 , 26 , 
27 ) . 13C NMR ( 151 MHz , Acetone ) & [ 172 . 6 , 172 . 5 — 8 , 18 ] , 
[ 144 . 3 — 4 ] , [ 140 . 5 , 131 . 2 , 129 . 4 , 126 . 9 — 1 , 2 , 3 , 61 , 93 . 2 
( 5 ) , 68 . 3 ( 10 ) , 53 . 5 ( 25 ) , 39 . 4 ( 21 ) , 36 . 9 ( 11 ) , [ 32 . 7 , 32 . 51 , 
32 . 48 , 32 . 4 , 32 . 2 , 31 . 51 , 31 . 46 , 31 . 4 , 30 . 4 , 28 . 6 , 27 . 2 , 27 . 0 , 
26 . 9 , 26 . 81 , 26 . 79 , 26 . 72 , 26 . 68 , 26 . 63 , 26 . 58 , 26 . 5 , 26 . 4 , 
25 . 7 , 21 . 8 , 21 . 5 , 21 . 0 , 20 . 9 , 20 . 82 , 20 . 78 , 20 . 7 , 20 . 5 , 20 . 1 , 
14 . 5 — 13 , 14 , 15 , 16 , 17 , 22 , 23 ] , [ 21 . 8 , 20 . 5 — 26 , 27 ) , 14 . 1 
( 24 ) . FAB - HRMS ( m / z ) : calcd . For C22H33IN , O2 + H : 485 . 
1665 , found 485 . 1658 . 
fgpa : 
[ 0244 ] ' H NMR ( 600 MHz , Acetone - do ) 8 [ 7 . 94 - 7 . 82 ( m ) ; 
7 . 52 - 7 . 38 ( m ) ; 7 . 33 - 7 . 10 ( m ) , 4H , aromatic ] , [ 7 . 56 ( br s ) ; 
7 . 38 - 7 . 09 ( m ) ; 6 . 94 ( m ) , 1H , NH - 20 ] , [ 4 . 68 ( d , J = 11 . 1 Hz ) ; 
4 . 26 ( brs ) , 1H , 10 ] , [ 3 . 91 - 3 . 78 ( m ) ; 3 . 64 - 3 . 55 ( m ) ; 3 . 52 - 3 . 
39 ( m ) ; 3 . 34 - 3 . 13 ( m ) ; 3 . 13 - 3 . 06 ( m ) , 2H , 251 , 3 . 34 - 3 . 13 ( m , 
2H , 21 ) , [ 2 . 32 ( d , J = 12 . 0 Hz ) ; 2 . 13 - 2 . 08 ( m ) , 1H , 11 ] , 
2 . 00 - 0 . 53 ( m , 26H , 13 , 14 , 15 , 16 , 17 , 22 , 23 , 24 , 26 , 27 , 28 , 
29 ) . 13C NMR ( 151 MHz , Acetone ) 8 [ 172 . 3 , 171 . 0 , 170 . 9 , 
170 . 2 , 169 . 7 — 8 , 18 ] , 143 . 9 ( 4 ) , [ 141 . 0 , 140 . 7 , 140 . 4 , 131 . 1 , 
130 . 6 , 129 . 1 , 129 . 0 , 128 . 9 , 128 . 8 — 1 , 2 , 3 , 6 ] , 93 . 2 ( 5 ) , 62 . 9 
( 10 ) , [ 45 . 7 , 43 . 1 — 25 ] , [ 39 . 6 , 39 . 4 — 21 ) , 36 . 9 ( 11 ) , 36 . 6 
( 27 ) , [ 39 . 3 , 38 . 6 , 37 . 6 , 37 . 3 , 37 . 2 , 37 . 0 , 33 . 3 , 32 . 6 , 32 . 4 , 
32 . 3 , 31 . 3 , 31 . 2 , 31 . 1 , 30 . 52 , 30 . 47 , 27 . 9 , 27 . 3 , 27 . 2 , 27 . 1 , 
26 . 9 , 26 . 81 , 26 . 76 , 26 . 6 , 26 . 5 , 23 . 23 , 23 . 19 , 23 . 1 , 23 . 0 , 21 . 1 , 
21 . 0 – 13 , 14 , 15 , 16 , 17 , 22 , 23 , 26 ] , [ 22 . 7 , 22 . 42 , 22 . 37 , 
22 . 3 — 28 , 29 ] , 14 . 2 ( 24 ) . FAB - HRMS ( m / z ) : calcd . For 
C24H , , N , O2 + H : 512 . 1900 , found 513 . 1973 . 
fgqa : 
[ 0245 ] ' H NMR ( 600 MHz , Acetone - do ) 8 [ 7 . 72 - 7 . 66 ( m ) ; 
7 . 47 - 6 . 56 ( m ) , 9H , aromatic ] , 7 . 47 - 6 . 56 ( m , 1H , NH - 20 ) , 
[ 4 . 70 ( br s ) ; 4 . 44 - 4 . 40 ( m ) , 1H , 11 ] , 3 . 34 - 3 . 12 ( m , 2H , 21 ) , 
[ 2 . 24 - 2 . 15 ( m ) ; 1 . 80 - 0 . 77 ( m ) , 17H , 13 , 14 , 15 , 16 , 17 , 22 , 
23 , 24 ] , 2 . 04 - 1 . 93 ( m , 1H , 12 ) . 13C NMR ( 151 MHz , 
Acetone ) & [ 178 . 4 , 171 . 5 — 8 , 18 ] , [ 143 . 9 , 94 . 2 — 4 , 5 , 25 ) , [ 139 . 9 , 130 . 5 , 130 . 4 , 130 . 0 , 129 . 5 , 129 . 2 , 128 . 5 , 128 . 2 — 1 , 
2 , 3 , 6 , 26 , 27 , 28 , 29 , 30 ) , 60 . 5 ( 11 ) , 39 . 5 ( 21 ) , 37 . 1 ( 12 ) , 
[ 32 . 5 , 32 . 4 , 31 . 1 , 30 . 7 , 30 . 4 , 30 . 3 , 27 . 1 , 26 . 5 , 26 . 4 , 26 . 3 , 
26 . 2 , 20 . 8 – 13 , 14 , 15 , 16 , 17 , 22 , 23 ] , 14 . 1 ( 24 ) . FAB 
HRMS ( m / z ) : calcd . For C25H3 , IN2O2 + H : 519 . 1509 , found 
519 . 1523 . 
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22 , 23 ] , 14 . 1 ( 24 ) . FAB - HRMS ( m / z ) : calcd . For 
C2H3 . CIIN , O2 + H : 553 . 1119 , found 553 . 1120 . x = 31 - 30 
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[ 0246 ] * H NMR ( 600 MHz , Acetone - do ) & [ 8 . 30 ( br s ) ; 
8 . 10 - 7 . 05 ( m ) , 1H , NH - 20 ] , 8 . 10 - 7 . 05 ( m , 9H , aromatic ) , [ 5 . 73 - 5 . 58 ( m ) ; 5 . 03 - 4 . 79 ( m ) , 1H , 25 ] , [ 3 . 90 - 3 . 71 ( m ) ; 
3 . 51 - 3 . 09 ( m ) , 1H , 10 ] , [ 3 . 51 - 3 . 09 ( m ) ; 2 . 98 - 2 . 91 ( m ) , 2H , 
21 ] , 2 . 72 - 2 . 56 ( m , 11 , 11 ) , 2 . 01 - 0 . 56 ( m , 20H , 13 , 14 , 15 , 16 , 
17 , 22 , 23 , 24 , 26 ) . 13C NMR ( 151 MHz , Acetone ) 8 [ 172 . 9 , 
172 . 7 , 170 . 8 — 8 , 18 ] , [ 142 . 9 , 139 . 0 4 , 27 ] , [ 141 . 4 , 140 . 9 , 
139 . 8 , 131 . 8 , 131 . 5 , 131 . 1 , 130 . 4 , 129 . 8 , 129 . 7 , 129 . 5 , 
129 . 33 , 129 . 29 , 129 . 2 , 129 . 1 , 128 . 9 , 128 . 8 , 128 . 62 , 128 . 55 , 
128 . 4 , 128 . 1 , 127 . 8 — 1 , 2 , 3 , 6 , 28 , 29 , 30 , 31 , 32 ) , 94 . 4 ( 5 ) , 
[ 69 . 3 , 68 . 5 — 10 ] , [ 60 . 0 , 59 . 6 — 25 ] , [ 39 . 5 , 39 . 3 — 21 ] , 36 . 8 
( 11 ) , [ 32 . 6 , 32 . 5 , 32 . 3 , 31 . 9 , 31 . 41 , 31 . 36 , 31 . 3 , 30 . 5 , 27 . 04 , 
26 . 96 , 26 . 85 , 26 . 8 , 26 . 7 , 26 . 5 , 26 . 4 , 26 . 2 , 20 . 96 , 20 . 93 , 20 . 8 , 
19 . 4 , 19 . 1 — 13 , 14 , 15 , 16 , 17 , 22 , 23 ] , 17 . 6 ( 26 ) , 14 . 1 ( 24 ) . 
FAB - HRMS ( m / z ) : calcd . For C2 , H35IN O2 + H : 547 . 1822 , 
found 547 . 1825 . 
fgta : 
[ 0247 ] ' H NMR ( 600 MHz , Acetone - do ) 8 [ 7 . 71 ( d , J = 7 . 9 
Hz ) ; 7 . 49 - 7 . 37 ( m ) ; 7 . 23 - 7 . 18 ( m ) ; 6 . 94 - 6 . 91 ( m ) , 8H , 
aromatic ] , [ 7 . 49 - 7 . 37 ( m ) ; 7 . 37 - 7 . 31 ( m ) , 1H , NH - 20 ] , [ 4 . 81 ( br s ) ; 4 . 58 ( d , J = 11 . 0 Hz ) , 1H , 10 ] , [ 3 . 30 - 3 . 24 ( m ) ; 3 . 20 
3 . 13 ( m ) , 2H , 21 ] , [ 2 . 16 - 2 . 08 ( m ) ; 1 . 98 - 1 . 93 ( m ) ; 1 . 78 - 1 . 59 
( m ) ; 1 . 17 - 1 . 04 ( m ) , 10H , 13 , 14 , 15 , 16 , 17 ] , 1 . 92 - 1 . 84 ( m , 
1H , 11 ) , 1 . 59 - 1 . 51 ( m , 2H , 22 ) , 1 . 44 - 1 . 36 ( m , 2H , 23 ) , 0 . 92 
( t , J = 7 . 4 Hz , 3H , 24 ) . 13C NMR ( 151 MHz , Acetone ) 
[ 171 . 2 , 170 . 9 — 8 , 18 ] , [ 143 . 7 , 133 . 7 , 115 . 3 , 94 . 1 — 4 , 5 , 25 , 
28 ] , [ 140 . 01 , 140 . 00 , 132 . 4 , 130 . 7 , 129 . 5 , 129 . 1 , 128 . 3 — 1 , 
2 , 3 , 6 , 26 , 27 , 29 , 30 ) , 67 . 0 ( 10 ) , 39 . 6 ( 21 ) , 37 . 2 ( 11 ) , [ 32 . 4 , 
31 . 0 , 30 . 5 , 30 . 3 , 27 . 0 , 26 . 4 , 26 . 3 , 20 . 8 — 13 , 14 , 15 , 16 , 17 , 
fgua : 
[ 0248 ] H NMR ( 600 MHz , Acetone - d ) 8 [ 7 . 72 - 7 . 67 ( m ) ; 
7 . 61 - 7 . 56 ( m ) ; 7 . 44 - 7 . 39 ( m ) ; 7 . 35 - 7 . 30 ( m ) ; 7 . 21 - 7 . 15 ( m ) ; 
7 . 06 ( br s ) ; 6 . 98 - 6 . 85 ( m ) ; 6 . 75 - 6 . 67 ( m ) , 8H , aromatic ] , [ 7 . 44 - 7 . 39 ( m ) ; 7 . 35 - 7 . 30 ( m ) , 1H , NH - 20 ] , [ 4 . 71 ( brs ) ; 
4 . 45 ( d , J = 11 . 1 Hz ) , 1H , 10 ) , 3 . 69 ( s , 3H , 32 ) , 3 . 32 - 3 . 14 ( m , 
2H , 21 ) , [ 2 . 28 - 2 . 08 ( m ) ; 1 . 99 - 0 . 57 ( m ) , 18H , 11 , 13 , 14 , 15 , 
16 , 17 , 22 , 23 , 24 ) . 13C NMR ( 151 MHz , Acetone ) 8 [ 171 . 7 , 
159 . 7 — 8 , 18 ] , [ 144 . 2 , 133 . 7 , 115 . 5 , 94 . 1 – 4 , 5 , 25 , 28 ] , 
[ 139 . 9 , 131 . 6 , 130 . 6 , 129 . 4 , 128 . 2 , 121 . 6 , 115 . 3 , 114 . 7 , 
114 . 2 — 1 , 2 , 3 , 6 , 26 , 27 , 29 , 30 ) , 67 . 7 ( 10 ) , 55 . 6 ( 32 ) , 39 . 6 
( 21 ) , [ 39 . 2 , 37 . 1 , 32 . 5 , 31 . 1 , 30 . 6 , 30 . 4 , 27 . 1 , 26 . 5 , 26 . 3 , 
26 . 2 , 20 . 8 — 13 , 14 , 15 , 16 , 17 , 22 , 23 ) , 37 . 0 ( 11 ) , 14 . 1 ( 24 ) . 
FAB - HRMS ( m / z ) : calcd . For C26H33IN2O3 + H : 549 . 1614 , 
found 549 . 1624 . 
fgva 
[ 0249 ] H NMR ( 600 MHz , Acetone - da ) 8 [ 7 . 86 - 6 . 90 ( m ) ; 
6 . 59 - 6 . 47 ( m ) , 9H , 1 , 2 , 3 , 6 , NH - 21 , 25 , 26 , 28 , 29 ] , [ 4 . 78 
( br s ) ; 4 . 55 ( d , J = 10 . 9 Hz ) , 1H , 11 ] , 3 . 33 - 3 . 08 ( m , 2H , 21 ) , [ 2 . 12 ( s ) ; 2 . 00 - 0 . 81 ( m ) , 17H , 13 , 14 , 15 , 16 , 17 , 22 , 23 , 24 ] . 
[ 0250 ] 13C NMR ( 151 MHz , Acetone - do ) d 171 . 1 ( 7 , 18 ) , 
143 . 7 ( 4 , 10 ) , [ 140 . 0 , 139 . 1 , 138 . 3 , 132 . 8 , 130 . 7 , 129 . 5 , 
128 . 3 — 1 , 2 , 3 , 6 , 25 , 26 , 28 , 29 ] , 116 . 5 ( 27 ) , [ 94 . 1 , 
93 . 5 — 5 ) , 43 . 1 ( 11 ) , [ 39 . 6 , 39 . 3 — 21 ] , 37 . 2 ( 12 ) , [ 32 . 43 , 
32 . 39 , 31 . 0 , 30 . 6 , 30 . 4 , 27 . 0 , 26 . 4 , 26 . 3 , 26 . 1 , 20 . 8 — 13 , 14 , 
15 , 16 , 17 , 22 , 23 ] 14 . 1 ( 24 ) . 
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[ 0251 ] FAB - HRMS ( m / z ) : calcd . For C25H3012N2O3 + H : 
645 . 0475 , found 645 . 0476 . 
132 . 3 , 132 . 2 , 130 . 7 , 129 . 5 , 128 . 3 — 1 , 2 , 3 , 6 , 25 , 26 , 28 , 29 ] , 
115 . 8 ( 27 ) , 94 . 0 ( 5 ) , 43 . 1 ( 11 ) , [ 39 . 6 , 39 . 3 — 21 ] , [ 37 . 2 , 
37 . 2 — 12 ] , [ 32 . 4 , 32 . 4 , 31 . 0 , 30 . 8 , 30 . 7 , 30 . 5 , 30 . 4 , 27 . 1 , 
27 . 04 , 26 . 98 , 26 . 5 , 26 . 42 , 26 . 39 , 26 . 3 , 26 . 1 , 20 . 8 , 20 . 7 , 
20 . 6 — 13 , 14 , 15 , 16 , 17 , 22 , 23 ] , [ 14 . 1 , 14 . 03 , 13 . 99 — 241 . 
[ 0257 ] FAB - HRMS ( m / z ) : calcd . For C25H3 BrIN2O2 + H : 
597 . 0614 , found 599 . 0597 . 
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[ 0252 ] " H NMR ( 600 MHz , Acetone - da ) 8 8 . 18 - 6 . 47 ( m , 
9H , 1 , 2 , 3 , 6 , NH - 20 , 25 , 26 , 28 , 29 ) , [ 14 . 85 ( br s , 1H ) ; 4 . 63 ( d , J = 11 . 0 Hz ) ; 3 . 89 ( s ) ; 3 . 83 - 3 . 78 ( m ) ; 3 . 72 - 3 . 67 ( m ) , 1H , 
11 ] , 3 . 32 - 3 . 12 ( m , 2H , 21 ) , [ 2 . 16 - 2 . 07 ( m ) ; 2 . 00 - 0 . 81 ( m ) , 
13 , 14 , 15 , 16 , 17 , 22 , 23 , 24 ] . 
[ 0253 ] 13C NMR ( 151 MHz , Acetone - da ) 8 [ 172 1 , 171 . 
0 - 7 , 18 ] , [ 143 . 5 , 141 . 9 - 4 , 10 , 27 ] , 140 . 1 , 131 . 4 , 130 . 9 , 129 . 6 , 
128 . 4 , 127 . 1 , 126 . 1 , 113 . 3 , 113 . 0 — 1 , 2 , 3 , 6 , 25 , 26 , 28 , 29 ] , 
125 . 9 ( 31 ) , 167 . 0 , 63 . 9 , 52 . 7 , 52 . 0 — 11 ] , [ 39 . 6 , 39 . 4 , 39 . 3 — 
21 ] , [ 43 . 2 , 42 . 0 , 37 . 4 , 37 . 3 — 121 , 41 . 6 , 40 . 7 , 37 . 3 , 32 . 5 , 
32 . 4 , 31 . 0 , 30 . 7 , 30 . 6 , 30 . 5 , 30 . 3 , 27 . 0 , 26 . 9 , 26 . 44 , 26 . 39 , 
26 . 35 , 26 . 2 , 26 . 1 , 20 . 8 , 20 . 7 , 20 . 6 — 13 , 14 , 15 , 16 , 17 , 22 , 
23 ] , [ 14 . 1 , 14 . 0 24 ] . 
[ 0254 ] FAB - HRMS ( m / z ) : calcd . For C26H3 . F3IN2O2 + H : 
587 . 1382 , found 587 . 1381 . 
fgxa 
[ 0255 ] " H NMR ( 600 MHz , Acetone - do ) 5 [ 7 . 75 - 6 . 90 ( m ) ; 
6 . 66 - 6 . 48 ( m ) , 9H , 1 , 2 , 3 , 6 , NH - 20 , 25 , 26 , 28 , 29 ] , [ 4 . 80 
( brs ) ; 4 . 62 - 4 . 48 ( m ) ; 3 . 66 - 3 . 52 ( m ) , 1H , 11 ) , 3 . 30 - 3 . 13 ( m , 
2H , 21 ) , [ 2 . 18 - 2 . 07 ( m ) ; 1 . 98 - 0 . 80 ( m ) , 17H , 13 , 14 , 15 , 16 , 
17 , 22 , 23 , 24 ) . 
[ 0256 ] 13C NMR ( 151 MHz , Acetone - do ) 5 [ 177 . 0 , 171 . 0 , 
167 . 0 — 7 , 18 ] , [ 143 . 7 , 121 . 8 — 4 , 10 ] , [ 140 . 0 , 133 . 0 , 132 . 7 , 
[ 0258 ] ' H NMR ( 600 MHz , Acetone - do ) 8 7 . 90 - 6 . 79 ( m , 
13H , 1 , 2 , 5 , 6 , NH - 20 , 25 , 26 , 27 , 28 , 29 , 31 , 32 , 33 , 34 , 35 ) , 
6 . 62 ( br d , J = 7 . 7 Hz , 2H , 1 , 2 , 5 , 6 , 25 , 26 , 27 , 28 , 29 , 31 , 
32 , 33 , 34 , 35 ) , 4 . 73 - 4 . 40 ( m , 1H , 11 ) , 3 . 34 - 3 . 11 ( m , 2H , 21 ) , 
[ 2 . 34 - 2 . 07 ( m ) ; 2 . 01 - 0 . 76 ( m ) , 171 , 13 , 14 , 15 , 16 , 17 , 22 , 
23 , 24 ] . [ 0259 ] 13C NMR ( 151 MHz , Acetone - do ) 8 [ 172 . 5 , 169 . 
5 — 7 , 18 ] , [ 141 . 1 , 139 . 2 , 137 . 7 , 135 . 0 , 131 . 0 , 129 . 7 , 127 . 
7 – 3 , 4 , 10 , 30 ) , [ 130 . 4 , 130 . 2 , 130 . 1 , 130 . 0 , 129 . 8 , 129 . 6 , 
129 . 33 , 129 . 25 , 129 . 1 , 128 . 9 , 128 . 6 , 128 . 3 , 128 . 3 , 128 . 2 , 
127 . 9 , 127 . 4 — 1 , 2 , 5 , 6 , 25 , 26 , 27 , 28 , 29 , 31 , 32 , 33 , 34 , 
35 ] , 49 . 5 ( 11 ) , [ 39 . 5 , 39 . 4 , 39 . 3 — 21 ] , [ 37 . 2 , 37 . 1 — 12 ] , 
[ 32 . 4 , 30 . 9 , 30 . 8 , 30 . 7 , 30 . 6 , 30 . 4 , 27 . 13 , 27 . 07 , 26 . 41 , 
26 . 38 , 26 . 3 , 26 . 1 , 20 . 8 , 20 . 7 – 13 , 14 , 15 , 16 , 17 , 22 , 23 ) , 
[ 14 . 1 , 14 . 0 — 24 ) , 
[ 0260 ] FAB - HRMS ( m / z ) : calcd . For Cz1H36N2O2 + H : 
469 . 2855 , found 469 . 2853 . 
MO - 03 
[ 0261 ] ' H NMR ( 600 MHz , Acetone - do ) d 8 . 33 - 8 . 21 ( m 
1H , NH - 20 ) , 7 . 90 - 7 . 00 ( m , 9H , 1 , 2 , 5 , 6 , 33 , 34 , 35 , 36 , 37 ) , 
3 . 78 - 3 . 48 ( m , 1H , 21 ) , [ 3 . 37 - 3 . 30 ( m ) ; 3 . 26 ( tt , J = 12 . 0 , 3 . 6 
Hz ) ; 3 . 11 - 3 . 04 ( m ) , 1H , 10 ] , [ 3 . 14 ( d , J = 11 . 1 Hz ) ; 3 . 11 - 3 . 04 
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40 
- 26 28 - 2 
25 
12 
10 NH CH3 
23 
= 
( m ) , 1H , 11 ] , 2 . 75 - 2 . 50 ( m , 1H , 12 ) , 1 . 99 - 0 . 24 ( m , 30H , 13 , 
14 , 15 , 16 , 17 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ) . [ 0262 ] 13C NMR ( 151 MHz , Acetone - da ) 8 [ 173 5 , 173 . 1 , 
171 . 8 , 171 . 1 — 7 , 18 ] , [ 141 . 2 , 141 . 0 , 139 . 8 , 138 . 8 , 138 . 3 , 
138 . 0 3 , 32 ] , [ 130 . 8 , 130 . 7 , 130 . 1 , 129 . 9 , 129 . 7 , 129 . 5 , 
129 . 4 , 129 . 2 , 128 . 6 , 128 . 4 , 127 . 2 , 126 . 9 , 126 . 7 — 1 , 2 , 5 , 6 , 
33 , 34 , 35 , 36 , 37 ] , [ 70 . 0 , 69 . 4 — 11 ] , [ 61 . 9 , 61 . 2 — 10 ] , 
48 . 7 , 48 . 0 21 ) , [ 37 . 2 , 37 . 0 , 36 . 9 — 12 ) , [ 33 . 6 , 33 . 4 , 33 . 2 , 
33 . 0 , 32 . 3 , 31 . 8 , 31 . 64 , 31 . 56 , 31 . 5 , 31 . 3 , 31 . 2 , 31 . 1 , 30 . 6 , 
30 . 4 , 27 . 12 , 27 . 06 , 27 . 04 , 26 . 96 , 26 9 , 26 . 8 , 26 . 7 , 26 . 6 , 
26 . 48 , 26 . 46 , 26 . 4 , 26 . 30 , 26 . 26 , 25 . 9 , 25 . 6 , 25 . 5 , 25 . 3 , 25 . 2 , 
25 . 1 , 23 . 3 , 14 . 4 — 13 , 14 , 15 , 16 , 17 , 22 , 23 , 24 , 25 , 25 , 26 , 
27 , 28 , 29 , 30 , 31 ] . 
[ 0263 ] FAB - HRMS ( m / z ) : calcd . For C33H44N2O2 + H : 
501 . 3481 , found 501 . 3483 . 
O 
13 14 
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[ 0267 ] rgka ' H NMR ( 600 MHz , Acetone - d6 ) 8 8 . 55 ( s , 
1H , 16 ) , 7 . 53 - 7 . 45 ( m , 3H , 1 , 2 , 4 ) , 7 . 45 - 7 . 39 ( m , 2H , 3 , 6 ) , 
3 . 54 - 3 . 46 ( m , 1H , 24 ) , 3 . 37 ( d , J = 11 . 0 Hz , 1H , 10 ) , 3 . 34 
3 . 09 ( m , 2H , 19 ) , 2 . 70 ( m , J = 14 . 3 , 12 . 9 Hz , 1H , 11 ) , 
1 . 92 - 1 . 53 ( m , 13H ) , 1 . 53 - 1 . 46 ( m , 2H , 21 ) , 1 . 43 - 1 . 35 ( m , 
2H , 22 ) , 1 . 34 - 0 . 95 ( m , 6H ) , 0 . 94 ( t . J = 7 . 3 Hz , 3H , 23 ) . 
MO - 04 
[ 0264 ] " H NMR ( 600 MHz , Acetone - do ) 8 [ 8 . 60 ( brs ) ; 
8 . 35 - 8 . 19 ( m ) , 1H , NH - 20 ] , 7 . 78 - 6 . 83 ( m , 13H , 1 , 2 , 5 , 6 , 33 , 
34 , 36 , 37 , 40 , 41 , 42 , 43 , 441 , 3 . 80 - 3 . 43 ( m , 1H , 21 ) , 
[ 3 . 40 - 3 . 27 ( m ) ; 3 . 21 ( tt , J = 11 . 9 , 3 . 6 Hz ) ; 3 . 18 - 3 . 06 ( m ) , 1H , 
10 ] , 3 . 18 - 3 . 06 ( m , 1H , 11 ) , 2 . 77 - 2 . 64 ( m , 1H , 12 ) , 1 . 98 - 0 . 40 
( m , 30H , 13 , 14 , 15 , 16 , 17 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 
30 , 31 ) . 
[ 0265 ] 13C NMR ( 151 MHz , Acetone ) d [ 173 . 6 , 173 . 2 , 
171 . 8 , 171 . 0 — 7 , 18 ] , [ 158 . 20 , 158 . 18 , 157 . 9 , 157 . 7 – 35 , 
39 ] , [ 138 . 9 , 138 . 4 , 138 . 1 , 138 . 0 , 136 . 1 , 136 . 0 — 3 , 4 , 32 ] , 
[ 131 . 7 , 131 . 3 , 130 . 9 , 130 . 8 , 130 . 7 , 130 . 5 , 130 . 0 , 129 . 8 , 
129 . 5 , 128 . 5 , 128 . 4 , 127 . 3 , 126 . 9 , 124 . 6 , 124 . 5 , 121 . 9 , 
120 . 0 , 119 . 9 , 119 . 4 , 119 . 3 , 118 . 0 , 117 . 1 — 1 , 2 , 5 , 6 , 33 , 34 , 
36 , 37 , 40 , 41 , 42 , 43 , 44 ] , [ 70 . 0 , 69 . 3 — 11 ] , [ 61 . 9 , 61 . 2 — 
10 ] , [ 48 . 8 , 48 . 0 — 21 ] , [ 37 . 3 , 37 . 1 , 37 . 0 — 12 ] , [ 33 . 6 , 33 . 4 , 
33 . 1 , 31 . 84 , 31 . 76 , 31 . 7 , 31 . 54 , 31 . 51 , 31 . 3 , 31 . 2 , 30 . 6 , 30 . 4 , 
27 . 12 , 27 . 06 , 27 . 0 , 26 . 9 , 26 . 84 , 26 . 77 , 26 . 7 , 26 . 6 , 26 . 5 , 26 . 4 , 
26 . 4 , 26 . 29 , 26 . 27 , 26 . 2 , 25 . 9 , 25 . 6 , 25 . 5 , 25 . 3 , 25 . 2 , 25 . 1 — 
13 , 14 , 15 , 16 , 17 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ] . 
[ 0266 ] FAB - HRMS ( m / z ) : calcd . For Cz9H43N2O3 + H : 
593 . 3743 , found 593 . 3751 . 
[ 0268 ] 13C NMR ( 151 MHz , Acetone ) & 173 . 88 ( 7 ) , 173 . 
06 ( 7 ) , 138 . 73 ( 12 ) , 130 . 46 ( 5 ) , 129 . 47 ( 1 , 2 , 4 ) , 126 . 91 ( 3 , 
6 ) , 69 . 57 ( 10 ) , 61 . 99 ( 24 ) , 39 . 15 ( 19 ) , 36 . 80 ( 11 ) , 32 . 39 , 
31 . 84 , 31 . 49 , 31 . 38 , 30 . 23 , 30 . 10 , 29 . 97 , 29 . 84 , 29 . 71 , 
29 . 58 , 29 . 45 , 27 . 13 , 27 . 07 , 26 . 80 , 26 . 76 , 26 . 61 , 26 . 30 , 25 . 65 
( 21 ) , 20 . 74 ( 22 ) , 20 . 62 , 14 . 02 ( 23 ) , 13 . 98 . 
[ 0269 ] rgoa ' H NMR ( 600 MHz , Acetone - d6 ) 8 8 . 56 ( s , 
1H , 17 ) , 7 . 52 - 7 . 39 ( m , 5H , 1 , 2 , 3 , 4 , 6 ) , 3 . 98 ( m , 1H , 10 ) , 
3 . 37 - 3 . 27 ( m , 2H , 13 , 18 ) , 3 . 18 - 3 . 08 ( m , 1H , 18 ) , 2 . 75 - 2 . 67 
( m , 1H , 14 ) , 1 . 91 - 1 . 64 ( m , 6H , 20 , 21 , 22 , 23 , 24 ) , 1 . 54 - 1 . 45 
( m , 2H , 19 ) , 1 . 44 - 1 . 35 ( m , 2H , 25 ) , 1 . 29 - 1 . 19 ( m , 6H , 11 , 12 , 
20 , 21 , 22 , 23 , 24 ) , 1 . 09 ( d , J = 6 . 8 Hz , 3H , 11 , 12 ) , 1 . 05 - 0 . 97 
( m , 1H , 20 , 21 , 22 , 23 , 24 ) , 0 . 94 ( t , J = 7 . 3 Hz , 3H , 26 ) . 
[ 0270 ] 13C NMR ( 151 MHz , Acetone ) & 173 . 72 ( 7 , 15 ) , 
173 . 17 ( 7 , 15 ) , 138 . 72 ( 5 ) , 130 . 43 ( 1 , 2 , 3 , 4 , 6 ) , 129 . 50 ( 1 , 
2 , 3 , 4 , 6 ) , 126 . 97 ( 1 , 2 , 3 , 4 , 6 ) , 68 . 34 ( 13 ) , 53 . 33 ( 10 ) , 39 . 12 
( 18 ) , 36 . 70 ( 14 ) , 32 . 37 ( 19 ) , 31 . 42 ( 20 , 24 ) , 31 . 34 ( 20 , 24 ) , 
27 . 05 ( 21 , 22 , 23 ) , 26 . 79 ( 21 , 22 , 23 ) , 26 . 76 ( 21 , 22 , 23 ) , 
21 . 44 ( 11 , 12 ) , 20 . 75 ( 11 , 12 , 25 ) , 20 . 72 ( 11 , 12 , 25 ) , 14 . 01 
( 26 ) . 
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rgkc : qgkc : 
23 0 
22 O - 16 
Ow = 17 15 33 31 
Zo 12 1214 NH 
11 
30 Zoo * 13 7 9 NH 28 
CO = 20 H?c 3 s , 
28 , 30 20 - JO 
[ rgkc ] 
Yield : 140 . 9 mg ( 0 . 33 mmol , 66 % ) 
[ qgkc ] 
Yield : 110 . 0 mg ( 0 . 24 mmol , 48 % ) 
[ 0271 ] ' H NMR ( 600 MHz , Chloroform - d ) 8 [ 8 . 72 ( d , 
J = 5 . 2 Hz ) NH major ; 8 . 54 ( d , J = 5 . 2 Hz ) NH minor , 1H ) , 
7 . 49 - 7 . 35 ( m , 5H ) aromatic , [ 3 . 81 ( m ) 12 major ; 3 . 72 ( m ) 12 
minor , 1H ] , [ 3 . 58 ( tt , J = 12 . 0 , 3 . 2 Hz ) 19 minor ; 3 . 48 ( tt , 
J = 12 . 0 , 3 . 2 Hz ) 19 major , 1H ] , [ 3 . 38 ( d , J = 10 . 9 Hz ) 9 major ; 
3 . 19 ( d , J = 10 . 9 Hz ) 9 minor , 1H ] , [ 2 . 76 ( qt , J = 11 . 4 , 3 . 2 Hz ) 
20 major ; 2 . 46 ( qt , J = 11 . 4 , 3 . 2 Hz ) 20 minor , 1H ) , 1 . 99 - 0 . 85 
( m , 30H ) 13 , 14 , 15 , 16 , 17 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 
30 , 31 . 
[ 0272 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 173 . 36 , 
172 . 26 ( 7 , 10 ) , 137 . 39 ( 4 ) , 129 . 77 ( 1 ) , 128 . 66 ( 3 , 5 ) , 126 . 02 
( 2 , 6 ) , 69 . 18 ( 9 ) , 61 . 48 ( 19 ) , 47 . 31 ( 12 ) , 35 . 69 ( 20 ) , [ 32 . 80 , 
32 . 59 , 31 . 59 , 31 . 22 , 30 . 99 , 30 . 51 , 26 . 35 , 25 . 96 , 25 . 93 , 
25 . 83 , 25 . 67 , 25 . 49 , 24 . 79 , 24 . 47 , 24 . 40 ( 13 , 14 , 15 , 16 , 17 , 
22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ) ) . 
rgna : 
[ 0275 ] ' H NMR ( 600 MHz , Chloroform - d ) & [ 8 . 58 ( d , 
J = 7 . 1 Hz ) NH minor ; 8 . 48 ( dd , J = 7 . 1 Hz ) NH major , 1H ] , 
7 . 37 - 6 . 87 ( m , 4H ) aromatic , [ 3 . 97 ( s ) 14 minor ; 3 . 90 ( s ) 14 
minor ; 3 . 79 ( d , J = 3 . 5 Hz ) 14 major , 12 major , 4H ] , [ 3 . 82 ( d , 
J = 3 . 5 Hz ) 12 major , 14 major ; 3 . 71 ( m ) 12 minor , 1H ] , [ 3 . 56 
( t , J = 11 . 9 Hz ) 16 minor ; 3 . 26 ( m ) 16 major ; 2 . 44 ( t , J = 10 . 9 
Hz ) 16 minor , 1H ] , [ 3 . 35 ( d , J = 11 . 1 Hz ) 9 minor ; 3 . 31 ( d , 
J = 11 . 2 Hz ) 9 major ; 3 . 17 ( d , J = 10 . 9 Hz ) 9 minor , 1H ) , [ 2 . 83 
( m ) 17 major ; 2 . 62 ( m ) 17 minor , 1H ] , 2 . 19 - 0 . 66 ( m , 30H ) 
19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 . [ 0276 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 172 . 39 , 
172 . 15 , 171 . 11 , 170 . 92 ( 7 , 10 ) ] , [ 155 . 30 , 154 , 62 ( 3 ) ] , [ 130 . 26 , 130 . 00 , 127 . 39 , 125 . 80 , 121 . 13 , 120 . 86 , 111 . 02 , 
110 . 80 ( 1 , 2 , 5 , 6 ) ] , [ 127 . 36 , 127 . 26 ( 4 ) ] , [ 69 . 20 , 68 . 91 ( 9 ) ] , 
[ 61 . 58 , 61 . 16 ( 16 ) ] , [ 55 . 37 , 55 . 27 ( 14 ) ] , 47 . 26 ( 12 ) , [ 36 . 03 , 
35 . 97 ( 17 ) ] , [ 32 . 91 , 32 . 67 , 32 . 62 , 32 . 60 , 31 . 57 , 31 . 54 , 31 . 09 , 
31 . 06 , 31 . 00 , 30 . 67 , 30 . 60 , 30 . 46 , 26 . 49 , 26 . 40 , 26 . 08 , 
26 . 04 , 26 . 01 , 25 . 95 , 25 . 88 , 25 . 81 , 25 . 76 , 25 . 72 , 25 . 66 , 
25 . 57 , 24 . 89 , 24 . 86 , 24 . 52 , 24 . 41 ( 19 , 20 , 21 , 22 , 23 , 24 , 25 , 
26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ) ] . 
ng?c : 
6 
CH3 
16 
H3CLCH3 5 14 11 15 18 
22 
= 
0 32 30 
24 
- 26 - 17 NH 25 28 bozor [ rgna ] Yield : 96 . 2 mg ( 0 . 26 mmol , 52 % ) 50 = 14 - 27 
24 . 26 25 
[ ngkc ] 
Yield : 157 . 9 mg ( 0 . 34 mmol , 69 % ) 
[ 0273 ] ' H NMR ( 600 MHz , Chloroform - d ) 8 9 . 11 ( s , 1H ) 
NH , [ 8 . 08 - 7 . 50 ( m ) aromatic minor ; 7 . 50 - 7 . 35 ( m ) aromatic 
major , 5H ] , [ 6 . 00 ( s ) 19 minor ; 3 . 25 ( q , J = 6 . 5 Hz ) 19 major , 
2H , 15 . 30 ( d , J = 4 . 3 Hz ) 10 minor ; 3 . 56 ( d , J = 9 . 8 Hz ) 10 
major , 1H ] , [ 2 . 51 ( q , J = 11 Hz ) 13 major ; 2 . 16 ( s ) 13 minor , 
1H ] , 1 . 95 - 0 . 88 ( m , 26H ) 14 , 15 , 16 , 20 , 21 , 22 , 23 , 24 , 25 , 
26 , 27 . 
[ 0274 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 175 . 15 , 
174 . 18 , 169 . 44 , 165 . 69 ( 7 , 12 ) , [ 141 . 28 , 133 . 91 ( 4 ) , [ 130 . 
48 , 130 . 06 , 129 . 79 , 129 . 03 , 128 . 58 , 127 . 86 ( 1 , 2 , 3 , 5 , 61 ,
[ 78 . 63 , 72 . 30 ( 10 ) ] , [ 59 . 88 , 59 . 77 ( 11 ) ] , [ 40 . 49 , 35 . 95 ( 13 ) ] , 
39 . 28 ( 19 ) , [ 31 . 96 , 31 . 79 , 31 . 72 , 30 . 94 , 29 . 78 ( 14 , 15 , 16 ) , 
[ 31 . 50 , 27 . 60 , 26 . 60 , 26 . 40 , 26 . 37 , 26 . 32 , 26 . 29 , 20 . 51 , 
20 . 34 ( 20 , 21 , 23 , 24 , 25 , 26 , 27 ) ] [ 14 . 13 , 14 . 03 ( 22 ) ] . 
[ 0277 ] ' H NMR ( 600 MHz , Chloroform - d ) 8 [ 8 . 35 ( s ) NH 
major ; 8 . 30 ( s ) NH minor , 1H ] , 7 . 42 ( m , 1H ) 2 , 7 . 32 ( m , 2H ) 
( 1 , 6 ) , 17 . 20 ( m ) 5 major ; 7 . 10 ( m ) 5 minor , 1H ) , 3 . 77 ( m , 
1H ) 17 . [ 3 . 41 ( d , J = 11 . 1 Hz ) 11 minor ; 3 . 35 ( d , J = 11 . 1 Hz ) 
11 major , 1H ) , 3 . 19 ( m , 1H ) 12 , 2 . 81 ( m , 1H ) 14 , 2 . 18 - 0 . 80 
( m , 30H ) 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 
31 , 32 . 
f0278 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 171 . 90 , 
170 . 33 ( 8 , 13 ) ] , 137 . 35 ( 3 ) , 130 . 91 ( 4 ) , [ 130 . 33 , 130 . 29 ( 1 ) ] , [ 130 . 24 , 130 . 19 ( 2 ) ] , [ 127 . 59 , 127 . 40 ( 6 ) ] , [ 127 . 11 , 126 . 32 
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( 5 ) 1 , 69 . 35 ( 11 ) , [ 62 . 14 , 61 . 81 ( 12 ) ] , [ 48 . 05 , 47 . 72 ( 17 ) ] , 
[ 36 . 73 , 36 . 23 ( 14 ) ] , [ 33 . 40 , 33 . 15 , 33 . 11 , 32 . 94 , 31 . 90 , 
31 . 72 , 31 . 42 , 31 . 27 , 31 . 21 , 30 . 94 , 30 . 88 , 26 . 70 , 26 . 66 , 
26 . 31 , 26 . 25 , 26 . 17 , 26 . 15 , 26 . 10 , 26 . 02 , 25 . 97 , 25 . 93 , 
25 . 81 , 25 . 08 , 24 . 99 , 24 . 92 ( 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 
27 , 28 , 29 , 30 , 31 , 32 ) ] . 
ogkc : 
f0282 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 173 . 27 , 
172 . 53 ( 7 , 12 ) , 143 . 52 ( 4 ) , 139 . 83 ( 2 ) , 130 . 49 ( 1 ) , 128 . 58 
( 6 ) , 125 . 98 ( 5 ) , 92 . 93 ( 3 ) , 68 . 47 ( 10 ) , 61 . 82 ( 11 ) , 39 . 48 ( 16 ) , 
39 . 41 ( 13 ) , [ 32 . 12 , 32 . 10 , 31 . 48 , 31 . 20 , 30 . 62 , 26 . 11 , 25 . 78 , 
25 . 52 , 25 . 21 , 25 . 06 , 20 . 67 , 14 . 18 ( 17 , 18 , 19 , 20 , 21 , 22 , 23 , 
24 , 26 , 27 , 28 , 29 ) ] . 
fhkc : 
32 30 31 
1 
. . 
" NH C28 - Zoo 16 . 4 - 778 - 10 15 nar NH 11 14 5o =
- 14 , 7 
23 26 
[ ogkc ] 
Yield : 182 . 5 mg ( 0 . 36 mmol , 72 % ) 
24 - 25 
[ fhkc ] 
Yield : 179 . 6 mg ( 0 . 33 mmol , 67 % ) 
[ 0279 ] ' H NMR ( 600 MHz , Chloroform - d ) 8 [ 8 . 37 ( s ) NH 
major ; 8 . 30 ( s ) NH minor , 1H ) , 7 . 60 ( ddd J = 8 . 1 , 4 . 1 , 1 . 1 Hz , 
1H ) 2 , 7 . 35 ( td , J = 7 . 5 , 1 . 1 Hz , 1H ) 6 , 7 . 25 ( td , J = 7 . 8 , 1 . 7 Hz , 
1H ) 1 , [ 7 . 18 ( dd , J = 7 . 6 , 1 . 7 Hz ) 5 major ; 7 . 07 ( dd , J = 7 . 6 , 1 . 7 
Hz ) 5 minor , 1H ) , 3 . 77 ( m , 1H ) 17 , [ 3 . 41 ( d , J = 11 . 2 Hz ) 11 
minor ; 3 . 34 ( d , J = 11 . 0 Hz ) 11 major , 1 Hz ) , [ 3 . 24 ( m ) 12 
minor ; 3 . 17 ( tt , J = 11 . 7 , 3 . 6 Hz ) 12 major , 1H ] , [ 2 . 88 ( m ) 14 
minor ; 2 . 80 ( qt , J = 11 . 5 , 3 . 3 Hz ) 14 major , 1H ] , 2 . 29 - 0 . 78 ( m , 
30H ) 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 
32 . 
f0280 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 171 . 79 , 
171 . 02 ( 8 , 13 ) ] , [ 139 . 64 , 139 . 46 ( 4 ) ] , [ 133 . 43 , 133 . 41 ( 2 ) , 
[ 130 . 46 , 130 . 37 ( 1 ) ] , 128 . 06 , 127 . 92 ( 6 ) ] , 1126 . 99 , 126 . 48 
( 5 ) 1 , 119 . 80 ( 3 ) , 69 . 33 ( 11 ) , 61 . 82 ( 12 ) , [ 48 . 18 , 47 . 73 ( 17 ) ] , 
[ 36 . 81 , 36 . 19 ( 14 ) ] , 33 . 45 , 33 . 29 , 33 . 20 , 32 . 95 , 31 . 97 , 
31 . 75 , 31 . 64 , 31 . 43 , 30 . 95 , 30 . 85 , 26 . 69 , 26 . 66 , 26 . 31 , 
26 . 26 , 26 . 14 , 26 . 12 , 25 . 99 , 25 . 92 , 25 . 80 , 25 . 09 , 25 . 06 , 24 . 97 
( 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ) ] . 
fhka : 
[ 0283 ] ' H NMR ( 600 MHz , Chloroform - d ) 8 [ 8 . 36 ( d , 
J = 7 . 8 Hz ) NH major ; 8 . 12 ( s ) NH minor , 1H ] , 7 . 85 ( dd , 
J = 8 . 0 , 1 . 1 Hz , 1H ) 2 , 7 . 38 ( td , J = 7 . 5 , 1 . 1 Hz , 1H ) 6 , [ 7 . 12 ( dd , J = 7 . 6 , 1 . 6 Hz ) 5 major ; 7 . 02 ( d , J = 7 . 5 Hz ) 5 minor , 1H ) , 
7 . 09 ( m , 1H ) 1 , 3 . 78 ( m , 1H ) 16 , [ 3 . 47 ( s ) 10 minor ; 3 . 41 ( d , 
J = 11 . 2 Hz ) 10 major , 1 - 1 ) , 3 . 31 ( m , 1H ) 13 , 3 . 13 ( tt , J = 11 . 8 . 
3 . 7 Hz , 1H ) 11 , 1 . 98 - 0 . 80 ( m , 28H ) 17 , 18 , 19 , 20 , 21 , 23 , 
24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 . 
[ 0284 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 172 . 52 , 
172 . 26 ( 7 , 10 ) , 143 . 64 ( 4 ) , [ 139 . 91 , 139 . 81 ( 2 ) , [ 130 . 46 , 
130 . 32 ( 1 ) ] , 128 . 56 ( 6 ) , 126 . 08 ( 5 ) , 93 . 12 ( 3 ) , 68 . 65 ( 10 ) , 
61 . 79 ( 11 ) , 48 . 36 ( 16 ) , 39 . 32 ( 13 ) , [ 33 . 59 , 33 . 21 , 32 . 13 , 
31 . 52 , 31 . 10 , 30 . 49 , 26 . 13 , 26 . 00 , 25 . 78 , 25 . 54 , 25 . 26 , 
25 . 14 , 25 . 07 , 25 . 00 ( 17 , 18 , 19 , 20 , 21 , 23 , 24 , 25 , 26 , 27 , 
28 , 29 , 30 , 31 ) ] . 
tgka : 
1221 
H3C 
23 
H3C 
25 Z 12 . 
- 8 CH 10 0 17 NH 
14 24 12 19 
= oa
13 15 26 29 
27 – 28 
[ fhka ] 
Yield : 131 . 0 mg ( 0 . 27 mmol , 53 % ) 
[ tgka ] 
Yield : 138 . 6 mg ( 0 . 35 mmol , 71 % ) 
[ 0281 ] H NMR ( 600 MHz , Chloroform - d ) 8 [ 8 . 37 ( s ) NH 
major ; 8 . 11 ( s ) NH minor , 1H ] , 7 . 85 ( dd , J = 8 . 0 Hz , 1H ) 2 , 
7 . 38 ( td , J = 7 . 5 . 1 . 1 Hz , 1H ) 6 . 7 . 13 ( dd . J = 7 . 6 , 1 . 6 Hz , 1H ) 
5 , 7 . 09 ( td , J = 7 . 7 , 1 . 6 Hz , 1H ) 1 , 3 . 44 ( d , J = 11 . 3 Hz , 1H ) 10 , 
3 . 32 ( m , 1H ) 13 , 3 . 30 - 3 . 18 ( m , 2H ) 16 , 3 . 14 ( tt , J = 11 . 8 , 3 . 7 
Hz , 1H ) 11 , 1 . 99 - 0 . 78 ( m , 25H ) 17 , 18 , 19 , 20 , 21 , 22 , 23 , 
24 , 26 , 27 , 28 , 29 . 
[ 0285 ] ' H NMR ( 600 MHz , Chloroform - d ) 8 8 . 53 ( s , 1H ) 
NH , 3 . 60 ( tt , J = 11 . 9 , 3 . 6 Hz ) 6 , 13 . 26 ( m , 1H ) 11 ; 3 . 09 ( m , 
1H ) 11 ] . 3 . 19 ( d , J = 10 . 6 Hz , 1H ) 5 , 2 . 63 ( q . J = 11 . 7 , 11 . 1 Hz , 
1H ) 8 , [ 12 . 42 ( d , J = 14 . 0 Hz , 1H ) 1 ; 2 . 16 ( d , J = 14 . 0 Hz , 1H ) 
1 ] , 1 . 87 - 0 . 66 ( m , 36H ) 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 
23 , 24 , 25 , 26 , 27 , 28 . 
[ 0286 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 173 . 64 , 
173 . 35 ( 2 , 7 ) ] , 69 . 15 ( 5 ) , 59 . 85 ( 6 ) , 46 . 41 ( 1 ) , 38 . 73 ( 11 ) , 
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35 . 96 ( 8 ) , 31 . 63 ( 22 ) , 30 . 16 ( 23 , 24 , 25 ) , [ 31 . 57 , 31 . 49 , 
31 . 44 , 31 . 24 , 30 . 85 , 30 . 65 , 30 . 16 , 26 . 37 , 26 . 14 , 25 . 96 , 
25 . 93 , 24 . 96 , 20 . 16 , 20 . 02 ( 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 
21 , 26 , 27 ) ] , 13 . 71 ( 28 ) . 
tgkc : 
26 . 27 , 26 . 20 , 26 . 15 , 26 . 13 , 26 . 09 , 25 . 98 , 25 . 35 , 25 . 31 , 
25 . 10 , 24 . 77 ( 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 
30 , 31 , 32 ) . 
[ 0291 ] 9F NMR ( 565 MHz , Chloroform - d ) [ 114 . 35 , 116 . 
86 ( 13 ) ] . 
vgkc : 
26 16 30 - 29 30 28 
15 O 18 29 
23 24 NH 
H C 
23 
HzC 
25 
C26 Í Zoo 
- 
- 10 
CH3 0 NH 27 
24 
F - 32 — s 22 13 . 26 
23 . 25 [ tgkc ] 
Yield : 154 . 5 mg ( 0 . 37 mmol , 74 % ) 24 [ vgke ] 
Yield : 131 . 0 mg ( 0 . 27 mmol , 53 % ) 
[ 0287 ] H NMR ( 600 MHz , Chloroform - d ) 8 8 . 55 ( d , 
J = 8 . 2 Hz , 1H ) NH , 3 . 69 ( m , 1H ) 11 , 3 . 60 ( tt , J = 12 . 0 , 3 . 6 Hz , 
1H ) 6 , 3 . 16 ( d , J = 10 . 8 Hz , 1H ) 5 , 2 . 66 ( g , J = 11 . 6 Hz , 1H ) 
8 , [ 2 . 44 ( d , J = 13 . 7 Hz , 1H ) 1 ; 2 . 13 ( d , J = 13 . 9 Hz , 1H ) 1 , 
1 . 87 - 0 . 66 ( m , 39H ) 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 23 , 
24 , 25 , 26 , 27 , 28 , 29 , 30 . 
[ 0288 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 173 . 94 , 
172 . 78 ( 2 , 7 ) ] , 69 . 63 ( 5 ) , 60 . 25 ( 6 ) , 47 . 65 ( 11 ) , 46 . 72 ( 1 ) , 
36 . 24 ( 8 ) , [ 33 . 12 , 33 . 06 , 31 . 58 , 31 . 22 , 30 . 90 , 26 . 72 , 26 . 48 , 
26 . 34 , 26 . 29 , 26 . 25 , 25 . 96 , 25 . 29 , 24 . 90 , 24 . 81 ( 12 , 13 , 14 , 
15 , 16 , 17 , 18 , 19 , 20 , 21 ) ] , 31 . 78 ( 22 ) , 30 . 54 ( 23 , 34 , 25 ) . 
ugko : 
[ 0292 ] " H NMR ( 600 MHz , Chloroform - d ) 8 [ 8 . 52 ( s ) 11 
minor ; 8 . 27 ( d , J = 8 . 1 Hz ) 11 major ; 8 . 05 ( s ) 11 minor , 1H ] , 
[ 7 . 74 ( d , J = 7 . 8 Hz ) 2 major ; 7 . 72 ( d , J = 7 . 9 Hz ) 2 minor , 1H ) , 
7 . 60 ( t , J = 7 . 5 Hz , 1H ) 6 , 7 . 54 ( t , J = 7 . 7 Hz , 1H ) 1 , 7 . 33 ( d , 
J = 7 . 5 Hz ) 5 major ; 7 . 17 ( d , J = 7 . 6 Hz ) 5 minor , 1H ) , 
3 . 84 - 3 . 64 ( m , 1H ) 12 , [ 3 . 56 ( m ) 15 minor ; 3 . 12 ( tt , J = 11 . 4 , 
3 . 8 Hz ) 15 major ; 2 . 45 ( m ) 15 minor , 1H ] , [ 3 . 42 ( d , J = 11 . 7 
Hz ) 9 minor ; 3 . 35 ( d , J = 11 . 1 Hz ) 9 major ; 3 . 17 ( d , J = 11 . 4 
Hz ) 9 minor , 1H ] , [ 2 . 85 ( d , J = 11 . 5 Hz ) 14 minor ; 2 . 77 ( qt , 
J = 11 . 5 , 3 . 3 Hz , 1H ) 14 major ; 2 . 62 ( m ) 14 minor , 1H ] , 
2 . 02 - 0 . 63 ( m , 30H ) 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 
28 , 29 , 30 , 31 . 
[ 0293 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 171 . 67 , 
170 . 67 ( 7 , 10 ) , 136 . 10 ( 4 ) , [ 132 . 31 , 129 . 83 , 127 . 47 , 136 . 31 
( 1 , 2 , 5 , 6 ) ] , 124 . 96 ( 3 ) , 123 . 15 ( 32 ) , [ 69 . 37 , 61 . 84 , 48 . 28 , 
36 . 18 ( 9 , 12 , 14 , 15 ) ] , 33 . 16 , 32 . 54 , 31 . 48 , 31 . 09 , 30 . 84 , 
30 . 80 , 26 . 75 , 26 . 65 , 26 . 34 , 26 . 32 , 26 . 28 , 26 . 04 , 25 . 99 , 
25 . 79 , 25 . 10 ( 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 
29 , 30 , 31 ) . 
[ 0294 ] 19F NMR ( 565 MHz , Chloroform - d ) 8 59 . 17 ( 33 , 
34 , 35 ) 
faqa : 
20 
21 19 
- 
NH 
[ ugkc ] 
Yield : 171 . 9 mg ( 0 . 39 mmol , 78 % ) 26 - 25 
10 
NH 18 
11 CH3 20 
13 12H C CH3 
14 15 
[ 0289 ] ' H NMR ( 600 MHz , Chloroform - d ) 8 8 . 37 ( d , 
J = 64 . 8 Hz , 1H ) NH , [ 7 . 85 ( dd , J = 8 . 0 , 1 . 2 Hz ) 2 minor ; 7 . 39 ( dqd , J = 8 . 8 , 4 . 6 , 3 . 9 , 1 . 8 Hz ) 2 major , 1H ) , 7 . 21 ( m , 2H ) 5 , 
6 , 7 . 11 ( m , 1H ) 1 , [ 3 . 78 ( m ) 12 major ; 3 . 68 ( m ) 12 minor , 
1H ] , [ 3 . 55 ( m ) 15 minor ; 3 . 31 ( tt , J = 11 . 8 , 3 . 9 Hz ) 15 major ; 
2 . 44 ( t , J = 11 . 8 Hz ) 15 minor , 1H ] , [ 3 . 36 ( d , J = 21 . 2 Hz ) 9 
major , 3 . 15 ( m ) 9 minor , 1H ] , [ 2 . 78 ( m ) 16 major ; 2 . 63 ( m ) 
16 minor , 1H ] , 2 . 27 - 0 . 66 ( m , 30H ) 18 , 19 , 20 , 21 , 22 , 23 , 24 , 
25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 . 
[ 0290 ] 13C NMR ( 151 MHz , Chloroform - d ) 8 [ 172 . 21 , 
168 . 74 ( 7 , 10 ) ] , [ 139 . 89 , 131 . 29 , 130 . 46 , 128 . 63 , 126 . 78 , 
126 . 18 , 124 . 95 , 116 . 32 ( 1 , 2 , 5 , 61 , 69 . 57 ( 9 ) , 62 . 07 ( 15 ) , 
47 . 75 ( 12 ) , [ 36 . 32 , 36 . 23 ( 16 ) ] , [ 33 . 23 , 32 . 93 , 32 . 23 , 31 . 86 , 
31 . 36 , 31 . 11 , 30 . 90 , 30 . 82 , 30 . 03 , 26 . 74 , 26 . 69 , 26 . 29 , 
[ faqa ] 
[ 0295 ] ' H NMR ( 600 MHz , Chloroform - d ) 8 [ Missing NH 
peak ] , [ 7 . 71 - 6 . 77 ( m , 9H ) ( 1 , 2 , 3 , 6 , 23 , 24 , 25 , 26 , 27 ) , 
4 . 46 ( d , J = 12 . 1 Hz , 1H ) 9 , 3 . 35 ( 9 , J = 6 . 9 Hz , 2H ) 17 , 2 . 46 
( s , 1H ) 13 , 1 . 63 - 0 . 84 ( m , 13H ) 14 , 15 , 18 , 19 , 20 . 
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faaAa : [ 0299 ] ESI ( + ) - LRMS ( m / z ) : Calcd for C33Hz5N204 
[ M + H ] + 651 . 16 , found 651 . 56 , 673 . 28 [ M + Na + ] . 
2 - cyclohexyl - 2 - ( 2 - iodo - N - ( prop - 2 - yn - 1 - yl ) ben 
zamido acetic acid ( EM68a ) 
[ 0300 ] 
Zoo NH 
11 20 T i m LiOH , ( H2O2 ) THF - H20 ( 4 : 1 ) , rt 2 , 70,9%CH3 
15 
[ faaAa ] Boc 
EM67 
[ 0296 ] " H NMR ( 600 MHz , Chloroform - d ) 8 [ Missing an 
aromatic peak ] , [ 7 . 73 - 6 . 75 ( m , 10H ) 1 , 2 , 3 , 6 , 23 , 24 , 27 , 
29 ] , 4 . 46 ( d , J = 10 . 9 Hz , 1H ) 9 , 3 . 35 ( q , J = 6 . 5 Hz , 2H ) 17 , 
2 . 46 ( s , 1H ) 13 , 1 . 61 - 1 . 53 ( m , 2H ) 18 , 1 . 40 ( m , 2H ) 19 , 1 . 09 
( d , J = 6 . 5 Hz , 3H ) 14 or 15 , 1 . 01 ( d , J = 6 . 6 Hz , 3H ) 14 or 15 , 
0 . 93 ( t , J = 7 . 4 Hz , 3H ) 20 . 
OH 
Example 3 : Additional Synthetic Procedures 
tert - butyl ( 2 - cyclohexyl - 2 - ( 2 - iodo - N - ( pro - 2 - yn - 1 - yl ) 
benzamido ) acetyl ) ( naphthalen - 2 yl ) carbamate 
( EM67 ) 
EM68 [ 0297 ] 
Boc20 , DMAP 
TEA , DCM 35° C . 
H 
[ 0301 ] EM67 ( 7 . 5 mg , 0 . 012 mmol ) was dissolved in 
THF - H20 ( 4 : 1 , 1 mL ) . LiOH . H20 ( 1 . 8 mg , 0 . 042 mmol ) 
was added and the mixture was stirred at room temperature . 
After 3 d the reaction was complete by TLC ( 3 : 1 hexanes / 
EtoAc and 5 : 1 DCM / MeOH ) and the reaction was 
quenched with 1 M HCl ( 1 mL ) . The product was extracted 
3x with DCM ( 0 . 5 mL ) , dried over Na2SO4 , and the solvent 
removed in vacuo . 
fgbd 
. 
[ 0302 ] Crude yield 6 . 5 mg ( 0 . 015 mmol , excess mass ) . 
Product was not purified . 
Boc 
2 - cyclohexyl - 2 - ( 2 - iodo - N - ( prop - 2 - yn - 1 - yl ) ben 
zamido ) acetic acid ( EM75 ) 
EM67 [ 0303 ] 
LiOH , ( H2O2 ) 
THF - H20 ( 4 : 1 ) , rt 
[ 0298 ] A two - necked flask was charged with fgbd ( 100 
mg , 0 . 18 mmol ) in dry DCM ( 2 mL ) under nitrogen atmo 
sphere . To this was added triethylamine ( 25 . 4 ul , 0 . 18 
mmol ) . DMAP ( 22 mg , 0 . 18 mmol ) , and Boc , O ( 119 mg , 
0 . 55 mmol ) . The reaction mixture was stirred for 7 h at 25° 
C . An additional 3 equivalents of Boc , O ( 119 mg , 0 . 55 
mmol ) were added to the flask . The reaction was stopped 
after 21 h . Volatiles were then removed in vacuo and the 
crude product was purified using a silica plug with 3 : 1 
hexanes / EtOAc . Yield 118 mg ( 99 % , 0 . 18 mmol ) , yellow 
Boc 
EM67 
oil . 
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- continued available were explored . A new route to introduce varied functionality at the C - terminus of the dipeptide was thus 
investigated . 
[ 0308 ] As described herein , a library of GlcNAc triazoles ( GNTs ) as well as dipeptides without a sugar moiety were 
tested in whole - cell conditions against B . subtilis using a 
resazurin microtiter assay . These data were used both to 
evaluate the relative inhibitory capabilities of the com 
pounds as well as determine MIC values in vivo . 
OH 
EM68 
[ 0304 ] EM67 ( 118 mg , 0 . 18 mmol ) was dissolved in 
THF - H2O ( 4 : 1 , 10 mL ) . LiOH . H2O ( 23 mg , 0 . 54 mmol ) and 
H , O , ( 30 % w / v , 98 UL , 0 . 98 mmol ) were added and the 
mixture was stirred at room temperature . After 3 h the 
reaction was complete by TLC ( 3 : 1 hexanes / EtoAc and 5 : 1 
DCM / MeOH ) and the reaction was quenched with 1 M HC1 
( 3 mL ) . The product was extracted 3x with DCM ( 2 mL ) , 
dried over Na S04 , and the solvent removed in vacuo . Yield : 
39 mg ( 51 % , 0 . 092 mmol ) , yellow solid . 
Ugi Synthesis 
[ 0309 ] Terminal alkynes were prepared using the Ugi 
four - component condensation reaction . The Ugi condensa 
tion is a one - pot reaction that combines an acid , an amine , 
an aldehyde , and an isocyanide to form a dipeptide . The 
general Ugi reaction utilized is shown in Scheme 2 . In 
certain non - limiting embodiments , propargylamine and 
n - butyl isocyanide were held constant for all Ugi - derived 
compounds . The first four Ugi compounds synthesized held 
all aspects of the fgba structure ( Scheme 3 ) constant while 
varying the substituent on the benzyl ring of the acid . The 
last two Ugi compounds instead varied only the aldehyde 
substituent while retaining the iodobenzoic acid . The syn 
thetic schemes and final structures of non - limiting Ugi 
compounds are illustrated in Scheme 4 . JEH 
12 
1 OH Scheme 2 . General Ugi reaction using propargyl amine and n - butyl isocyanide . 
R2 + R H + NC + 
O 
0 . 1M in MeOH 
R2 OH 3 - 4 h , A 
' H NMR ( 600 MHz , Methanol - da ) 8 7 . 98 - 7 . 88 ( m , 1H , 7 ) , 
7 . 53 - 7 . 16 ( m , 3H , 1 , 2 , 4 ) , [ 4 . 88 - 4 . 77 ( m ) ; 3 . 75 - 3 . 66 ( m ) , 
1H , 11 ] , [ 4 . 68 - 4 . 35 ( m ) ; 4 . 17 - 4 . 02 ( m ) ; 3 . 81 ( d , J = 18 . 6 Hz ) , 
2H , 12 ] , 2 . 72 - 2 . 58 ( m , 1H , 20 ) , 2 . 29 - 0 . 85 ( m , 11H , 13 , 16 , 
17 , 21 , 22 , 23 ) ppm . ESI ( + ) - LRMS ( m / z ) : Calcd for 
C18H20INO3 [ M + H ] + 426 . 05 . found 426 . 87 . 
ö Rj 
Scheme 3 . 
Example 4 : Chemical Synthesis 
[ 0305 ] As demonstrated herein , the compounds of the 
invention inhibit bacterial GlcNAcases . For example , com 
pound BI .fgba inhibits the GlcNAcase LytG , and has con 
centration - dependent bacteriostatic activity in the bacterial 
strain B . subtilis . This compound has exhibited a minimum 
inhibitory concentration ( MIC ) of 63 uM in whole cell 
assays . 
[ 0306 ] In order to identify a more potent GlcNAcase 
inhibitor , analogs of BI . fgba were prepared . Specifically , 
seven compounds were synthesized , each involving a small 
modification to the BI .fgba structure : five with alternate 
substituents off of the benzoic acid moiety , and two with 
alternate substituents off of the aldehyde . The sugar and 
triazole linker were kept constant across all compounds . 
[ 0307 ] In addition to a second - generation library of com 
pounds , alternate routes to obtain the dipeptide Ugi - derived 
compounds were explored . In particular , synthetic routes 
that allow for the modification of the isocyanide substituent 
beyond the limited number of isocyanides commercially 
NH 
fgba 
fgba 
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Scheme 4 . Synthesis of Ugi compounds : varied substituents highlighted in red . 
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- continued [ 0310 ] As a non - limiting procedure , first , the aldehyde and propargylamine were reacted for 30 minutes at elevated 
temperature to form the imine intermediate . The n - butyl 
isocyanide was then added , followed by the benzoic acid 
after another 20 minutes . All reagents were used in a 1 : 1 
ratio . The reaction was run to completion according to TLC . 
Products were analyzed with ' H - and COSY NMR Gener 
ally , products were pure enough to be used directly in the 
click reaction with the GlcNAc - azide . In certain embodi 
ments , an acid / base extraction was used to purify the com 
pound . 
[ 0311 ] The compounds depicted in Schemes 5 - 6 were also 
prepared using the Ugi reaction . 
fgla ( 89 % ) 
Scheme 5 . 
, Ph 
Ph 
fgca ( 87 % ) 
fgma ( 80 % ) 
fgia ( 64 % ) 
fgna ( 23 % ) 
fgja ( 92 % ) fgoa ( 46 % ) 
7c 
fgka ( 78 % ) fgpa ( 71 % ) 
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- continued - continued 
OMe 
NH 
fgqa ( 81 % ) 
fgua ( 69 % ) 
Scheme 6 . 
N 
ZH 
fgra ( 72 % ) 
NO2 fgke ( 68 % ) 
N IZ 
fgsa ( 90 % crude ) fgbc ( 67 % ) 
fgqc ( 52 % ) 
fgta ( 76 % ) 
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- continued - continued 
IZ 
rgba ( 96 % ) 
fgkb ( 81 % ) 
NH NH 
HOMO 
NH 
fgbb ( 82 % ) 
BI . fgba 
OH 
NH 
HOTO 
fgqb ( 88 % ) NH 
BI .rgba ( 80 % ) 
GNT Synthesis 
[ 0312 ] Terminal alkyne Ugi products were then coupled to 
1 - azido - N - acetylglucosamine ( 1 ) using the click reaction . 
The general scheme for the click process is shown in 
Scheme 7 . OMe 
fbqb ( 15 % ) 
Scheme 7 . General synthesis of GNT products . 
OH 
ZI 
HO HO LN3 + 
NH 
fgba 
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- continued 
CuSO4 , Cu - powder 
MeCN : H20 ( 1 : 1 ) , 
45° C . 
R1 
0 = 
N . 
NH 
07 
[ 0313 ] The redox couple of Cu ( 0 ) powder and Cu ( II ) 
sulfate was used to catalyze the azide - alkyne coupling . The 
terminal alkyne was used in excess to ensure that all of the 
azide was consumed . Unreacted alkyne could then be easily 
removed using a silica plug following the reaction . Thus , no 
column chromatography was necessary for purification . 
Copper was removed from the reaction mixture prior to 
silica plug purification using commercially available copper 
chelating resin . The synthetic schemes and final structures 
are shown in Schemes 8 - 9 . 
1 :| onasons A )US 2018 / 0290967 A1 ? Oct . 11 , 2018 51 
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Scheme 8 . Synthesis of GNT compounds ; varied substituent highlighted in red . 
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Scheme 9 . Synthesis of GNT compounds ; varied substituent highlighted in red . 
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- continued 
OH 46 % 
NH 
Peptide Hydrolysis Route 
[ 03141 An alternate method to achieve variable terminal 
amide moieties was pursued . Instead of constructing the 
dipeptide backbone stepwise , the Ugi reaction was used . 
Once the product was isolated , the N - terminal secondary 
amide was selectively hydrolyzed to yield an acid . The acid 
was then converted to an amine of choice through peptide 
coupling or left as an acid or ester . It should be noted that 
removal the C - terminal amide moiety after the Ugi reaction 
is complete is done in the presence of a second amide . A 
number of " convertible isocyanides ” such as Gilley ' s 
indole - isocyanide or Pirrung ' s ortho - substituted phe 
nylisonitriles allow for the ready removal of the secondary 
amide using mild conditions , though these isocyanides are 
synthesized themselves through multi - step processes . Using 
exclusively commercially available starting materials and 
reagents , the acid derivative of fgba ( EM68 ) was success fully synthesized . 
T03151 Two fgba derivates , fgbd and fgkd , were synthe 
sized through the Ugi reaction utilizing 2 - napthylisocyanide 
in place of n - butylisocyanide as illustrated in Scheme 12 . 
2 - Napthylisocyanide proved to be poorly soluble in the 
methanol solvent because of the large nonpolar aromatic 
structure . Both products were purified via column chroma 
tography to remove starting material remaining after incom 
plete reaction . Without wishing to be limited by any theory , 
the highly conjugated ring system of 2 - napthylisocyanide 
may improve the capability of the amine to act as a leaving 
group during hydrolysis through stabilization of the inter 
mediate charge on the nitrogen . Under basic conditions , a 
negative charge may be transiently formed on the nitrogen 
as it leaves , but this should be delocalized by resonance 
throughout the large conjugated aromatic system . 
fgkd 
[ 0316 ] fgbd was subjected to acidic hydrolysis conditions 
( 1 : 1 3 N HC1 / THF , 50° C . , 24 h ) . Using ESI - MS , masses 
correlating to a mixture of single and double hydrolysis 
products were observed , with little apparent specificity for 
cleavage of one peptide bond over the other . Selective 
cleavage was attempted by first adding tert - butyloxycarbo 
nyl to the secondary amide followed by basic hydrolysis 
conditions as shown in Scheme 13 . Basic hydrolysis was 
performed using lithium hydroxide , both with and without 
hydrogen peroxide . Both conditions were successful , though 
the reaction proceeded to completion in 3 hours with addi 
tion of H2O2 and required 3 days without it . No hydrolysis 
of the 2 - iodobenzoic acid substituent was observed and the 
reaction went cleanly to completion . This facile and selec 
tive modification of the C - terminal amide moiety provides 
access to a wide range of substituents , either through esteri 
fication of the acid group or amide couplings , and circum 
vents the need for convertible isocyanides . 
Scheme 12 . Ugi reaction synthesis of fgbd and fgkd 
CNH - + H + 
Scheme 13 . Synthesis of fgba acid derivative 
NC 
OH 54 % 
Boc20 , DMAP 
TEA , DCM 35°C . mod ac 96800 = N N fgbd 
LiOH , ( H2O2 ) 
THF - H20 
( 4 : 1 ) , it fgbd 
Boc 
NH2 
+ H + 
EM67 
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“ ?? 
EM68 
Procedure for Suzuki Coupling to make MO2 , MO3 , MO4 [ 0317 ] A mixture of an iodide Ugi substrate ( 1 equiv ) , a 
boronic acid ( 1 . 5 equiv ) , a degassed 2 M aqueous solution 
of Na2CO3 ( 3 equiv ) and Pd ( PPhz ) 4 ( 2 mol % ) in equal parts 
toluene and water was heated at 100° C . in a scaled vial in 
the microwave for 10 h . The reaction progress was moni 
tored by TLC by inserting a capillary tube through a vent 
needle . The reaction mixture was cooled to room tempera 
ture and extracted with saturated brine solution , dried with 
NaSO4 , and concentrated in vacuo . Finally , the residue was 
subjected to flash Sio , column chromatography ( eluent : 
EtOAc / hexanes ) to yield the product in approximately 70 % 
yield . 
added and the plate was immediately placed in a plate 
reader . Fluorescence of each well was measured at 590 nm 
at 0 , 5 , 10 , 20 , and 60 min after addition of the dye . A higher 
growth rate of bacteria produces more resorufin and thus 
more fluorescence . Lower fluorescence therefore indicates 
better growth inhibition . [ 0321 ] Several compounds exhibited significant antibac 
terial activity . At a single concentration of inhibitor , it was 
also possible to qualify the relative inhibitory activity by 
comparing the fluorescence between any two wells . At 250 
UM , a wide range of fluorescence values were observed after 
60 minutes as opposed to an " on or off " fluorescence reading 
for each compound . This indicates that the more active 
inhibitors measurably reduced fluorescence more efficiently 
than less active inhibitors , even when evaluated at one 
concentration . In certain embodiments , it may be possible to 
identify potent inhibitors exclusively by single - concentra 
tion fluorescence analysis . 
[ 0322 ] Fluorescence was further evaluated as it developed 
over time . After 60 minutes of incubation with dye , all the 
fluorescence values continued to increase even at the end 
point time , without signs of saturation . Without wishing to 
be limited by any theory , while 60 minutes was enough time 
to observe resolution of the compounds ' inhibitory efficacy , 
additional incubation time may yield even further resolution 
especially at low fluorescence values . Due to the constantly 
increasing fluorescence , the pain of the plate reader had to 
be lowered for each consecutive reading . Thus , in order to 
compare fluorescence values over time , the factor by which 
the measured fluorescence was greater than the background 
fluorescence of only the dye at each individual time point is 
reported . The graphs of the fluorescence over time and at 60 
minutes are given in FIGS . 3 - 4 , respectively . A reproduction 
of the plate is illustrated in FIG . 6B , with selected com 
pounds outlined in red . Table 1 illustrates the identity of each 
of the plate wells , and Table 2 illustrates the fluorescence 
values for each well at 60 minutes . FIG . 5 illustrates 
fluorescence values at 60 minutes . 
TABLE 1 
Example 5 : Resazurin In Vivo Assay 
[ 0318 ] Selected compounds of the invention were assayed 
for antibiotic activity . The initial screens were performed 
against whole cells , and not purified enzymes , in order to 
eliminate those compounds that did not reduce bacterial 
growth 
[ 0319 ] Compounds were tested in vivo for their capacity 
to inhibit B . subtilis growth . In order to determine growth 
inhibition , a resazurin whole - cell assay was used ( Kuhn , et 
al . , 2014 , Medchemcomm 5 : 1213 - 1217 ) . Briefly , second 
passage bacteria were incubated with inhibitor in a 96 - well 
plate for four hours , then resazurin dye was added and 
color / fluorescence change was observed . The resazurin is 
naturally a blue color , but with reductive species produced 
during bacterial growth , it is reduced to resorufin , which 
appears pink . Resorufin is also fluorescent and can be 
measured by a plate - reader . 
[ 0320 ] BI . ngba , BI . ogba , BI . pgba , BI . qgba , BI . fhba , 
BI . fiba showed no significant growth inhibition at 125 uM . 
Tested compounds are exemplified in Scheme 14 . In an 
initial set - up , each compound was evaluated at the single 
concentration of 250 uM in triplicate . Growth controls 
containing no inhibitory compound , sterility controls with 
out inoculation , and controls containing a known antibiotic , 
chloramphenicol , were also included . After incubation of the 
bacteria with the inhibitors for four hours , resazurin dye was 
Minimum inhibitory concentration ( MIC ) of several diamide 
compounds against Gram - positive organisms 
Compound S . aureus ( ug / mL ) P . difficile ( ug / mL ) 
S . pneumoniae 
( ug / mL ) B . subtilis ( ug / mL ) 
2 . 81 
3 . 64 
fgba 
fgqa 
fgbb 
fgbc 
fgna 
fgka fgkc 
3 . 62 
3 . 56 
| 17 . 52 
11 . 53 
1 . 65 
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Table 2 . Fluorescence values of single concentration whole - cell resazurin assay at 60 min . 
HEMA 
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- continued [ 0323 ] Compounds fgkc , fgkb , rgba , fgka , fgoa , and fgna 
exhibited the highest degree of inhibition as shown by the 
smallest values of fluorescence . 
[ 0324 ] fgkc , fgkb , rgba , fgoa , fgka and fgna — B . subtilis 
Lyt G . 
[ 0325 ] fgkc , fgbb , and fgbc - S . pneumoniae . 
[ 0326 ] fgnaC . difficile . 
[ 0327 ] fgba or fgqa S . aureus . 
HL 
fgba 
Scheme 14 . GNT and Ugi - derived compounds 
used in resazurin microtiter assay . 
N 
fgoa 
OME 
fbqb 
N 
V 
fgbb 
fgka 
fgpa 
fgna 
2 
fgqb fgkb 
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- continued - continued 
rgba 
fgla 
N 
fgqa 
IZ 
fgta loglo oglooofgqc 
NH 
NH 
fgke 
fgra 
Dh 
NH ZI 
fgbc fgma 
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- continued 
?Me 
IZ 
fgua 
NO 
IZ 
fgsa 
poor activity compared to aliphatic derivatives . As single 
aromatic groups were sequentially replaced by aliphatic 
groups ( primarily cyclohexyl ) , the efficacy of the resulting 
compounds uniformly increased . The trend was illustrated in 
the sequence . fbqb , fgqb , fgqc / fgkb , fgka / fgkc . Within this 
overall trend , modification of the amine component 
appeared to have a more substantial effect on efficacy , 
compared to modification of the isocyanide component . In 
addition , the specific aliphatic groups utilized both for the 
isocyanide and amine moieties had significant impact . Inclu 
sion of cyclohexyl groups generally appeared to exhibit the 
greatest improvement , while longer and less branched ali 
phatic groups were less effective . This was illustrated in the 
sequence : fgba , fgpa , fgna / fgoa , fgka . In particular , a sec 
ondary carbon immediately adjacent to the nitrogen of the 
amine component appears to be advantageous . While the 
sugar moiety may contribute to the specificity of the inhibi 
tor , its presence decreases efficacy in comparison to the 
dipeptide alone . This was illustrated in the disparity between 
BI .rgba and rgba . 
[ 0329 ] In order to verify our results , the 250 uM single 
concentration resazurin assay was repeated twice more . The 
cumulative results are plotted in FIG . 5 . Though some 
deviation was observed among runs , the results were within 
the predicted range of error . The four most potent inhibitors 
fgkc , fgka , fgoa , and rgba demonstrated the highest degree 
of inhibitory activity across all three runs . 
[ 0330 ] Using the four most potent inhibitors fgkc , fgka , 
fgoa , and rgba , a serial dilution resazurin assay was per 
formed in which each inhibitor was sequentially diluted 
across a 96 - well plate beginning at 250 uM and halving in 
concentration down to 7 . 9 uM . Each dilution was run in 
triplicate . Each well contained a total of 100 uL of liquid , 
including DMSO with dissolved compound , LB broth , and 
40 uL of cells ( a 1 : 20 dilution ) . Growth controls containing 
no inhibitory compound , sterility controls without inocula 
tion , and controls containing a known antibiotic , chloram 
phenicol , were also included . At this point , plates were 
incubated at 37° C . for 4 hours under aerobic conditions , but 
due to experimental error plates were only incubated for 30 
minutes . After incubation , resazurin solution was added to 
each well and plates were incubated . A change in color from 
blue to pink indicated reduction of resazurin , and therefore 
bacterial growth . Minimum inhibitory concentration ( MIC ) 
was determined as the lowest drug concentration that pre 
vented the color change from blue to pink . The fluorescence 
was again quantified by a plate reader , and two identical 
plates were run simultaneously . Images of the resulting well 
plates along with a table indicating the layout of the plates 
are shown in FIG . 6 . Even without a quantitative analysis , it 
is very clear from the color change from blue to pink at 
which concentration each compound became too dilute . rgba 
exhibited an MIC of 250 UM . fgoa inhibited bacterial growth 
down to a concentration of 62 . 5 uM . fgkc and fgka inhibited 
growth down to the lowest concentration of 7 . 9 uM . 
[ 0331 ] The disclosures of each and every patent , patent 
application , and publication cited herein are hereby incor 
porated herein by reference in their entirety . 
[ 0332 ] Although the invention has been disclosed and 
described with reference to specific embodiments , it is 
apparent that other embodiments and variations of this 
invention may be devised by others skilled in the art without 
departing from the true spirit and scope of the invention . The 
N HO 
HO ?? ?? 
NH 
BI . fgba 
?? 
ZI 
HOTO 
NH 
BI . rgba 
[ 0328 ] In one aspect , as for the inclusion of aromatic 
substituents aside from the benzoyl moiety . fbqb , compound 
with aromatic groups on all substituents of the dipeptide 
exhibited lower activity . fgla , fgma , fgra , and fgta also 
contained large aromatic amine substituents and exhibited 
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appended claims are intended to be construed to include all 
such embodiments and equivalent variations . 
1 . A compound of formula I , or a salt or solvate thereof : 
5 . The compound of claim 1 , wherein R , is selected from 
the group consisting of C . - C . alkyl , Cz - Co cycloalkyl , allyl , 
propargyl , homopropargyl , phenyl , heteroaryl , aryl - ( CH2 ) 1 
27 , and heteroaryl - ( CH2 ) 1 - 24 , wherein the alkyl , 
cycloalkyl , phenyl , heteroaryl , aryl - ( CH2 ) 1 - 2 — , or het 
eroaryl - ( CH2 ) 1 - 2 - group is optionally substituted with 1 - 3 
substituents independently selected from the group consist 
ing of C , - C , alkyl , OH , O ( C . - C . alkyl ) , F , C1 , Br , I , and 
QRzR4 
en R52 R NO2 . 
R 6 . The compound of claim 5 , wherein R , is selected from 
the group consisting of CZ - C6 alkyl , C5 - Co cycloalkyl , allyl , 
propargyl , homopropargyl , phenyl , o - iodophenyl , o - bro 
mophenyl , o - chlorophenyl , o - fluorophenyl , o - methoxyphe 
nyl , p - iodophenyl , p - bromophenyl , p - chlorophenyl , p - fluo 
rophenyl , p - methoxyphenyl , benzyl , Ph ( CH2 ) 2 - , 
Ph _ CHCH2 , and Ph ( CH3 ) CH — . 
7 . The compound of claim 1 , wherein Rz is selected from 
the group consisting of C3 - Co cycloalkyl , phenyl , o - iodo 
phenyl , o - bromophenyl , 0 - chlorophenyl , o - fluorophenyl , 
0 - methoxyphenyl , p - iodophenyl , p - bromophenyl , p - chloro 
phenyl , p - fluorophenyl , and p - methoxyphenyl . 
8 . The compound of claim 1 , wherein R4 is selected from 
the group consisting of C , - Co alkyl , C3 - C , cycloalkyl , ben 
zyl , and phenyl - ( CH2 ) 2 — , wherein the alkyl , cycloalkyl , 
phenyl or benzyl group is optionally substituted with 1 - 3 
substituents independently selected from the group consist 
ing of C , - Co alkyl , OH , O ( C . - C . alkyl ) , F , Cl , Br , and I . 
9 . The compound of claim 1 , which is selected from the 
group consisting of : 
wherein in compound I : 
R , is selected from the group consisting of aryl and 
heteroaryl , wherein the aryl or heteroaryl group is 
optionally substituted with 1 - 3 substituents indepen 
dently selected from the group consisting of C , - Co 
alkyl , OH , O ( C - Co alkyl ) , F , C1 , Br , I , NO2 , CEO ) 
H , - C ( = O ) OH , C ( O ) O ( C . - C . alkyl ) , CEO ) 
NH2 , C O ) NH ( C , - Co alkyl ) , and CEO ) N ( C 
Co alkyl ) ( CZ - C . alkyl ) ; 
R2 is selected from the group consisting of C , - C , alkyl , 
Cz - C , cycloalkyl , allyl , propargyl , homopropargyl , 
aryl , heteroaryl , arylalkyl , and heteroarylalkyl , wherein 
the alkyl , cycloalkyl , aryl , heteroaryl , arylalkyl or het 
eroarylalkyl group is optionally substituted with 1 - 3 
substituents independently selected from the group 
consisting of C1 - C6 alkyl , OH , O ( C1 - C , alkyl ) , F , C1 ,
Br , I , NO2 , - C ( OH , C ( = O ) OH , — C ( = O ) O 
( C1 - C6 alkyl ) , 2C ( O ) NH ) , C ( - O ) NH ( C - C6 
alkyl ) , and C ( = O ) N ( C7 - C alkyl ) ( C - C . alkyl ) ; 
Rz is selected from the group consisting of Cz - Cg 
cycloalkyl , aryl and heteroaryl , wherein the cycloalkyl , 
aryl or heteroaryl group is optionally substituted with 
1 - 3 substituents independently selected from the group 
consisting of C , - C , alkyl , OH , O ( C . - C . alkyl ) , F , C1 , 
Br , I , NO2 , CEO ) H , C ( O ) OH , CEO ) O ( Cz - C , alkyl ) , C ( = O ) NH2 , CEO ) NH ( C , - C6 
alkyl ) , and CEO ) N ( C1 - C6 alkyl ) ( C1 - C6 alkyl ) ; 
R4 is selected from the group consisting of C3 - C , alkyl , 
Cz - C , cycloalkyl , arylalkyl and heteroarylalkyl , 
wherein the alkyl , cycloalkyl , arylalkyl or heteroaryl 
alkyl group is optionally substituted with 1 - 3 substitu 
ents independently selected from the group consisting 
of C , - Co alkyl , OH , O ( C , - C6 alkyl ) , F , C1 , Br , I , NO2 , 
C ( = O ) H , CEO ) OH , CEO ) O ( C - C , alkyl ) , 
C ( = O ) NH2 , CEO ) NH ( CZ - C6 alkyl ) , and 
CEO ) N ( C - C alkyl ) ( C . - C . alkyl ) ; and 
R , is H or methyl . 
2 . The compound of claim 1 , wherein in R , has at least 
one substituent ortho to the carbonyl group a selected from 
the group consisting of C , - Cd alkyl , OH , O ( C1 - C6 alkyl ) , F , 
Cl , Br , I , NO , , - C ( OH , CCOOH , CEO ) O ( C , 
Co alkyl ) , CEO ) NH2 , - C ( O ) NH ( C1 - C alkyl ) , and 
- C ( = O ) N ( C , - C6 alkyl ) ( C . - C . alkyl ) . 
3 . The compound of claim 2 , wherein at least one sub 
stituent ortho to the carbonyl group a is selected from the 
group consisting of C . - C . alkyl , OH , O ( C - C alkyl ) , F , C1 , 
Br and I . 
4 . The compound of claim 1 , wherein R , is selected from 
the group consisting of phenyl , o - iodophenyl , o - bromophe 
nyl , 0 - chlorophenyl , o - fluorophenyl , 0 - methoxyphenyl , 
p - iodophenyl , p - bromophenyl , p - chlorophenyl , p - fluoro 
phenyl and p - methoxyphenyl . 
fgca 
IZ 
fgia 
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- continued - continued 
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M02 
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11 . The compound of claim 10 , wherein the compound is 
fgkc , fgkb , rgba , fgoa , fgka or fgna . 
12 . The compound of claim 10 , wherein the compound is 
fgkc , fgbb , or fgbc . 
13 . The compound of claim 10 , wherein the compound is 
fgba or fgqa . 
14 . The compound of claim 10 , wherein the compound is 
fgna . 
15 . The compound of claim 1 , wherein the salt of com 
pound I is an acid addition salt and is selected from the group 
consisting of sulfate , hydrogen sulfate , hydrochloric , hyd 
robromic , hydriodic , nitric , carbonic , sulfuric , phosphoric , 
formic , acetic , propionic , succinic , glycolic , gluconic , lactic , 
malic , tartaric , citric , ascorbic , glucuronic , maleic , fumaric , 
pyruvic , aspartic , glutamic , benzoic , anthranilic , 4 - hydroxy 
benzoic , phenylacetic , mandelic , embonic ( pamoic ) , meth 
anesulfonic , ethanesulfonic , benzenesulfonic , pantothenic , 
trifluoromethanesulfonic , 2 - hydroxyethanesulfonic , p - tolu 
enesulfonic , sulfanilic , cyclohexylaminosulfonic , stearic , 
alginic , B - hydroxybutyric , salicylic , galactaric and galactur 
onic acid , and any combinations thereof . 
16 . The compound of claim 1 , wherein the salt is a base 
addition salt and is selected from the group consisting of 
calcium , magnesium , potassium , sodium , ammonium , zinc , 
a basic amine salt , and any combinations thereof , wherein 
the basic amine is selected from the group consisting of 
triethylamine , diisopropylethylamine , trimethylamine , N , N 
dibenzylethylene - diamine , chloroprocaine , choline , dietha 
nolamine , ethylenediamine , meglumine , procaine and any 
combinations thereof . 
17 . A pharmaceutical composition comprising a com 
pound of claim 1 and a pharmaceutically acceptable carrier . 
18 - 20 . ( canceled ) 
21 . A method of inhibiting a N - acetylglucosaminidase in 
a cell , the method comprising contacting the cell with a 
compound of claim 1 . 
22 . A method of inhibiting an N - acetylglucosaminidase in 
the cytosol of a cell , the method comprising contacting the 
N - acetylglucosaminidase with a compound of claim 1 . 
23 . ( canceled ) 
24 . ( canceled ) 
25 . A method of treating or preventing a bacterial infec 
tion in a subject comprising administering to a subject in 
need thereof a therapeutically effective amount of a com 
pound of claim 1 , thereby treating or preventing a bacterial 
infection in a subject . 
26 - 42 . ( canceled ) 
43 . A prepackaged pharmaceutical composition compris 
ing a compound of claim 1 , or a salt or solvate thereof and 
an instructional material for use thereof . 
44 . ( canceled ) 
45 . ( canceled ) 
N and 
fgaDa 
In = 225 
NH 
fgaEa ( n = 2 ) , fgaFa I ( n = 3 ) , 
fgaGa ( n = 4 ) , fgaHa ( n = 5 ) 
10 . The compound of claim 9 , which is selected from the 
group consisting of fgkc , fgkb , rgba , fgoa , fgka , fgna , fgbb , 
fgqa and fgbc . * * * * * 
